Professor Michael Friedlander
Conjoint Professor

Professor Michael Friedlander

Medicine & Health
School of Clinical Medicine
Phone
9382 2606
  • Book Chapters | 2022
    2022, 'Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer', in , Wiley, pp. 1 - 23, http://dx.doi.org/10.1002/9781119000822.hfcm105.pub2
    Book Chapters | 2022
    2022, 'Nonepithelial Ovarian Malignancies', in , Wiley, pp. 1 - 18, http://dx.doi.org/10.1002/9781119000822.hfcm106.pub2
    Book Chapters | 2020
    Christie EL; Freimund AE; Fereday S; Alsop K; Hoang T; Pishas K; Au-Yeung G; Friedlander M; Bowtell DD, 2020, 'The development of drug resistance through reversion mutation in BRCA genes in ovarian cancer', in Overcoming Ovarian Cancer Chemoresistance, Elsevier, pp. 43 - 53, http://dx.doi.org/10.1016/B978-0-12-819840-7.00013-3
    Book Chapters | 2020
    2020, 'Management of Rare Uterine Malignant Tumors', in Management of Endometrial Cancer, Springer International Publishing, pp. 277 - 312, http://dx.doi.org/10.1007/978-3-319-64513-1_19
    Book Chapters | 2017
    Berek JS; Friedlander ML; Bast RC, 2017, 'Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer', in , John Wiley & Sons, Inc., pp. 1 - 27, http://dx.doi.org/10.1002/9781119000822.hfcm105
    Book Chapters | 2017
    2017, 'Nonepithelial Ovarian Malignancies', in , John Wiley & Sons, Inc., pp. 1 - 17, http://dx.doi.org/10.1002/9781119000822.hfcm106
    Book Chapters | 2014
    Berek JS; Friedlander ML; Hacker NF, 2014, 'Epithelial ovarian, fallopian tube, and peritoneal cancer', in Berek and Hacker's Gynecologic Oncology: Sixth Edition, pp. 464 - 529
    Book Chapters | 2014
    Berek JS; Friedlander ML; Hacker NF, 2014, 'Germ cell and nonepithelial ovarian cancer', in Berek and Hacker's Gynecologic Oncology: Sixth Edition, pp. 530 - 559
    Book Chapters | 2014
    Friedlander M; Thigpen JT, 2014, 'Response as a measure of treatment efficacy in clinical trials: Should recist be abandoned?', in Controversies in the Management of Gynecological Cancers, pp. 91 - 100, http://dx.doi.org/10.1007/978-0-85729-910-9_9
    Book Chapters | 2014
    Friedlander ML; Markman M, 2014, 'Chemotherapy', in Berek and Hacker's Gynecologic Oncology: Sixth Edition, pp. 58 - 84
    Book Chapters | 2014
    Hacker NF; Friedlander ML, 2014, 'Uterine cancer', in Berek and Hacker's Gynecologic Oncology: Sixth Edition, pp. 390 - 442
    Book Chapters | 2011
    Berek JS; Longacre T; Friedlander M, 2011, 'Ovarian, Fallopian Tube and Peritoneal Cancer', in Berek JS (ed.), Berek and Novak's Gynecology, edn. 15th, Royal College of Obstetricians and Gynaecologists, UK, pp. 1350 - 1427
    Book Chapters | 2011
    2011, 'Squamous Cell Carcinomas Arising From Dermoids', in Reed N; Green JA; Gershenson DM; Siddiqui N; Connor R (ed.), Rare and Uncommon Gynecological Cancers, Springer, USA, pp. 131 - 134, http://dx.doi.org/10.1007/978-3-642-13492-0_11
    Book Chapters | 2010
    2010, 'Breast Disease: A Gynecologic Perspective', in Hacker &amp Moore's Essentials of Obstetrics and Gynecology, Elsevier, pp. 326 - 331, http://dx.doi.org/10.1016/b978-1-4160-5940-0.00029-1
    Book Chapters | 1997
    Friedlander ML; Gershenson D; Hacker NF; Arjun G; Smitj ; Barber HM, 1997, 'Stage IIC ovarian cancer which is completely resected. In expert consultations in gynecological cancers.', in Stage IIC ovarian cancer which is completely resected. In expert consultations in gynecological cancers., edn. Original, Mercel Dekker, New York, pp. 263 - 270
  • Journal articles | 2023
    DiSilvestro P; Banerjee S; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Oza A; González-Martí A; Aghajanian C; Bradley W; Mathews C; Liu J; McNamara J; Lowe ES; Ah-See ML; Moore KN, 2023, 'Overall Survival with Maintenance Olaparib at a 7-Year Follow-up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial', Obstetrical and Gynecological Survey, 78, pp. 25 - 27, http://dx.doi.org/10.1097/OGX.0000000000001120
    Journal articles | 2023
    Johnston EA; Ibiebele TI; Friedlander ML; Grant PT; van der Pols JC; Webb PM; Ovarian cancer Prognosis And Lifestyle (OPAL) Study Group , 2023, 'Association of Protein Intake with Recurrence and Survival Following Primary Treatment of Ovarian Cancer.', Am J Clin Nutr, http://dx.doi.org/10.1016/j.ajcnut.2023.05.002
    Journal articles | 2023
    Morra A; Mavaddat N; Muranen TA; Ahearn TU; Allen J; Andrulis IL; Auvinen P; Becher H; Behrens S; Blomqvist C; Bojesen SE; Bolla MK; Brauch H; Camp NJ; Carvalho S; Castelao JE; Cessna MH; Chang-Claude J; Chenevix-Trench G; Sahlberg KK; Børresen-Dale AL; Gram IT; Olsen KS; Engebråten O; Naume B; Geisler J; OSBREAC ; Grenaker Alnæs GI; Czene K; Decker B; Dennis J; Dörk T; Dorling L; Dunning AM; Ekici AB; Eriksson M; Evans DG; Fasching PA; Figueroa JD; Flyger H; Gago-Dominguez M; García-Closas M; Geurts-Giele WRR; Giles GG; Guénel P; Gündert M; Hahnen E; Hall P; Hamann U; Harrington PA; He W; Heikkilä P; Hooning MJ; Hoppe R; Howell A; Humphreys K; Amor D; Andrews L; Antill Y; Balleine R; Beesley J; Bennett I; Bogwitz M; Botes L; Brennan M; Brown M; Buckley M; Burke J; Butow P; Caldon L; Campbell I; Cao M; Chakrabarti A; Chauhan D; Chauhan M; Christian A; Cohen P; Colley A; Crook A; Cui J; Courtney E; Cummings M; Dawson SJ; DeFazio A; Delatycki M; Dickson R; Dixon J; Edkins T; Edwards S; Farshid G; Fellows A; Fenton G; Field M; Flanagan J; Fong P; Forrest L; Fox S; French J; Friedlander M; Gaff C, 2023, 'The impact of coding germline variants on contralateral breast cancer risk and survival', American Journal of Human Genetics, 110, pp. 475 - 486, http://dx.doi.org/10.1016/j.ajhg.2023.02.003
    Journal articles | 2023
    Praiss AM; Miller A; Smith J; Lichtman SM; Bookman M; Aghajanian C; Sabbatini P; Backes F; Cohn DE; Argenta P; Friedlander M; Goodheart MJ; Mutch DG; Gershenson DM; Tewari KS; Wenham RM; Wahner Hendrickson AE; Lee RB; Gray H; Secord AA; Van Le L; O'Cearbhaill RE, 2023, 'Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study.', Gynecol Oncol, 174, pp. 213 - 223, http://dx.doi.org/10.1016/j.ygyno.2023.05.013
    Journal articles | 2023
    Sia TY; Tew WP; Purdy C; Chi DS; Menzin AW; Lovecchio JL; Bookman MA; Cohn DE; Teoh DG; Friedlander M; Bender D; Mutch DG; Gershenson DM; Tewari KS; Wenham RM; Wahner Hendrickson AE; Lee RB; Gray HJ; Secord AA; Van Le L; Lichtman SM, 2023, 'The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study', Gynecologic Oncology, 173, pp. 130 - 137, http://dx.doi.org/10.1016/j.ygyno.2023.03.018
    Journal articles | 2023
    2023, '16P Response to taxanes in low-grade serous ovarian cancer patients and cell lines', ESMO Open, 8, pp. 101037 - 101037, http://dx.doi.org/10.1016/j.esmoop.2023.101037
    Journal articles | 2023
    2023, 'Abstract CT033: Safety, pharmacokinetics, and antitumor activity findings from a phase 1b, open-label, dose-escalation and expansion study investigating RAF dimer inhibitor lifirafenib in combination with MEK inhibitor mirdametinib in patients with advanced or refractory solid tumors', Cancer Research, 83, pp. CT033 - CT033, http://dx.doi.org/10.1158/1538-7445.am2023-ct033
    Journal articles | 2023
    2023, 'CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis from the VELIA/GOG-3005 Study', Journal of Clinical Oncology, 41, pp. 107 - 116, http://dx.doi.org/10.1200/JCO.22.00430
    Journal articles | 2023
    2023, 'Common analgesics and ovarian cancer survival: the Ovarian cancer Prognosis And Lifestyle (OPAL) Study.', J Natl Cancer Inst, 115, pp. 570 - 577, http://dx.doi.org/10.1093/jnci/djac239
    Journal articles | 2023
    2023, 'Exercise during CHemotherapy for Ovarian cancer (ECHO) trial: Design and implementation of a randomised controlled trial', BMJ Open, 13, pp. e067925, http://dx.doi.org/10.1136/bmjopen-2022-067925
    Journal articles | 2023
    2023, 'Getting the MOST out of follow-up: A randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer', International Journal of Gynecological Cancer, 32, pp. 560 - 565, http://dx.doi.org/10.1136/ijgc-2021-002999
    Journal articles | 2023
    2023, 'Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma', Translational Oncology, 31, pp. 101638, http://dx.doi.org/10.1016/j.tranon.2023.101638
    Journal articles | 2023
    2023, 'Overall Survival With Maintenance Olaparib at a 7-Year Follow-up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial', Obstetrical & Gynecological Survey, 78, pp. 25 - 27, http://dx.doi.org/10.1097/ogx.0000000000001120
    Journal articles | 2023
    2023, 'Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes', JNCCN Journal of the National Comprehensive Cancer Network, 21, pp. 125 - 132, http://dx.doi.org/10.6004/jnccn.2022.7074
    Journal articles | 2023
    2023, 'Physical activity behaviors in cancer survivors treated with neurotoxic chemotherapy', Asia-Pacific Journal of Clinical Oncology, 19, pp. 243 - 249, http://dx.doi.org/10.1111/ajco.13834
    Journal articles | 2023
    2023, 'Profiling the immune landscape in mucinous ovarian carcinoma', Gynecologic Oncology, 168, pp. 23 - 31, http://dx.doi.org/10.1016/j.ygyno.2022.10.022
    Journal articles | 2023
    2023, 'Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA)', Cancers, 15, pp. 254 - 254, http://dx.doi.org/10.3390/cancers15010254
    Journal articles | 2022
    Han HS; Arun BK; Kaufman B; Wildiers H; Friedlander M; Ayoub JP; Puhalla SL; Bach BA; Kundu MG; Khandelwal N; Feng D; Bhattacharya S; Maag D; Ratajczak CK; Diéras V, 2022, 'Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial', Annals of Oncology, 33, pp. 299 - 309, http://dx.doi.org/10.1016/j.annonc.2021.11.018
    Journal articles | 2022
    Konstantinopoulos PA; Gonzalez-Martin A; Cruz FM; Friedlander M; Glasspool R; Lorusso D; Marth C; Monk BJ; Kim JW; Hinson P; Ajipa O; Pretre V; Han Y; Matulonis UA, 2022, 'EPIK-O/ENGOT-OV61: Alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study)', Future Oncology, 18, pp. 3481 - 3492, http://dx.doi.org/10.2217/fon-2022-0666
    Journal articles | 2022
    Meagher NS; Gorringe KL; Wakefield M; Bolithon A; Pang CNI; Chiu DS; Anglesio MS; Mallitt KA; Doherty JA; Harris HR; Schildkraut JM; Berchuck A; Cushing-Haugen KL; Chezar K; Chou A; Tan A; Alsop J; Barlow E; Beckmann MW; Boros J; Bowtell DDL; Brand AH; Brenton JD; Campbell I; Cheasley D; Cohen J; Cybulski C; Elishaev E; Erber R; Farrell R; Fischer A; Fu Z; Gilks B; Gill AJ; Gourley C; Grube M; Harnett PR; Hartmann A; Hettiaratchi A; Høgdall CK; Huzarski T; Jakubowska A; Jimenez-Linan M; Kennedy CJ; Kim BG; Kim JW; Kim JH; Klett K; Koziak JM; Lai T; Laslavic A; Lester J; Leung Y; Li N; Liauw W; Lim BWX; Linder A; Lubinski J; Mahale S; Mateoiu C; McInerny S; Menkiszak J; Minoo P; Mittelstadt S; Morris D; Orsulic S; Park SY; Pearce CL; Pearson JV; Pike MC; Quinn CM; Mohan GR; Rao J; Riggan MJ; Ruebner M; Salfinger S; Scott CL; Shah M; Steed H; Stewart CJR; Subramanian D; Sung S; Tang K; Timpson P; Ward RL; Wiedenhoefer R; Thorne H; Cohen PA; Crowe P; Fasching PA; Gronwald J; Hawkins NJ; Høgdall E; Huntsman DG; James PA; Karlan BY; Kelemen LE; Kommoss S; Konecny GE; Modugno F, 2022, 'Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes', Clinical Cancer Research, 28, pp. 5383 - 5395, http://dx.doi.org/10.1158/1078-0432.CCR-22-1206
    Journal articles | 2022
    2022, 'A nomogram to predict progression-free survival benefit with maintenance olaparib and bevacizumab following response to first line chemotherapy in advanced ovarian cancer', GYNECOLOGIC ONCOLOGY, 166, pp. S160 - S160, http://dx.doi.org/10.1016/s0090-8258(22)01527-x
    Journal articles | 2022
    2022, 'Adverse events in the placebo arm of maintenance therapy trials in advanced ovarian cancer: A systematic review and meta-analysis', European Journal of Cancer, 170, pp. 169 - 178, http://dx.doi.org/10.1016/j.ejca.2022.04.022
    Journal articles | 2022
    2022, 'CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors', Journal of Experimental and Clinical Cancer Research, 41, pp. 355, http://dx.doi.org/10.1186/s13046-022-02570-4
    Journal articles | 2022
    2022, 'Clinical Predictors And Levels Of Physical Activity Among Cancer Survivors Treated With Neurotoxic Chemotherapy', Medicine & Science in Sports & Exercise, 54, pp. 322 - 322, http://dx.doi.org/10.1249/01.mss.0000879060.88938.0b
    Journal articles | 2022
    2022, 'Copy number variants are ovarian cancer risk alleles at known and novel risk loci', Journal of the National Cancer Institute, 114, pp. 1533 - 1544, http://dx.doi.org/10.1093/jnci/djac160
    Journal articles | 2022
    2022, 'Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns)', Gynecologic Oncology, 164, pp. 437 - 445, http://dx.doi.org/10.1016/j.ygyno.2021.12.006
    Journal articles | 2022
    2022, 'Germline BRCA variants, lifestyle and ovarian cancer survival', Gynecologic Oncology, 165, pp. 437 - 445, http://dx.doi.org/10.1016/j.ygyno.2022.03.020
    Journal articles | 2022
    2022, 'Impact of Homologous Recombination Status and Responses with Veliparib Combined with First-Line Chemotherapy in Ovarian Cancer in the Phase 3 VELIA/GOG-3005 Study', Journal of Bone and Joint Surgery, 77, pp. 277 - 278, http://dx.doi.org/10.1097/01.ogx.0000827620.82650.68
    Journal articles | 2022
    2022, 'Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study', Gynecologic Oncology, 164, pp. 245 - 253, http://dx.doi.org/10.1016/j.ygyno.2021.12.003
    Journal articles | 2022
    2022, 'Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer – an ancillary data analysis of the VELIA trial', Gynecologic Oncology, 164, pp. 278 - 287, http://dx.doi.org/10.1016/j.ygyno.2021.12.012
    Journal articles | 2022
    2022, 'Interobserver and intraobserver variability of RECIST assessment in ovarian cancer', International Journal of Gynecological Cancer, 32, pp. 656 - 661, http://dx.doi.org/10.1136/ijgc-2021-003319
    Journal articles | 2022
    2022, 'Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer', Gynecologic Oncology, 166, pp. 254 - 262, http://dx.doi.org/10.1016/j.ygyno.2022.05.024
    Journal articles | 2022
    2022, 'Multi-modal immune profiling of mucinous ovarian carcinoma: analysis from the Ovarian Tumor Tissue Analysis/Multidisciplinary Ovarian Cancer Outcomes Group consortia', JOURNAL OF IMMUNOLOGY, 208, http://dx.doi.org/10.4049/jimmunol.208.Supp.179.04
    Journal articles | 2022
    2022, 'Next-generation sequencing, should I use anti-HER2 therapy for HER2-amplified tumors off-label? Illustrating an extrapolation framework', Therapeutic Advances in Medical Oncology, 14, http://dx.doi.org/10.1177/17588359221112822
    Journal articles | 2022
    2022, 'Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trial', ANNALS OF ONCOLOGY, 33, pp. S779 - S779, http://dx.doi.org/10.1016/j.annonc.2022.07.645
    Journal articles | 2022
    2022, 'Polygenic risk of paclitaxel-induced peripheral neuropathy: a genome-wide association study', Journal of Translational Medicine, 20, pp. 564, http://dx.doi.org/10.1186/s12967-022-03754-4
    Journal articles | 2022
    2022, 'Pregnancy induced hyperplasia of residual breast tissue following risk reducing contralateral mastectomy - simply interesting or a clinically important observation', Cancer Treatment and Research Communications, 30, pp. 100504, http://dx.doi.org/10.1016/j.ctarc.2021.100504
    Journal articles | 2022
    2022, 'Risk of Peritoneal Cancer after Risk-Reducing Bilateral Salpingo-Oophorectomy for Women with Germline BRCA Pathogenic Variants: A Cause for Concern or Potentially Avoidable?', Journal of Clinical Oncology, 40, pp. 1850 - 1852, http://dx.doi.org/10.1200/JCO.22.00325
    Journal articles | 2022
    2022, 'Symptom Burden and Quality of Life With Chemotherapy for Recurrent Ovarian Cancer: The Gynecologic Cancer InterGroup-Symptom Benefit Study', Obstetrical & Gynecological Survey, 77, pp. 531 - 533, http://dx.doi.org/10.1097/ogx.0000000000001075
    Journal articles | 2022
    2022, 'Symptom Burden and Quality of Life With Chemotherapy for Recurrent Ovarian Cancer: The Gynecologic Cancer InterGroup-Symptom Benefit Study', Obstetrical and Gynecological Survey, 77, pp. 531 - 533, http://dx.doi.org/10.1097/OGX.0000000000001075
    Journal articles | 2022
    2022, 'TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members', Journal of Clinical Oncology, 40, pp. 2036 - 2047, http://dx.doi.org/10.1200/JCO.21.02108
    Journal articles | 2022
    2022, 'The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer', Nature Genetics, 54, pp. 1853 - 1864, http://dx.doi.org/10.1038/s41588-022-01230-9
    Journal articles | 2022
    2022, 'The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors', Journal of Cancer Survivorship, 16, pp. 223 - 232, http://dx.doi.org/10.1007/s11764-021-01012-y
    Journal articles | 2022
    2022, 'The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer', Annals of Oncology, 33, pp. 593 - 601, http://dx.doi.org/10.1016/j.annonc.2022.02.222
    Journal articles | 2022
    2022, 'The validity of progression-free survival 2 as a surrogate trial end point for overall survival', Cancer, 128, pp. 1449 - 1457, http://dx.doi.org/10.1002/cncr.34085
    Journal articles | 2022
    2022, 'Treatment patterns after poly-ADP ribose polymerase (PARP) inhibitors in epithelial ovarian cancer patients', International Journal of Gynecological Cancer, 32, pp. 906 - 912, http://dx.doi.org/10.1136/ijgc-2021-003009
    Journal articles | 2022
    2022, 'What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer', Gynecologic Oncology, 166, pp. 410 - 416, http://dx.doi.org/10.1016/j.ygyno.2022.07.004
    Journal articles | 2021
    Banerjee S; Moore KN; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Oza A; González-Martín A; Aghajanian C; Bradley WH; Holmes E; Lowe ES; DiSilvestro P, 2021, 'Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial', The Lancet Oncology, 22, pp. 1721 - 1731, http://dx.doi.org/10.1016/S1470-2045(21)00531-3
    Journal articles | 2021
    Banerjee SN; Tang M; O'Connell RL; Sjoquist K; Clamp AR; Millan D; Nottley S; Lord R; Mullassery VM; Hall M; Gourley C; Bonaventura T; Goh JC; Sykes P; Grant PT; McNally O; Alexander L; Kelly C; Carty K; Divers L; Bradshaw N; Edmondson RJ; Friedlander M, 2021, 'A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial', Gynecologic Oncology, 163, pp. 72 - 78, http://dx.doi.org/10.1016/j.ygyno.2021.07.024
    Journal articles | 2021
    Cameron B; Webber K; Li H; Bennett BK; Boyle F; de Souza P; Wilcken N; Lynch J; Friedlander M; Goldstein D; Lloyd AR, 2021, 'Genetic associations of fatigue and other symptoms following breast cancer treatment: A prospective study', Brain, Behavior, and Immunity - Health, 10, pp. 100189, http://dx.doi.org/10.1016/j.bbih.2020.100189
    Journal articles | 2021
    Edmondson RJ; O'Connell RL; Banerjee S; Mileshkin L; Sykes P; Beale P; Fisher A; Bonaventura A; Millan D; Nottley S; Benson C; Hamilton A; Sjoquist K; Alexander L; Kelly C; Carty K; Divers L; Bradshaw N; Friedlander M, 2021, 'Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903)', Gynecologic Oncology, 163, pp. 524 - 530, http://dx.doi.org/10.1016/j.ygyno.2021.09.010
    Journal articles | 2021
    Evans DG; Phillips K-A; Milne RL; Fruscio R; Cybulski C; Gronwald J; Lubinski J; Huzarski T; Hyder Z; Forde C; Metcalfe K; Senter L; Weitzel J; Tung N; Zakalik D; Ekholm M; Sun P; Narod SA; kConFab Investigators, Polish Hereditary Breast Cancer Consortium, Hereditary Breast Cancer Clinical Study Group , 2021, 'Survival from breast cancer in women with a BRCA2 mutation by treatment.', Br J Cancer, 124, pp. 1524 - 1532, http://dx.doi.org/10.1038/s41416-020-01164-1
    Journal articles | 2021
    Friedlander M; Moore KN; Colombo N; Scambia G; Kim BG; Oaknin A; Lisyanskaya A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian C; Bradley WH; Liu J; Mathews C; Selle F; Lortholary A; Lowe ES; Hettle R; Flood E; Parkhomenko E; DiSilvestro P, 2021, 'Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial', The Lancet Oncology, 22, pp. 632 - 642, http://dx.doi.org/10.1016/S1470-2045(21)00098-X
    Journal articles | 2021
    Kang EY; Cheasley D; LePage C; Wakefield MJ; da Cunha Torres M; Rowley S; Salazar C; Xing Z; Allan P; Bowtell DDL; Mes-Masson AM; Provencher DM; Rahimi K; Kelemen LE; Fasching PA; Doherty JA; Goodman MT; Goode EL; Deen S; Pharoah PDP; Brenton JD; Sieh W; Mateoiu C; Sundfeldt K; Cook LS; Le ND; Anglesio MS; Gilks CB; Huntsman DG; Kennedy CJ; Traficante N; Chenevix-Trench G; Green A; Webb P; De Fazio A; Gertig D; Fereday S; Moore S; Hung J; Harrap K; Sadkowsky T; Pandeya N; Malt M; Mellon A; Robertson R; Bergh TV; Jones M; Mackenzie P; Maidens J; Nattress K; Chiew YE; Stenlake A; Sullivan H; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Ferguson K; Martin K; Martyn A; Ranieri B; White J; Jayde V; Mamers P; Bowes L; Galletta L; Giles D; Hendley J; Alsop K; Schmidt T; Shirley H; Ball C; Young C; Viduka S; Tran H; Bilic S; Glavinas L; Brooks J; Stuart-Harris R; Kirsten F; Rutovitz J; Clingan P; Glasgow A; Proietto A; Braye S; Otton G; Shannon J; Bonaventura T; Stewart J; Begbie S; Friedlander M; Bell D; Baron-Hay S; Ferrier A; Gard G; Nevell D; Pavlakis N, 2021, 'Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses', Modern Pathology, 34, pp. 194 - 206, http://dx.doi.org/10.1038/s41379-020-0618-9
    Journal articles | 2021
    Kurtz JE; Gebski V; Sukhin V; Carey M; Kong I; Glasspool RM; Berek JS; de Paiva Batista M; Hall M; Kim JW; Yeoshoua E; Fujiwara N; Nam BH; Polleis S; Lee JY; Strojna A; Farrelly L; Schwameis R; Fossati R; Darlington AS; Lai CH; Wright AA; Rosenblat O; Harter P; Roxburgh P; Chowdhury RR; Chang TC; Paoletti X; Friedlander M, 2021, 'Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee', Gynecologic Oncology, 161, pp. 502 - 507, http://dx.doi.org/10.1016/j.ygyno.2021.02.018
    Journal articles | 2021
    Ledermann JA; Embleton-Thirsk AC; Perren TJ; Jayson GC; Rustin GJS; Kaye SB; Hirte H; Oza A; Vaughan M; Friedlander M; González-Martín A; Deane E; Popoola B; Farrelly L; Swart AM; Kaplan RS; Parmar MKB, 2021, 'Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial', ESMO Open, 6, pp. 100043, http://dx.doi.org/10.1016/j.esmoop.2020.100043
    Journal articles | 2021
    Park HA; Neumeyer S; Michailidou K; Bolla MK; Wang Q; Dennis J; Ahearn TU; Andrulis IL; Anton-Culver H; Antonenkova NN; Arndt V; Aronson KJ; Augustinsson A; Baten A; Beane Freeman LE; Becher H; Beckmann MW; Behrens S; Benitez J; Bermisheva M; Bogdanova NV; Bojesen SE; Brauch H; Brenner H; Brucker SY; Burwinkel B; Campa D; Canzian F; Castelao JE; Chanock SJ; Chenevix-Trench G; Clarke CL; Børresen-Dale AL; Grenaker Alnæs GI; Sahlberg KK; Ottestad L; Kåresen R; Schlichting E; Holmen MM; Sauer T; Haakensen V; Engebråten O; Naume B; Fosså A; Kiserud CE; Reinertsen KV; Helland Å; Riis M; Geisler J; Conroy DM; Couch FJ; Cox A; Cross SS; Czene K; Daly MB; Devilee P; Dörk T; dos-Santos-Silva I; Dwek M; Eccles DM; Eliassen AH; Engel C; Eriksson M; Evans DG; Fasching PA; Flyger H; Fritschi L; García-Closas M; García-Sáenz JA; Gaudet MM; Giles GG; Glendon G; Goldberg MS; Goldgar DE; González-Neira A; Grip M; Guénel P; Hahnen E; Haiman CA; Håkansson N; Hall P; Hamann U; Han S; Harkness EF; Hart SN; He W; Heemskerk-Gerritsen BAM; Hopper JL; Hunter DJ; Clarke C; Marsh D; Scott R; Baxter R; Yip D; Carpenter J; Davis A; Pathmanathan N; Simpson P; Graham D; Sachchithananthan M, 2021, 'Mendelian randomisation study of smoking exposure in relation to breast cancer risk', British Journal of Cancer, 125, pp. 1135 - 1145, http://dx.doi.org/10.1038/s41416-021-01432-8
    Journal articles | 2021
    Poveda A; Floquet A; Ledermann JA; Asher R; Penson RT; Oza AM; Korach J; Huzarski T; Pignata S; Friedlander M; Baldoni A; Park-Simon TW; Tamura K; Sonke GS; Lisyanskaya A; Kim JH; Filho EA; Milenkova T; Lowe ES; Rowe P; Vergote I; Pujade-Lauraine E; Byrski T; Pautier P; Harter P; Colombo N; Scambia G; Nicoletto M; Nussey F; Clamp A; Penson R; Poveda Velasco A; Rodrigues M; Lotz JP; Selle F; Ray-Coquard I; Provencher D; Prat Aparicio A; Vidal Boixader L; Scott C; Yunokawa M; Medioni J; Pécuchet N; Dubot C; De La Motte Rouge T; Kaminsky MC; Weber B; Lortholary A; Parkinson C; Williams S; Banerjee S; Cosin J; Hoffman J; Plante M; Covens A; Joly F; Hirte H; Amit A; Matsumoto K; Tjulandin S; Hoon Kim J; Gladieff L; Sabbatini R; O'Malley D; Timmins P; Kredentser D; Laínez Milagro N; Barretina Ginesta MP; Tibau Martorell A; Gómez De Liaño Lista A; Ojeda González B; Mileshkin L; Mandai M; Boere I; Ottevanger P; Nam JH; Filho E; Hamizi S; Cognetti F; Warshal D; Dickson-Michelson E; Kamelle S; McKenzie N; Rodriguez G; Armstrong D; Chalas E; Celano P; Behbakht K; Davidson S; Welch S; Helpman L; Fishman A; Bruchim I; Sikorska M; Słowińska A; Rogowski W; Bidziński M; Śpiewankiewicz B, 2021, 'Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial', The Lancet Oncology, 22, pp. 620 - 631, http://dx.doi.org/10.1016/S1470-2045(21)00073-5
    Journal articles | 2021
    Trinh T; Park SB; Murray J; Pickering H; Lin CSY; Martin A; Friedlander M; Kiernan MC; Goldstein D; Krishnan AV, 2021, 'Neu-horizons: neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathy—a randomised controlled trial', Supportive Care in Cancer, 29, pp. 1103 - 1110, http://dx.doi.org/10.1007/s00520-020-05591-x
    Journal articles | 2021
    Xu X; Wang Y; Bryce NS; Tang K; Meagher NS; Kang EY; Kelemen LE; Köbel M; Ramus SJ; Friedlander M; Ford CE; Hardeman EC; Gunning PW, 2021, 'Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents', British Journal of Cancer, 125, pp. 265 - 276, http://dx.doi.org/10.1038/s41416-021-01420-y
    Journal articles | 2021
    2021, 'Bilateral salpingo-oophorectomy and breast cancer risk for BRCA1 and BRCA2 mutation carriers: Assessing the evidence', Cancer Prevention Research, 14, pp. 983 - 994, http://dx.doi.org/10.1158/1940-6207.CAPR-21-0141
    Journal articles | 2021
    2021, 'Breast cancer chemoprevention: Use and views of australian women and their clinicians', Cancer Prevention Research, 14, pp. 131 - 144, http://dx.doi.org/10.1158/1940-6207.CAPR-20-0369
    Journal articles | 2021
    2021, 'Cancer of the ovary, fallopian tube, and peritoneum: 2021 update', International Journal of Gynecology and Obstetrics, 155, pp. 61 - 85, http://dx.doi.org/10.1002/ijgo.13878
    Journal articles | 2021
    2021, 'Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial', Journal for ImmunoTherapy of Cancer, 9, http://dx.doi.org/10.1136/jitc-2020-002255
    Journal articles | 2021
    2021, 'Concurrent maternal malignancy and fetal trisomy detected using genome-wide noninvasive prenatal screening', Prenatal Diagnosis, 41, pp. 1273 - 1276, http://dx.doi.org/10.1002/pd.6020
    Journal articles | 2021
    2021, 'Corneal dendritic cells and the subbasal nerve plexus following neurotoxic treatment with oxaliplatin or paclitaxel', Scientific Reports, 11, http://dx.doi.org/10.1038/s41598-021-02439-0
    Journal articles | 2021
    2021, 'Development and validation of the measure of ovarian symptoms and treatment concerns for surveillance (MOST-S26): An instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatment', Gynecologic Oncology, 163, pp. 398 - 407, http://dx.doi.org/10.1016/j.ygyno.2021.08.022
    Journal articles | 2021
    2021, 'EPIK-O/ENGOT-OV61: A PHASE 3, RANDOMIZED STUDY OF ALPELISIB plus OLAPARIB IN PATIENTS WITH NO GERMLINE BRCA MUTATION DETECTED, PLATINUM-RESISTANT OR -REFRACTORY, HIGH-GRADE SEROUS OVARIAN CANCER', INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 31, pp. A139 - A140, http://dx.doi.org/10.1136/ijgc-2021-IGCS.350
    Journal articles | 2021
    2021, 'Efficacy and safety of first-line veliparib and carboplatin–paclitaxel in patients with HER2− advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial', European Journal of Cancer, 154, pp. 35 - 45, http://dx.doi.org/10.1016/j.ejca.2021.05.037
    Journal articles | 2021
    2021, 'Identification of a locus near ULK1 associated with progression-free survival in ovarian cancer', Cancer Epidemiology Biomarkers and Prevention, 30, pp. 1669 - 1680, http://dx.doi.org/10.1158/1055-9965.EPI-20-1817
    Journal articles | 2021
    2021, 'Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis', Cancer, 127, pp. 2432 - 2441, http://dx.doi.org/10.1002/cncr.33517
    Journal articles | 2021
    2021, 'Motivators of Inappropriate Ovarian Cancer Screening: A Survey of Women and Their Clinicians', JNCI Cancer Spectrum, 5, http://dx.doi.org/10.1093/jncics/pkaa110
    Journal articles | 2021
    2021, 'Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial', Obstetrical and Gynecological Survey, 76, pp. 535 - 536, http://dx.doi.org/10.1097/OGX.0000000000000962
    Journal articles | 2021
    2021, 'Pre- And post-diagnosis diet quality and ovarian cancer survival', Cancer Epidemiology Biomarkers and Prevention, 30, pp. 229 - 232, http://dx.doi.org/10.1158/1055-9965.EPI-20-1036
    Journal articles | 2021
    2021, 'Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy', European Journal of Cancer, 154, pp. 190 - 200, http://dx.doi.org/10.1016/j.ejca.2021.06.024
    Journal articles | 2021
    2021, 'Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial', Gynecologic Oncology, 162, pp. 375 - 381, http://dx.doi.org/10.1016/j.ygyno.2021.05.031
    Journal articles | 2021
    2021, 'REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer', Gynecologic Oncology, 161, pp. 374 - 381, http://dx.doi.org/10.1016/j.ygyno.2021.02.002
    Journal articles | 2021
    2021, 'Recreational Physical Activity and Outcomes After Breast Cancer in Women at High Familial Risk', JNCI Cancer Spectrum, 5, http://dx.doi.org/10.1093/jncics/pkab090
    Journal articles | 2021
    2021, 'Relevance of platinum-free interval and BRCA reversion mutations for veliparib monotherapy after progression on carboplatin/paclitaxel for gBRCA advanced breast cancer (BROCADE3 Crossover)', Clinical Cancer Research, 27, pp. 4983 - 4993, http://dx.doi.org/10.1158/1078-0432.CCR-21-0748
    Journal articles | 2021
    2021, 'Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reporting', European Journal of Cancer, 148, pp. 251 - 259, http://dx.doi.org/10.1016/j.ejca.2021.02.006
    Journal articles | 2021
    2021, 'Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial', Therapeutic Advances in Medical Oncology, 13, http://dx.doi.org/10.1177/17588359211059601
    Journal articles | 2021
    2021, 'The impasse on overall survival in oncology reimbursement decision-making: How can we resolve this?', Cancer Management and Research, 13, pp. 8457 - 8471, http://dx.doi.org/10.2147/CMAR.S328058
    Journal articles | 2021
    2021, 'Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial', Gynecologic Oncology, 163, pp. 41 - 49, http://dx.doi.org/10.1016/j.ygyno.2021.07.016
    Journal articles | 2021
    2021, 'Tumor Response End Points as Surrogates for Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-Analysis', JCO PRECISION ONCOLOGY, 5, pp. 1151 - 1159, http://dx.doi.org/10.1200/PO.21.00108
    Journal articles | 2021
    2021, 'Weekly Paclitaxel-Induced Neurotoxicity in Breast Cancer: Outcomes and Dose Response', Oncologist, 26, pp. 366 - 374, http://dx.doi.org/10.1002/onco.13697
    Journal articles | 2020
    Aghajanian C; Bookman MA; Fleming GF; Brady MF; Swisher EM; Steffensen KD; Friedlander M; Okamoto A; Moore KN; Sullivan DM; Fallstrom M; Dinh M; Ratajczak C; Coleman RL, 2020, 'PFS by blinded independent central review (BICR) in the VELIA trial of veliparib (V) plus carboplatin/paclitaxel (CP) and as monotherapy in newly diagnosed patients (pts) with high-grade serous ovarian cancer (HGSC).', Journal of Clinical Oncology, 38, pp. 6077 - 6077, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.6077
    Journal articles | 2020
    Beesley VL; Webber K; Nagle CM; DeFazio A; Obermair A; Williams M; Friedlander M; Webb PM, 2020, 'When will I feel normal again? Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancer', Gynecologic Oncology, 159, pp. 179 - 186, http://dx.doi.org/10.1016/j.ygyno.2020.07.029
    Journal articles | 2020
    Desai J; Deva S; Lee JS; Lin CC; Yen CJ; Chao Y; Keam B; Jameson M; Hou MM; Kang YK; Markman B; Lu CH; Rau KM; Lee KH; Horvath L; Friedlander M; Hill A; Sandhu S; Barlow P; Wu CY; Zhang Y; Liang L; Wu J; Paton V; Millward M, 2020, 'Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors', Journal for ImmunoTherapy of Cancer, 8, http://dx.doi.org/10.1136/jitc-2019-000453
    Journal articles | 2020
    Desai J; Gan H; Barrow C; Jameson M; Atkinson V; Haydon A; Millward M; Begbie S; Brown M; Markman B; Patterson W; Hill A; Horvath L; Nagrial A; Richardson G; Jackson C; Friedlander M; Parente P; Tran B; Wang L; Chen Y; Tang Z; Huang W; Wu J; Zeng D; Luo L; Solomon B, 2020, 'Phase I, open-label, dose-escalation/ dose-expansion study of lifirafenib (BGB-283), an RAF family kinase inhibitor, in patients with solid tumors', Journal of Clinical Oncology, 38, pp. 2140 - 2150, http://dx.doi.org/10.1200/JCO.19.02654
    Journal articles | 2020
    DiSilvestro P; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian CA; Bradley WH; Mathews CA; Liu J; Lowe ES; Bloomfield R; Moore KN, 2020, 'Efficacy of Maintenance Olaparib for Patients with Newly Diagnosed Advanced Ovarian Cancer with a BRCA Mutation: Subgroup Analysis Findings from the SOLO1 Trial', Journal of Clinical Oncology, 38, pp. 3528 - 3537, http://dx.doi.org/10.1200/JCO.20.00799
    Journal articles | 2020
    Diéras V; Han HS; Kaufman B; Wildiers H; Friedlander M; Ayoub JP; Puhalla SL; Bondarenko I; Campone M; Jakobsen EH; Jalving M; Oprean C; Palácová M; Park YH; Shparyk Y; Yañez E; Khandelwal N; Kundu MG; Dudley M; Ratajczak CK; Maag D; Arun BK, 2020, 'Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial', The Lancet Oncology, 21, pp. 1269 - 1282, http://dx.doi.org/10.1016/S1470-2045(20)30447-2
    Journal articles | 2020
    Gleeson M; Kentwell M; Meiser B; Do J; Nevin S; Taylor N; Barlow-Stewart K; Kirk J; James P; Scott CL; Williams R; Gamet K; Burke J; Murphy M; Antill YC; Pearn A; Pachter N; Ebzery C; Poplawski N; Friedlander M; Tucker KM, 2020, 'The development and evaluation of a nationwide training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients', Gynecologic Oncology, 158, pp. 431 - 439, http://dx.doi.org/10.1016/j.ygyno.2020.05.001
    Journal articles | 2020
    Han HS; Arun B; Kaufman B; Wildiers H; Friedlander M; Ayoub J-PM; Puhalla SL; Bach BA; Dudley M; Kundu MG; Maag D; Ratajczak C; Dieras V, 2020, 'Veliparib (V) monotherapy (monoTx) following combination therapy with V + carboplatin/paclitaxel (CP) in patients with gBRCA-associated advanced breast cancer: Exploratory results from BROCADE3.', Journal of Clinical Oncology, 38, pp. 1091 - 1091, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.1091
    Journal articles | 2020
    Hansen JM; Nagle CM; Ibiebele TI; Grant PT; Obermair A; Friedlander ML; DeFazio A; Webb PM, 2020, 'A healthy lifestyle and survival among women with ovarian cancer', International Journal of Cancer, 147, pp. 3361 - 3369, http://dx.doi.org/10.1002/ijc.33155
    Journal articles | 2020
    Jones T; Spence R; Sandler C; Obermair A; Friedlander M; Mileshkin L; Davis A; Janda M; Eakin E; Barnes E; Beesley V; Gordon L; Brand A; Hayes S, 2020, 'Are The ACSM Exercise Guidelines Safe And Achievable For Women Receiving Chemotherapy For Ovarian Cancer?', Medicine & Science in Sports & Exercise, 52, pp. 483 - 484, http://dx.doi.org/10.1249/01.mss.0000679180.61253.83
    Journal articles | 2020
    Kasherman L; Siu DHW; Lee KWC; Lord S; Marschner I; Lewis CR; Friedlander M; Lee CK, 2020, 'Efficacy of immune checkpoint inhibitors in older adults with advanced stage cancers: A meta-analysis', Journal of Geriatric Oncology, 11, pp. 508 - 514, http://dx.doi.org/10.1016/j.jgo.2019.05.013
    Journal articles | 2020
    Li H; Terry MB; Antoniou AC; Phillips KA; Kast K; Mooij TM; Engel C; Nogues C; Stoppa-Lyonnet D; Lasset C; Berthet P; Mari V; Caron O; Barrowdale D; Frost D; Brewer C; Evans DG; Izatt L; Side L; Walker L; Tischkowitz M; Rogers MT; Porteous ME; Snape K; Meijers-Heijboer HEJ; Gille JJP; Blok MJ; Hoogerbrugge N; Daly MB; Andrulis IL; Buys SS; John EM; McLachlan SA; Friedlander M; Tan YY; Osorio A; Caldes T; Jakubowska A; Simard J; Singer CF; Olah E; Navratilova M; Foretova L; Gerdes AM; Roos-Blom MJ; Arver B; Olsson H; Schmutzler RK; Hopper JL; Milne RL; Easton DF; Van Leeuwen FE; Rookus MA; Andrieu N; Goldgar DE, 2020, 'Alcohol consumption, cigarette smoking, and risk of breast cancer for BRCA1 and BRCA2 mutation carriers: Results from the BRCA1 and BRCA2 cohort consortium', Cancer Epidemiology Biomarkers and Prevention, 29, pp. 368 - 378, http://dx.doi.org/10.1158/1055-9965.EPI-19-0546
    Journal articles | 2020
    Millstein J; Budden T; Goode EL; Anglesio MS; Talhouk A; Intermaggio MP; Leong HS; Chen S; Elatre W; Gilks B; Nazeran T; Volchek M; Bentley RC; Wang C; Chiu DS; Kommoss S; Leung SCY; Senz J; Lum A; Chow V; Sudderuddin H; Mackenzie R; George J; Bowtell DD; Chenevix-Trench G; Green A; Webb P; deFazio A; Gertig D; Traficante N; Fereday S; Moore S; Hung J; Harrap K; Sadkowsky T; Pandeya N; Malt M; Mellon A; Robertson R; Vanden Bergh T; Jones M; Mackenzie P; Maidens J; Nattress K; Chiew YE; Stenlake A; Sullivan H; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Ferguson K; Martin K; Martyn A; Ranieri B; White J; Jayde V; Mamers P; Bowes L; Galletta L; Giles D; Hendley J; Alsop K; Schmidt T; Shirley H; Ball C; Young C; Viduka S; Tran H; Bilic S; Glavinas L; Brooks J; Stuart-Harris R; Kirsten F; Rutovitz J; Clingan P; Glasgow A; Proietto A; Braye S; Otton G; Shannon J; Bonaventura T; Stewart J; Begbie S; Friedlander M; Bell D; Baron-Hay S; Ferrier,a A; Gard G; Nevell D; Pavlakis N; Valmadre S; Young B; Camaris C; Crouch R; Edwards L; Hacker N; Marsden D, 2020, 'Prognostic gene expression signature for high-grade serous ovarian cancer', Annals of Oncology, 31, pp. 1240 - 1250, http://dx.doi.org/10.1016/j.annonc.2020.05.019
    Journal articles | 2020
    Poveda A; Floquet A; Ledermann JA; Asher R; Penson RT; Oza AM; Korach J; Huzarski T; Pignata S; Friedlander M; Baldoni A; Park-Simon T-W; Sonke GS; Lisyanskaya AS; Kim J-H; Filho EA; Vergote I; Rowe P; Pujade-Lauraine E, 2020, 'Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.', Journal of Clinical Oncology, 38, pp. 6002 - 6002, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.6002
    Journal articles | 2020
    Puhalla SL; Dieras V; Arun B; Kaufman B; Wildiers H; Han HS; Ayoub J-PM; Stearns V; Yuan Y; Helsten TL; Riley-Gillis B; Murphy E; Kundu MG; Wu M; Maag D; Ratajczak C; Ramathal C; Friedlander M, 2020, 'Veliparib (V) monotherapy after progression on placebo (PL) + carboplatin/paclitaxel (CP) in patients with advanced HER2-negative gBRCA-associated breast cancer: Crossover outcomes and exploratory biomarker analyses in BROCADE3.', Journal of Clinical Oncology, 38, pp. 1097 - 1097, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.1097
    Journal articles | 2020
    Roncolato FT; O'Connell RL; Joly F; Lanceley A; Hilpert F; Buizen L; Okamoto A; Aotani E; Salutari V; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Fehm T; Ledermann J; Roemer-Becuwe C; Stockler MR; King MT; Friedlander ML, 2020, 'Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy – The GCIG symptom benefit study (SBS)', Gynecologic Oncology, 156, pp. 45 - 53, http://dx.doi.org/10.1016/j.ygyno.2019.10.001
    Journal articles | 2020
    Tjokrowidjaja A; Lee CK; Friedlander M; Gebski V; Gladieff L; Ledermann JA; Penson RT; Oza AM; Korach J; Huzarski T; Manso L; Pisano C; Asher R; Colombo N; Park-Simon T-W; Fujiwara K; Sonke GS; Vergote I; Kim J-W; Pujade-Lauraine E, 2020, 'Concordance between CA-125 and RECIST progression (PD) in patients with germline BRCA-mutated platinum-sensitive, relapsed ovarian cancer treated with a PARP inhibitor (PARPi) as maintenance therapy after response to chemotherapy.', Journal of Clinical Oncology, 38, pp. 6014 - 6014, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.6014
    Journal articles | 2020
    Trillsch F; Mahner S; Ataseven B; Asher R; Dubot C; Clamp AR; Penson RT; Oza AM; Amit A; Huzarski T; Casado A; Scambia G; Friedlander M; Colombo N; Fujiwara K; Sonke GS; denys H; Lowe ES; Pujade-Lauraine E, 2020, 'Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOT-Ov21) study.', Journal of Clinical Oncology, 38, pp. 6068 - 6068, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.6068
    Journal articles | 2020
    2020, '5. Neurophysiological characteristics in the development and recovery of peripheral neuropathy in oxaliplatin and paxlitaxel treated patients', Clinical Neurophysiology, 131, pp. e2 - e3, http://dx.doi.org/10.1016/j.clinph.2019.11.038
    Journal articles | 2020
    2020, 'A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)', International Journal of Gynecological Cancer, 30, pp. 1239 - 1242, http://dx.doi.org/10.1136/ijgc-2020-001604
    Journal articles | 2020
    2020, 'Chemoprevention for breast cancer: A survey of the views of Australian women and clinicians', European Journal of Cancer, 138, pp. S8, http://dx.doi.org/10.1016/S0959-8049(20)30547-5
    Journal articles | 2020
    2020, 'Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy', European Journal of Cancer, 139, pp. 59 - 67, http://dx.doi.org/10.1016/j.ejca.2020.08.021
    Journal articles | 2020
    2020, 'Considerations When Using Breast Cancer Risk Models for Women with Negative BRCA1/BRCA2 Mutation Results', Journal of the National Cancer Institute, 112, pp. 418 - 422, http://dx.doi.org/10.1093/jnci/djz194
    Journal articles | 2020
    2020, 'Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study', Gynecologic Oncology, 158, pp. 47 - 53, http://dx.doi.org/10.1016/j.ygyno.2020.04.706
    Journal articles | 2020
    2020, 'Insomnia and its association with quality of life in women with ovarian cancer', Gynecologic Oncology, 158, pp. 760 - 768, http://dx.doi.org/10.1016/j.ygyno.2020.06.500
    Journal articles | 2020
    2020, 'Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants', Genetics in Medicine, 22, pp. 1653 - 1666, http://dx.doi.org/10.1038/s41436-020-0862-x
    Journal articles | 2020
    2020, 'Recreational physical activity is associated with reduced breast cancer risk in adult women at high risk for breast cancer: A cohort study of women selected for familial and genetic risk', Cancer Research, 80, pp. 116 - 125, http://dx.doi.org/10.1158/0008-5472.CAN-19-1847
    Journal articles | 2020
    2020, 'Should MMMT still be treated with adjuvant taxane-based combination chemotherapy?', Journal of Cancer Research and Clinical Oncology, 146, pp. 695 - 704, http://dx.doi.org/10.1007/s00432-019-03091-y
    Journal articles | 2020
    2020, 'Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis', JAMA network open, 3, pp. e2011809, http://dx.doi.org/10.1001/jamanetworkopen.2020.11809
    Journal articles | 2019
    Antill Y; Kok PS; Stockler MR; Robledo K; Yip S; Parry M; Smith D; Spurdle A; Barnes E; Friedlander ML; Baron-Hay S; Shannon C; Coward J; Beale PJ; Goss G; Meniawy T; Andrews J; Kelly M; Mileshkin L, 2019, 'Updated results of activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601)', Annals of Oncology, 30, pp. ix192 - ix192, http://dx.doi.org/10.1093/annonc/mdz446.011
    Journal articles | 2019
    Coleman RL; Fleming GF; Brady MF; Swisher E; Steffensen KD; Friedlander M; Okamoto A; Moore K; Ben-Baruch N; Werner TL; Oaknin A; Nam J-H; Leath CA; Nicum S; Cella D; Sullivan DM; Ansell PJ; Dinh M; Aghajanian C; Bookman MA, 2019, 'VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC)', Annals of Oncology, 30, pp. v895 - v896, http://dx.doi.org/10.1093/annonc/mdz394.054
    Journal articles | 2019
    Coleman RL; Fleming GF; Brady MF; Swisher EM; Steffensen KD; Friedlander M; Okamoto A; Moore KN; Efrat Ben-Baruch N; Werner TL; Cloven NG; Oaknin A; DiSilvestro PA; Morgan MA; Nam JH; Leath CA; Nicum S; Hagemann AR; Littell RD; Cella D; Baron-Hay S; Garcia-Donas J; Mizuno M; Bell-McGuinn K; Sullivan DM; Bach BA; Bhattacharya S; Ratajczak CK; Ansell PJ; Dinh MH; Aghajanian C; Bookman MA, 2019, 'Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer', New England Journal of Medicine, 381, pp. 2403 - 2415, http://dx.doi.org/10.1056/NEJMoa1909707
    Journal articles | 2019
    Diéras VC; Han HS; Kaufman B; Wildiers H; Friedlander M; Ayoub J-P; Puhalla SL; Bondarenko I; Campone M; Jakobsen EH; Jalving M; Oprean C; Palácová M; Park YH; Shparyk Y; Yañez E; Dudley M; Ratajczak CK; Maag D; Arun BK, 2019, 'Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer', Annals of Oncology, 30, pp. v857 - v858, http://dx.doi.org/10.1093/annonc/mdz394.008
    Journal articles | 2019
    Figlioli G; Bogliolo M; Catucci I; Caleca L; Lasheras SV; Pujol R; Kiiski JI; Muranen TA; Barnes DR; Dennis J; Michailidou K; Bolla MK; Leslie G; Aalfs CM; Balleine R; Baxter R; Braye S; Carpenter J; Dahlstrom J; Forbes J; Lee CS; Marsh D; Morey A; Pathmanathan N; Scott R; Simpson P; Spigelman A; Wilcken N; Yip D; Zeps N; Adank MA; Adlard J; Agata S; Cadoo K; Agnarsson BA; Ahearn T; Aittomäki K; Ambrosone CB; Andrews L; Anton-Culver H; Antonenkova NN; Arndt V; Arnold N; Aronson KJ; Arun BK; Asseryanis E; Auber B; Auvinen P; Azzollini J; Balmaña J; Barkardottir RB; Barrowdale D; Barwell J; Beane Freeman LE; Beauparlant CJ; Beckmann MW; Behrens S; Benitez J; Berger R; Bermisheva M; Blanco AM; Blomqvist C; Bogdanova NV; Bojesen A; Bojesen SE; Bonanni B; Borg A; Brady AF; Brauch H; Brenner H; Brüning T; Burwinkel B; Buys SS; Caldés T; Caliebe A; Caligo MA; Campa D; Campbell IG; Canzian F; Castelao JE; Chang-Claude J; Chanock SJ; Claes KBM; Clarke CL; Collavoli A; Conner TA; Cox DG; Cybulski C; Czene K; Daly MB; de la Hoya M; Devilee P; Diez O; Ding YC; Dite GS; Ditsch N; Domchek SM; Dorfling CM; dos-Santos-Silva I; Durda K, 2019, 'The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer', npj Breast Cancer, 5, http://dx.doi.org/10.1038/s41523-019-0127-5
    Journal articles | 2019
    Kehm RD; Hopper JL; John EM; Phillips KA; MacInnis RJ; Dite GS; Milne RL; Liao Y; Zeinomar N; Knight JA; Southey MC; Vahdat L; Kornhauser N; Cigler T; Chung WK; Giles GG; McLachlan SA; Friedlander ML; Weideman PC; Glendon G; Nesci S; Andrulis IL; Buys SS; Daly MB; Terry MB, 2019, 'Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: A cohort study', Breast Cancer Research, 21, pp. 52, http://dx.doi.org/10.1186/s13058-019-1135-y
    Journal articles | 2019
    Kok PS; Beale P; O’Connell RL; Grant P; Bonaventura T; Scurry J; Antill Y; Goh J; Sjoquist K; Defazio A; Mapagu C; Amant F; Friedlander M, 2019, 'PARAGON (ANZGOG-0903): A phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression', Journal of Gynecologic Oncology, 30, http://dx.doi.org/10.3802/jgo.2019.30.e86
    Journal articles | 2019
    Lee CK; Scott C; Lindeman GJ; Hamilton A; Lieschke E; Gibbs E; Asher R; Badger H; Paterson R; Macnab L; Kwan EM; Francis PA; Boyle F; Friedlander M, 2019, 'Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer', British Journal of Cancer, 120, pp. 279 - 285, http://dx.doi.org/10.1038/s41416-018-0349-6
    Journal articles | 2019
    Lee KWC; Lord S; Finn RS; Lim E; Martin A; Loi S; Lynch J; Friedlander M; Lee CK, 2019, 'The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis', Breast Cancer Research and Treatment, 174, pp. 271 - 278, http://dx.doi.org/10.1007/s10549-018-5054-x
    Journal articles | 2019
    Mavaddat N; Michailidou K; Dennis J; Lush M; Fachal L; Lee A; Tyrer JP; Chen TH; Wang Q; Bolla MK; Yang X; Adank MA; Ahearn T; Aittomäki K; Allen J; Andrulis IL; Anton-Culver H; Antonenkova NN; Arndt V; Aronson KJ; Auer PL; Auvinen P; Barrdahl M; Beane Freeman LE; Beckmann MW; Behrens S; Benitez J; Bermisheva M; Bernstein L; Blomqvist C; Bogdanova NV; Bojesen SE; Bonanni B; Børresen-Dale AL; Brauch H; Bremer M; Brenner H; Brentnall A; Brock IW; Brooks-Wilson A; Brucker SY; Brüning T; Burwinkel B; Campa D; Carter BD; Castelao JE; Chanock SJ; Chlebowski R; Christiansen H; Clarke CL; Collée JM; Cordina-Duverger E; Cornelissen S; Couch FJ; Cox A; Cross SS; Czene K; Daly MB; Devilee P; Dörk T; dos-Santos-Silva I; Dumont M; Durcan L; Dwek M; Eccles DM; Ekici AB; Eliassen AH; Ellberg C; Engel C; Eriksson M; Evans DG; Fasching PA; Figueroa J; Fletcher O; Flyger H; Försti A; Fritschi L; Gabrielson M; Gago-Dominguez M; Gapstur SM; García-Sáenz JA; Gaudet MM; Georgoulias V; Giles GG; Gilyazova IR; Glendon G; Goldberg MS; Goldgar DE; González-Neira A; Grenaker Alnæs GI; Grip M; Gronwald J; Grundy A; Guénel P; Haeberle L; Hahnen E; Haiman CA; Håkansson N; Hamann U; Hankinson SE, 2019, 'Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes', American Journal of Human Genetics, 104, pp. 21 - 34, http://dx.doi.org/10.1016/j.ajhg.2018.11.002
    Journal articles | 2019
    McCabe M; Gauthier M-E; Chan C-L; Thompson T; De Sousa S; Puttick C; Grady J; Gayevskiy V; Tao J; Ying K; Cipponi A; Deng N; Swarbrick A; Thomas M; kConFab ; Lord R; Johns A; Kohonen-Corish M; O'Toole S; Clark J; Mueller S; Gupta R; McCormack A; Dinger M; Cowley M, 2019, 'Development and validation of a targeted gene sequencing panel for application to disparate cancers', Scientific Reports
    Journal articles | 2019
    Mileshkin L; Edmondson R; O'Connell RL; Sjoquist KM; Andrews J; Jyothirmayi R; Beale P; Bonaventura T; Goh J; Hall M; Clamp A; Green J; Lord R; Amant F; Alexander L; Carty K; Paul J; Scurry J; Millan D; Nottley S; Friedlander M, 2019, 'Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial – ANZGOG 0903', Gynecologic Oncology, 154, pp. 29 - 37, http://dx.doi.org/10.1016/j.ygyno.2019.05.007
    Journal articles | 2019
    Moore K; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian C; Bradley W; Mathews C; Liu J; Lowe ES; Bloomfield R; Disilvestro P, 2019, 'Maintenance Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer', Obstetrical and Gynecological Survey, 74, pp. 86 - 87, http://dx.doi.org/10.1097/01.ogx.0000552695.03241.d6
    Journal articles | 2019
    Oaknin A; Moore K; Colombo N; Scambia G; Kim B-G; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza AM; González-Martín A; Aghajanian C; Bradley W; Lowe ES; Bloomfield R; DiSilvestro P, 2019, 'Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): Phase III SOLO1 trial', Annals of Oncology, 30, pp. v405 - v405, http://dx.doi.org/10.1093/annonc/mdz250.003
    Journal articles | 2019
    Olawaiye AB; Java JJ; Krivak TC; Friedlander M; Mutch DG; Glaser G; Geller M; O'Malley DM; Wenham RM; Lee RB; Bodurka DC; Herzog TJ; Bookman MA, 2019, 'Corrigendum to “Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study” (Gynecologic Oncology (2018) 151(1) (18–23), (S0090825818310850) (10.1016/j.ygyno.2018.07.021))', Gynecologic Oncology, 152, pp. 220, http://dx.doi.org/10.1016/j.ygyno.2018.10.022
    Journal articles | 2019
    Terry MB; Liao Y; Whittemore AS; Leoce N; Buchsbaum R; Zeinomar N; Dite GS; Chung WK; Knight JA; Southey MC; Milne RL; Goldgar D; Giles GG; McLachlan SA; Friedlander ML; Weideman PC; Glendon G; Nesci S; Andrulis IL; John EM; Phillips KA; Daly MB; Buys SS; Hopper JL; MacInnis RJ, 2019, '10-year performance of four models of breast cancer risk: a validation study', The Lancet Oncology, 20, pp. 504 - 517, http://dx.doi.org/10.1016/S1470-2045(18)30902-1
    Journal articles | 2019
    2019, 'Alcohol consumption, cigarette smoking, and familial breast cancer risk: Findings from the Prospective Family Study Cohort (ProF-SC)', Breast Cancer Research, 21, http://dx.doi.org/10.1186/s13058-019-1213-1
    Journal articles | 2019
    2019, 'Balance deficits and functional disability in cancer survivors exposed to neurotoxic cancer treatments', JNCCN Journal of the National Comprehensive Cancer Network, 17, pp. 949 - 955, http://dx.doi.org/10.6004/jnccn.2019.7290
    Journal articles | 2019
    2019, 'Benign breast disease increases breast cancer risk independent of underlying familial risk profile: Findings from a Prospective Family Study Cohort', International Journal of Cancer, 145, pp. 370 - 379, http://dx.doi.org/10.1002/ijc.32112
    Journal articles | 2019
    2019, 'CART-WHEEL.org: An Ethically Approved Online Database for Patient-Entered Data to Facilitate Rare Cancer Research', JCO Clinical Cancer Informatics, 3, pp. 136 - 146, http://dx.doi.org/10.1200/CCI.19.00085
    Journal articles | 2019
    2019, 'Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy', European Journal of Cancer, 117, pp. 99 - 106, http://dx.doi.org/10.1016/j.ejca.2019.05.029
    Journal articles | 2019
    2019, 'Homologous recombination DNA repair defects in PALB2-associated breast cancers', npj Breast Cancer, 5, http://dx.doi.org/10.1038/s41523-019-0115-9
    Journal articles | 2019
    2019, 'Impact of radiological disease progression on the health status of patients (pts) with BRCA-mutated advanced ovarian cancer (OC) treated with maintenance olaparib (OL) or placebo (PL) after first-line platinum chemotherapy', Annals of Oncology, 30, pp. ix77 - ix78, http://dx.doi.org/10.1093/annonc/mdz426.001
    Journal articles | 2019
    2019, 'Nomogram for Predicting Individual Survival after Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma', Obstetrics and Gynecology, 133, pp. 245 - 254, http://dx.doi.org/10.1097/AOG.0000000000003086
    Journal articles | 2019
    2019, 'OVQUEST – Life after the diagnosis and treatment of ovarian cancer - An international survey of symptoms and concerns in ovarian cancer survivors', Gynecologic Oncology, 155, pp. 126 - 134, http://dx.doi.org/10.1016/j.ygyno.2019.08.009
    Journal articles | 2019
    2019, 'Optimizing Clinical Screening for Chemotherapy-Induced Peripheral Neuropathy', Journal of Pain and Symptom Management, 58, pp. 1023 - 1032, http://dx.doi.org/10.1016/j.jpainsymman.2019.07.021
    Journal articles | 2019
    2019, 'Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer', Gynecologic Oncology, 155, pp. 186 - 191, http://dx.doi.org/10.1016/j.ygyno.2019.08.024
    Journal articles | 2019
    2019, 'PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors', Gynecologic Oncology, 154, pp. 531 - 538, http://dx.doi.org/10.1016/j.ygyno.2019.06.011
    Journal articles | 2019
    2019, 'Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial', The Lancet Oncology, 20, pp. 1306 - 1315, http://dx.doi.org/10.1016/S1470-2045(19)30396-1
    Journal articles | 2019
    2019, 'Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)', Annals of Oncology, 30, pp. v405 - v406, http://dx.doi.org/10.1093/annonc/mdz250.004
    Journal articles | 2019
    2019, 'Publisher Correction: Homologous recombination DNA repair defects in PALB2-associated breast cancers (npj Breast Cancer, (2019), 5, 1, (23), 10.1038/s41523-019-0115-9)', npj Breast Cancer, 5, http://dx.doi.org/10.1038/s41523-019-0140-8
    Journal articles | 2019
    2019, 'Survival following chemotherapy in ovarian clear cell carcinoma is not associated with pathological misclassification of tumor histotype', Clinical Cancer Research, 25, pp. 3962 - 3973, http://dx.doi.org/10.1158/1078-0432.CCR-18-3691
    Journal articles | 2019
    2019, 'Validation of progression-free survival (PFS) as surrogate endpoint in randomised trials of immune checkpoint inhibitors in advanced solid cancers', Annals of Oncology, 30, pp. v520 - v520, http://dx.doi.org/10.1093/annonc/mdz253.103
    Journal articles | 2018
    Beesley VL; Smith DD; Nagle CM; Friedlander M; Grant P; DeFazio A; Webb PM, 2018, 'Coping strategies, trajectories, and their associations with patient-reported outcomes among women with ovarian cancer', Supportive Care in Cancer, 26, pp. 4133 - 4142, http://dx.doi.org/10.1007/s00520-018-4284-0
    Journal articles | 2018
    Berek JS; Kehoe ST; Kumar L; Friedlander M, 2018, 'Cancer of the ovary, fallopian tube, and peritoneum', International Journal of Gynecology and Obstetrics, 143, pp. 59 - 78, http://dx.doi.org/10.1002/ijgo.12614
    Journal articles | 2018
    Block MS; Vierkant RA; Rambau PF; Winham SJ; Wagner P; Traficante N; Toloczko A; Tiezzi DG; Taran FA; Sinn P; Sieh W; Sharma R; Rothstein JH; Ramón y Cajal T; Paz-Ares L; Oszurek O; Orsulic S; Ness RB; Nelson G; Modugno F; Menkiszak J; McGuire V; McCauley BM; Mack M; Lubinski J; Longacre TA; Li Z; Lester J; Kennedy CJ; Kalli KR; Jung AY; Johnatty SE; Jimenez-Linan M; Jensen A; Intermaggio MP; Hung J; Herpel E; Hernandez BY; Hartkopf AD; Harnett PR; Ghatage P; García-Bueno JM; Gao B; Fereday S; Eilber U; Edwards RP; de Sousa CB; de Andrade JM; Chudecka-Glaz A; Chenevix-Trench G; Cazorla A; Brucker SY; Bowtell DD; Green A; Webb P; de Fazio A; Gertig D; Moore S; Harrap K; Sadkowsky T; Pandeya N; Malt M; Mellon A; Robertson R; Vanden Bergh T; Jones M; Mackenzie P; Maidens J; Nattress K; Chiew YE; Stenlake A; Sullivan H; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Ferguson K; Martin K; Martyn A; Ranieri B; White J; Jayde V; Mamers P; Bowes L; Galletta L; Giles D; Hendley J; Alsop K; Schmidt T; Shirley H; Ball C; Young C; Viduka S; Tran H; Bilic S; Glavinas L; Brooks J; Stuart-Harris R, 2018, 'MyD88 and TLR4 Expression in Epithelial Ovarian Cancer', Mayo Clinic Proceedings, 93, pp. 307 - 320, http://dx.doi.org/10.1016/j.mayocp.2017.10.023
    Journal articles | 2018
    Deva S; Lee J-S; Lin C-C; Yen C-J; Millward M; Chao Y; Keam B; Jameson M; Hou M-M; Kang Y-K; Markman B; Lu C-H; Rau K-M; Lee K-H; Horvath L; Friedlander M; Hill A; Wu J; Hou J; Desai J, 2018, 'A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors', Annals of Oncology, 29, pp. x24 - x25, http://dx.doi.org/10.1093/annonc/mdy487.042
    Journal articles | 2018
    Friedlander M; Gebski V; Gibbs E; Davies L; Bloomfield R; Hilpert F; Wenzel LB; Eek D; Rodrigues M; Clamp A; Penson RT; Provencher D; Korach J; Huzarski T; Vidal L; Salutari V; Scott C; Nicoletto MO; Tamura K; Espinoza D; Joly F; Pujade-Lauraine E, 2018, 'Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial', The Lancet Oncology, 19, pp. 1126 - 1134, http://dx.doi.org/10.1016/S1470-2045(18)30343-7
    Journal articles | 2018
    Friedlander M; Matulonis U; Gourley C; du Bois A; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Shirinkin V; Selle F; Fielding A; Lowe ES; McMurtry EL; Spencer S; Rowe P; Mann H; Parry D; Ledermann J, 2018, 'Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy', British Journal of Cancer, 119, pp. 1075 - 1085, http://dx.doi.org/10.1038/s41416-018-0271-y
    Journal articles | 2018
    Friedlander M; Rau J; Lee CK; Meier W; Lesoin A; Kim JW; Poveda A; Buck M; Scambia G; Shimada M; Hilpert F; King MT; Debruyne P; Bologna A; Malander S; Monk BJ; Petru E; Calvert P; Herzog TJ; Barrett C; du Bois A, 2018, 'Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy', Annals of Oncology, 29, pp. 737 - 743, http://dx.doi.org/10.1093/annonc/mdx796
    Journal articles | 2018
    Garsed DW; Alsop K; Fereday S; Emmanuel C; Kennedy CJ; Etemadmoghadam D; Gao B; Gebski V; Gares V; Christie EL; Wouters MC A; Milne K; George J; Patch AM; Li J; Arnau GM; Semple T; Gadipally SR; Chiew YE; Hendley J; Mikeska T; Zapparoli GV; Amarasinghe K; Grimmond SM; Pearson JV; Waddell N; Hung J; Stewart C; Sharma R; Allan PE; Rambau PF; Traficante N; McNally O; Mileshkin L; Hamilton A; Ananda S; Grossi M; Cohen PA; Leung YC; Rome RM; Beale P; Blomfield P; Friedlander M; Brand A; Dobrovic A; Kobel M; Harnett P; Nelson BH; Bowtell DD L; DeFazio A, 2018, 'Homologous recombination DNA repair pathway disruption and retinoblastoma protein loss are associated with exceptional survival in high-grade serous ovarian cancer', Clinical Cancer Research, 24, pp. 569 - 580, http://dx.doi.org/10.1158/1078-0432.CCR-17-1621
    Journal articles | 2018
    Han HS; Diéras V; Robson M; Palácová M; Marcom PK; Jager A; Bondarenko I; Citrin D; Campone M; Telli ML; Domchek SM; Friedlander M; Kaufman B; Garber JE; Shparyk Y; Chmielowska E; Jakobsen EH; Kaklamani V; Gradishar W; Ratajczak CK; Nickner C; Qin Q; Qian J; Shepherd SP; Isakoff SJ; Puhalla S, 2018, 'Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: Randomized phase II study', Annals of Oncology, 29, pp. 154 - 161, http://dx.doi.org/10.1093/annonc/mdx505
    Journal articles | 2018
    Heinzelmann-Schwarz V; Knipprath Mészaros A; Stadlmann S; Jacob F; Schoetzau A; Russell K; Friedlander M; Singer G; Vetter M, 2018, 'Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients', Gynecologic Oncology, 148, pp. 79 - 85, http://dx.doi.org/10.1016/j.ygyno.2017.10.036
    Journal articles | 2018
    Hopper JL; Dite GS; MacInnis RJ; Liao Y; Zeinomar N; Knight JA; Southey MC; Milne RL; Chung WK; Giles GG; Genkinger JM; McLachlan SA; Friedlander ML; Antoniou AC; Weideman PC; Glendon G; Nesci S; Andrulis IL; Buys SS; Daly MB; John EM; Phillips KA; Terry MB, 2018, 'Age-specific breast cancer risk by body mass index and familial risk: Prospective family study cohort (ProF-SC)', Breast Cancer Research, 20, pp. 132, http://dx.doi.org/10.1186/s13058-018-1056-1
    Journal articles | 2018
    Joo JE; Dowty JG; Milne RL; Wong EM; Dugué PA; English D; Hopper JL; Goldgar DE; Giles GG; Southey MC; Sexton A; Christian A; Trainer A; Spigelman A; Fellows A; Shelling A; De Fazio A; Blackburn A; Crook A; Meiser B; Patterson B; Clarke C; Saunders C; Hunt C; Scott C; Amor D; Marsh D; Edkins E; Salisbury E; Haan E; Neidermayr E; Macrae F; Farshid G; Lindeman G; Chenevix-Trench G; Mann G; Gill G; Thorne H; Campbell I; Hickie I; Winship I; Goldblatt J; Flanagan J; Kollias J; Visvader J; Stone J; Taylor J; Burke J; Saunus J; Forbes J; Beesley J; Kirk J; French J; Tucker K; Wu K; Phillips K; Lipton L; Andrews L; Lobb E; Walker L; Kentwell M; Spurdle A; Cummings M; Gleeson M; Harris M; Jenkins M; Young MA; Delatycki M; Wallis M; Burgess M; Price M; Brown M; Bogwitz M; Field M; Friedlander M; Gattas M; Saleh M; Hayward N; Pachter N; Cohen P; Duijf P; James P; Simpson P; Fong P; Butow P; Williams R; Kefford R; Scott R; Balleine R; Dawson SJ; Lok S; O'Connell S; Greening S; Nightingale S; Edwards S; Fox S; McLachlan SA; Lakhani S; Thomas S; Antill Y, 2018, 'Heritable DNA methylation marks associated with susceptibility to breast cancer /631/67/69 /631/337/176/1988 /692/699/67/1347 /692/308/2056 /45 /45/61 article', Nature Communications, 9, http://dx.doi.org/10.1038/s41467-018-03058-6
    Journal articles | 2018
    King MT; Stockler MR; O’Connell RL; Buizen L; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Bryce J; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Sehouli J; Feeney A; Berton-Rigaud D; Costa DSJ; Friedlander ML, 2018, 'Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer', Quality of Life Research, 27, pp. 59 - 74, http://dx.doi.org/10.1007/s11136-017-1729-8
    Journal articles | 2018
    Kondrashova O; Topp M; Nesic K; Lieschke E; Ho GY; Harrell MI; Zapparoli GV; Hadley A; Holian R; Boehm E; Heong V; Sanij E; Pearson RB; Krais JJ; Johnson N; McNally O; Ananda S; Alsop K; Hutt KJ; Kaufmann SH; Lin KK; Harding TC; Traficante N; Chenevix-Trench G; Green A; Webb P; Gertig D; Fereday S; Moore S; Hung J; Harrap K; Sadkowsky T; Pandeya N; Malt M; Mellon A; Robertson R; Vanden Bergh T; Jones M; Mackenzie P; Maidens J; Nattress K; Chiew YE; Stenlake A; Sullivan H; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Ferguson K; Martin K; Martyn A; Ranieri B; White J; Jayde V; Mamers P; Bowes L; Galletta L; Giles D; Hendley J; Schmidt T; Shirley H; Ball C; Young C; Viduka S; Tran H; Bilic S; Glavinas L; Brooks J; Stuart-Harris R; Kirsten F; Rutovitz J; Clingan P; Glasgow A; Proietto A; Braye S; Otton G; Shannon J; Bonaventura T; Stewart J; Begbie S; Friedlander M; Bell D; Baron-Hay S; Ferrier A; Gard G; Nevell D; Pavlakis N; Valmadre S; Young B; Camaris C; Crouch R; Edwards L; Hacker N; Marsden D; Robertson G; Beale P; Beith J; Carter J, 2018, 'Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma', Nature Communications, 9, http://dx.doi.org/10.1038/s41467-018-05564-z
    Journal articles | 2018
    Loo CK C; Danieletto S; Friedlander M; Pearen MA; Ramm GA, 2018, 'Peritoneal hepatoid carcinoma with chemotherapy response and possible stem cell involvement', Human Pathology: Case Reports, 12, pp. 71 - 76, http://dx.doi.org/10.1016/j.ehpc.2018.02.008
    Journal articles | 2018
    Meagher NS; Schuster K; Voss A; Budden T; Pang CN I; deFazio A; Ramus SJ; Friedlander ML, 2018, 'Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials', Gynecologic Oncology, 150, pp. 527 - 533, http://dx.doi.org/10.1016/j.ygyno.2018.07.013
    Journal articles | 2018
    Moore K; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian C; Bradley W; Mathews C; Liu J; Lowe ES; Bloomfield R; DiSilvestro P, 2018, 'Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer', New England Journal of Medicine, 379, pp. 2495 - 2505, http://dx.doi.org/10.1056/NEJMoa1810858
    Journal articles | 2018
    Olawaiye AB; Java JJ; Krivak TC; Friedlander M; Mutch DG; Glaser G; Geller M; O'Malley DM; Wenham RM; Lee RB; Bodurka DC; Herzog TJ; Bookman MA, 2018, 'Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study', Gynecologic Oncology, 151, pp. 18 - 23, http://dx.doi.org/10.1016/j.ygyno.2018.07.021
    Journal articles | 2018
    Oskay-Özcelik G; Alavi S; Richter R; Keller M; Chekerov R; Cecere SC; Cormio G; Joly F; Kurtz JE; du Bois A; Maciejewski M; Jedryka M; Vergote I; Van Nieuwenhuysen E; Casado A; Mendiola C; Achimas-Cadariu P; Vlad C; Reimer D; Zeimet AG; Friedlander M; Sehouli J, 2018, 'Expression III: Patients' expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO/ ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries', Annals of Oncology, 29, pp. 910 - 916, http://dx.doi.org/10.1093/annonc/mdy037
    Journal articles | 2018
    Ritchie G; Gasper H; Man J; Lord S; Marschner I; Friedlander M; Lee CK, 2018, 'Defining the most appropriate primary end point in phase 2 trials of immune checkpoint inhibitors for advanced solid cancers a systematic review and meta-analysis', JAMA Oncology, 4, pp. 522 - 528, http://dx.doi.org/10.1001/jamaoncol.2017.5236
    Journal articles | 2018
    Roncolato FT; Berton-Rigaud D; O'Connell R; Lanceley A; Sehouli J; Buizen L; Okamoto A; Aotani E; Lorusso D; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Hilpert F; Ledermann JA; Kaminsky MC; Stockler MR; King MT; Friedlander M, 2018, 'Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) – Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS)', Gynecologic Oncology, 148, pp. 36 - 41, http://dx.doi.org/10.1016/j.ygyno.2017.10.019
    Journal articles | 2018
    Sandhu S; Hill A; Gan H; Friedlander M; Voskoboynik M; Barlow P; Townsend A; Song J; Zhang Y; Liang L; Desai J, 2018, 'Tislelizumab, an anti-PD-1 antibody, in patients with urothelial carcinoma (UC): Results from an ongoing phase I/II study', Annals of Oncology, 29, pp. x28 - x28, http://dx.doi.org/10.1093/annonc/mdy487.007
    Journal articles | 2018
    Schrijver LH; Olsson H; Phillips KA; Terry MB; Goldgar DE; Kast K; Engel C; Mooij TM; Adlard J; Barrowdale D; Davidson R; Eeles R; Ellis S; Evans DG; Frost D; Izatt L; Porteous ME; Side LE; Walker L; Berthet P; Bonadona V; Leroux D; Mouret-Fourme E; Venat-Bouvet L; Buys SS; Southey MC; John EM; Chung WK; Daly MB; Bane A; van Asperen CJ; Garcia EBG; Mourits MJE; Roos-Blom MJ; Friedlander ML; McLachlan SA; Singer CF; Foretova L; Gerdes AM; Caldes T; Olah E; Jakubowska A; Noguès C; Andrieu N; Easton DF; van Leeuwen FE; Hopper JL; Milne RL; Antoniou AC; Rookus MA; Laborde L; Pontois P; Stoppa-Lyonnet D; Gauthier-Villars M; Buecher B; Caron O; Fricker JP; Lasset C; Faivre L; Luporsi E; Frénay M; Gladieff L; Gesta P; Sobol H; Eisinger F; Moretta J; Longy M; Dugast C; Colas C; Soubrier F; Coupier I; Pujol P; Lortholary A; Vennin P; Adenis C; Nguyen TD; Delnatte C; Rossi A; Tinat J; Tennevet I; Limacher JM; Maugard C; Bignon YJ; Demange L; Dreyfus H; Cohen-Haguenauer O; Gilbert B; Zattara-Cannoni H, 2018, 'Oral contraceptive use and breast cancer risk: Retrospective and prospective analyses from a BRCA1 and BRCA2 mutation carrier cohort study', JNCI Cancer Spectrum, 2, http://dx.doi.org/10.1093/jncics/pky023
    Journal articles | 2018
    Sjoquist KM; Lord SJ; Friedlander ML; John Simes R; Marschner IC; Lee CK, 2018, 'Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis', Therapeutic Advances in Medical Oncology, 10, http://dx.doi.org/10.1177/1758835918788500
    Journal articles | 2018
    Sousa M; Peate M; Lewis C; Jarvis S; Willis A; Hickey M; Friedlander M, 2018, 'Exploring knowledge, attitudes and experience of genitourinary symptoms in women with early breast cancer on adjuvant endocrine therapy', European Journal of Cancer Care, 27, http://dx.doi.org/10.1111/ecc.12820
    Journal articles | 2018
    Wilson MK; Friedlander ML; Joly F; Oza AM, 2018, 'A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve', Oncologist, 23, pp. 203 - 213, http://dx.doi.org/10.1634/theoncologist.2017-0297
    Journal articles | 2018
    2018, 'A practical guide to understanding, using and including patient reported outcomes in clinical trials in ovarian cancer', Journal of Gynecologic Oncology, 29, pp. e81, http://dx.doi.org/10.3802/jgo.2018.29.e81
    Journal articles | 2018
    2018, 'Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial', Annals of oncology : official journal of the European Society for Medical Oncology, 29, pp. ix174 - ix175, http://dx.doi.org/10.1093/annonc/mdy483.002
    Journal articles | 2018
    2018, 'Medicare-funded cancer genetic tests: A note of caution clinicians need appropriate education and support in keeping pace with the genomics revolution', Medical Journal of Australia, 209, pp. 193 - 196.e1, http://dx.doi.org/10.5694/mja17.01124
    Journal articles | 2018
    2018, 'P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs).', Journal of Clinical Oncology, 36, pp. TPS4596 - TPS4596, http://dx.doi.org/10.1200/jco.2018.36.15_suppl.tps4596
    Journal articles | 2018
    2018, 'Practical considerations for clinicians for transitioning patients on maintenance therapy with olaparib capsules to the tablet formulation of olaparib', Asia-Pacific Journal of Clinical Oncology, 14, pp. 459 - 464, http://dx.doi.org/10.1111/ajco.13104
    Journal articles | 2018
    2018, 'The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations', JNCI Cancer Spectrum, 2, http://dx.doi.org/10.1093/JNCICS/PKY078
    Journal articles | 2018
    2018, 'The importance of patient-reported outcomes in clinical trials and strategies for future optimization', PATIENT-RELATED OUTCOME MEASURES, 9, pp. 353 - 367, http://dx.doi.org/10.2147/PROM.S156279
    Journal articles | 2018
    2018, 'The value of participating in clinical trials: The whole is greater than the sum of its parts', Medical Journal of Australia, 209, pp. 424 - 425, http://dx.doi.org/10.5694/mja17.01266
    Journal articles | 2018
    2018, 'Tumour profiling for treatment of patients with ovarian cancers', Pathology, 50, pp. S77 - S77, http://dx.doi.org/10.1016/j.pathol.2017.12.200
    Journal articles | 2017
    Bonaventura A; O'Connell RL; Mapagu C; Beale PJ; McNally OM; Mileshkin LR; Grant PT; Hadley AM; Goh JC H; Sjoquist KM; Martyn J; DeFazio A; Scurry J; Friedlander ML, 2017, 'Paragon (ANZGOG-0903): Phase 2 study of anastrozole in women with estrogen or progesterone receptorypositive platinum-resistant or -refractory recurrent ovarian cancer', International Journal of Gynecological Cancer, 27, pp. 900 - 906, http://dx.doi.org/10.1097/IGC.0000000000000978
    Journal articles | 2017
    Bookman MA; Okamoto A; Stuart G; Yanaihara N; Aoki D; Bacon M; Fujiwara K; González-Martín A; Harter P; Kim JW; Ledermann J; Pujade-Lauraine E; Quinn M; Ochiai K; Zeimet A; Marth C; du Bois A; Hilpert F; Pfisterer J; Reuss A; Friedlander M; Wilson MK; Kridelka F; Vergote I; Berek J; Dorigo O; Karam A; Bekkers RL M; Westermann A; Gatsonis C; Ng C; Herráez AC; Ottevanger N; Poveda A; Redondo A; Coleman R; Lu K; Gallardo-Rincón D; Gomez-Garcia E; Joly F; Leary A; Ray-Coquard I; Burger R; Moore KN; Fujiwara H; Hasegawa K; Gleeson N; Levy T; Rosengarten O; Katsumata N; Silverberg SG; Sugiyama T; Chang SJ; Kim BG; Nam BH; Colombo N; Ferrero A; Lorusso D; Scambia G; Edmondson R; McNeish I; Kohn E; Hirte H; McGee J; Provencher D; Sehouli J; Wimberger P; Maenpaa J; Mirza MR; Oza A; Welch S; Gaffney D; Small W; Glasspool R; Gourley C; Millan D; Zang R; Zhu J, 2017, 'Harmonising clinical trials within the Gynecologic Cancer InterGroup: Consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference', Annals of Oncology, 28, pp. viii30 - viii35, http://dx.doi.org/10.1093/annonc/mdx449
    Journal articles | 2017
    Coleman RL; Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Colombo N; Weberpals JI; Clamp A; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Garcia-Donas J; Swisher EM; Floquet A; Konecny GE; McNeish IA; Scott CL; Cameron T; Maloney L; Isaacson J; Goble S; Grace C; Harding TC; Raponi M; Sun J; Lin KK; Giordano H; Ledermann JA; Buck M; Dean A; Friedlander ML; Harnett P; Kichenadasse G; Denys H; Dirix L; Vergote I; Elit L; Ghatage P; Plante M; Provencher D; Welch S; Gladieff L; Joly F; Lortholary A; Lotz J; Medioni J; Tredan O; You B; El-Balat A; Hänle C; Krabisch P; Neunhöffer T; Pölcher M; Wimberger P; Amit A; Kovel S; Leviov M; Safra T; Shapira-Frommer R; Stemmer S; Bologna A; Pignata S; Sabbatini RF; Tamberi S; Zamagni C; O'Donnell A; Herraez AC; Guerra EM; Palacio I; Romero I; Sanchez A; Banerjee SN; Drew Y; Gabra HG; Jackson D; Parkinson C; Powell M; Birrer MJ; Buss MK; Chambers SK; Chen LM; Ma L; Morgan MA; Morris RT; Mutch DG; Slomovitz BM; Vanderkwaak T; Vulfovich M, 2017, 'Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial', The Lancet, 390, pp. 1949 - 1961, http://dx.doi.org/10.1016/S0140-6736(17)32440-6
    Journal articles | 2017
    Coleman RL; Oza AM; Lorusso D, 2017, 'Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial (vol 390, pg 1949, 2017)', LANCET, 390, pp. 1948 - 1948, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000413823200030&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Journal articles | 2017
    Gligorov J; Ataseven B; Verrill M; de Laurentiis M; Jung KH; Azim HA; Al-Sakaff N; Lauer S; Shing M; Pivot X; Koroveshi D; Bouzid K; Casalnuovo M; Cascallar D; Korbenfeld EP; Bastick P; Beith J; Colosimo M; Friedlander M; Ganju V; Green M; Patterson K; Redfern A; Richardson G; Ceric T; Gordana K; Beato CA; Ferrari M; Hegg R; Helena V; Ismael GF; Lessa AE; Mano M; Morelle A; Nogueira JA; Timcheva K; Tomova A; Tsakova M; Zlatareva-Petrova A; Asselah J; Assi H; Brezden-Masley C; Chia S; Freedman O; Harb M; Joy AA; Kulkarni S; Prady C; Gaete AA A; Matamala L; Torres R; Yanez E; Franco S; Urrego M; Gugić D; Vrbanec D; Melichar B; Prausová J; Vyzula R; Pilarte RG; León MI; Muñoz R; Ramos G; Azeem HA; Aziz AA; El Zawahry H; Osegueda FR; Alexandre J; Artignan X; Barletta H; Beguier E; Berdah JF; Marty CB; Bollet M; Bourgeois H; Bressac C; Burki F; Campone M; Coeffic D; Cojocarasu OZ; Dagada C; Dalenc F; Del Piano F; Desauw C; Desmoulins I; Dohollou N; Egreteau J; Ferrero JM; Foa C; Garidi R; Gasnault L; Guardiola E; Hamizi S; Jarcau R; Jacquin JP; Jaubert D; Jolimoy G; Mineur HL; Largillier R; Leduc B, 2017, 'Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients', European Journal of Cancer, 82, pp. 237 - 246, http://dx.doi.org/10.1016/j.ejca.2017.05.010
    Journal articles | 2017
    Gourley C; Friedlander M; Matulonis UA; Shirinkin V; Selle F; Scott CL; Safra T; Fielding A; Rowe P; Ledermann JA, 2017, 'Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).', Journal of Clinical Oncology, 35, pp. 5533 - 5533, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.5533
    Journal articles | 2017
    Hettle R; Sackeyfio A; Gill J; Siddiqui K; Nussey F; Friedlander M, 2017, 'Comparative Efficacy And Safety Of Olaparib 300 Mg Tablets Bid And Niraparib 300 Mg Tablets QD As Maintenance Treatment After Response To Chemotherapy In Patients With Platinum-Sensitive Relapsed Germline BRCA-Mutated Ovarian Cancer (PSROC)', Value in Health, 20, pp. A412 - A412, http://dx.doi.org/10.1016/j.jval.2017.08.088
    Journal articles | 2017
    Isakoff SJ; Puhalla S; Domchek SM; Friedlander M; Kaufman B; Robson M; Telli ML; Diéras V; Han HS; Garber JE; Johnson EF; Maag D; Qin Q; Giranda VL; Shepherd SP, 2017, 'A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: Design and rationale', Future Oncology, 13, pp. 307 - 320, http://dx.doi.org/10.2217/fon-2016-0412
    Journal articles | 2017
    Kondrashova O; Nguyen M; Shield-Artin K; Tinker AV; Teng NNH; Harrell MI; Kuiper MJ; Ho GY; Barker H; Jasin M; Prakash R; Kass EM; Sullivan MR; Brunette GJ; Bernstein KA; Coleman RL; Floquet A; Friedlander M; Kichenadasse G; O’Malley DM; Oza A; Sun J; Robillard L; Maloney L; Bowtell D; Giordano H; Wakefield MJ; Kaufmann SH; Simmons AD; Harding TC; Raponi M; McNeish IA; Swisher EM; Lin KK; Scott CL, 2017, 'Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma', Cancer Discovery, 7, pp. 984 - 998, http://dx.doi.org/10.1158/2159-8290.CD-17-0419
    Journal articles | 2017
    Kuchenbaecker KB; Hopper JL; Barnes DR; Phillips K-A; Mooij TM; Roos-Blom M-J; Jervis S; van Leeuwen FE; Milne RL; Andrieu N; Goldgar DE; Terry MB; Rookus MA; Easton DF; Antoniou AC, 2017, 'Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers', JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 317, pp. 2402 - 2416, http://dx.doi.org/10.1001/jama.2017.7112
    Journal articles | 2017
    Lee YC; Bressel M; Grant P; Russell P; Smith C; Picken S; Camm S; Kiely BE; Milne RL; McLachlan SA; Hickey M; Friedlander ML; Hopper JL; Phillips KA, 2017, 'Improved quality of risk-reducing salpingo-oophorectomy in Australasian women at high risk of pelvic serous cancer', Familial Cancer, 16, pp. 461 - 469, http://dx.doi.org/10.1007/s10689-017-9977-x
    Journal articles | 2017
    Lee YC; Milne RL; Lheureux S; Friedlander M; McLachlan SA; Martin KL; Bernardini MQ; Smith C; Picken S; Nesci S; Hopper JL; Phillips KA, 2017, 'Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers', European Journal of Cancer, 84, pp. 114 - 120, http://dx.doi.org/10.1016/j.ejca.2017.07.004
    Journal articles | 2017
    Mai PL; Piedmonte M; Han PK; Moser RP; Walker JL; Rodriguez G; Boggess J; Rutherford TJ; Zivanovic O; Cohn DE; Thigpen JT; Wenham RM; Friedlander ML; Hamilton CA; Bakkum-Gamez J; Olawaiye AB; Hensley ML; Greene MH; Huang HQ; Wenzel L, 2017, 'Factors Associated with Deciding between Risk-Reducing Salpingo-oophorectomy and Ovarian Cancer Screening among High-Risk Women Enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group Study', Obstetrical and Gynecological Survey, 72, pp. 336 - 337, http://dx.doi.org/10.1097/OGX.0000000000000451
    Journal articles | 2017
    Park SB; Kwok JB; Asher R; Lee CK; Beale P; Selle F; Friedlander M, 2017, 'Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinicianreported incidence and severity of neurotoxicity in the ICON7 trial', Annals of Oncology, 28, pp. 2733 - 2740, http://dx.doi.org/10.1093/annonc/mdx491
    Journal articles | 2017
    Pickett JL; Chou A; Andrici JA; Clarkson A; Sioson L; Sheen A; Reagh J; Najdawi F; Kim Y; Riley D; Maidens J; Nevell D; McIlroy K; Valmadre S; Gard G; Hogg R; Turchini J; Robertson G; Friedlander M; Gill AJ, 2017, 'Inflammatory Myofibroblastic Tumors of the Female Genital Tract Are Under-recognized: A Low Threshold for ALK Immunohistochemistry Is Required', American Journal of Surgical Pathology, 41, pp. 1433 - 1442, http://dx.doi.org/10.1097/PAS.0000000000000909
    Journal articles | 2017
    Pujade-Lauraine E; Ledermann JA; Selle F; Gebski V; Penson RT; Oza AM; Korach J; Huzarski T; Poveda A; Pignata S; Friedlander M; Colombo N; Harter P; Fujiwara K; Ray-Coquard IL; Banerjee S; Liu J; Lowe ES; Bloomfield R; Pautier P; Byrski T; Colombo N; Scambia G; Nicoletto M; Nussey F; Clamp A; Penson R; Poveda Velasco A; Rodrigues M; Lotz JP; Provencher D; Prat Aparicio A; Vidal Boixader L; Scott C; Tamura K; Yunokawa M; Lisyanskaya A; Medioni J; Pécuchet N; Dubot C; de la Motte Rouge T; Kaminsky MC; Weber B; Lortholary A; Parkinson C; Williams S; Banerjee S; Cosin J; Hoffman J; Plante M; Covens A; Sonke G; Joly F; Floquet A; Hirte H; Amit A; Park-Simon TW; Matsumoto K; Tjulandin S; Kim JH; Gladieff L; Sabbatini R; O'Malley D; Timmins P; Kredentser D; Laínez Milagro N; Barretina Ginesta MP; Tibau Martorell A; Gómez de Liaño Lista A; Ojeda González B; Mileshkin L; Mandai M; Boere I; Ottevanger P; Nam JH; Filho E; Hamizi S; Cognetti F; Warshal D; Dickson-Michelson E; Kamelle S; McKenzie N; Rodriguez G; Armstrong D; Chalas E; Celano P; Behbakht K; Davidson S; Welch S; Helpman L; Fishman A; Bruchim I, 2017, 'Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial', The Lancet Oncology, 18, pp. 1274 - 1284, http://dx.doi.org/10.1016/S1470-2045(17)30469-2
    Journal articles | 2017
    Rafii S; Gourley C; Kumar R; Geuna E; Ang JE; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Rhoda Molife L; Gore ME; Kaye SB; Yap TA, 2017, 'Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer', Oncotarget, 8, pp. 47154 - 47160, http://dx.doi.org/10.18632/oncotarget.17005
    Journal articles | 2017
    Rodgers RJ; Reid GD; Koch J; Deans R; Ledger WL; Friedlander M; Gilchrist RB; Walters KA; Abbott JA, 2017, 'The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: A systematic review', Human Reproduction, 32, pp. 1033 - 1045, http://dx.doi.org/10.1093/humrep/dex027
    Journal articles | 2017
    Roncolato FT; Gibbs E; Lee CK; Asher R; Davies LC; Gebski VJ; Friedlander M; Hilpert F; Wenzel L; Stockler MR; King M; Pujade-Lauraine E, 2017, 'Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: An AURELIA substudy', Annals of Oncology, 28, pp. 1849 - 1855, http://dx.doi.org/10.1093/annonc/mdx229
    Journal articles | 2017
    Roncolato FT; Joly F; O’Connell R; Lanceley A; Hilpert F; Buizen L; Okamoto A; Aotani E; Pignata S; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Heitz F; Feeney A; Berton-Rigaud D; Stockler MR; King M; Friedlander M, 2017, 'Reducing uncertainty: Predictors of stopping chemotherapy early and shortened survival time in platinum resistant/refractory ovarian cancer—The GCIG symptombenefit study', Oncologist, 22, pp. 1117 - 1124, http://dx.doi.org/10.1634/theoncologist.2017-0047
    Journal articles | 2017
    Rungruang BJ; Miller A; Krivak TC; Horowitz NS; Rodriguez N; Hamilton CA; Backes FJ; Carson LF; Friedlander M; Mutch DG; Goodheart MJ; Tewari KS; Wenham RM; Bookman MA; Maxwell GL; Richard SD, 2017, 'What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study', Cancer, 123, pp. 985 - 993, http://dx.doi.org/10.1002/cncr.30414
    Journal articles | 2017
    Sackeyfio A; Gill J; Hettle R; Siddiqui K; Friedlander M; Ledermann JA, 2017, 'Comparative Efficacy And Safety of Olaparib 400 Mg Capsules Bid And Niraparib 300 Mg Tablets QD As Maintenance Treatment After Response To Chemotherapy In Patients with Platinum-Sensitive Relapsed Non-Germline BRCA-Mutated Ovarian Cancer (PSROC)', Value in Health, 20, pp. A412 - A412, http://dx.doi.org/10.1016/j.jval.2017.08.087
    Journal articles | 2017
    Samimi G; Caga-Anan CF; Dean M; Mechanic LE; Minasian LM; Sherman ME; Brody LC; Bernardini MQ; Lheureux S; Shaw PA; Kwon JS; Campbell IG; James PA; Takenaka M; Bowtell DD; Chenevix-Trench G; Friedlander M; Ramus SJ; Couch FJ; De Hullu JA; Harmsen MG; Domchek SM; Drapkin R; Mai PL; Feigelson HS; Gaudet MM; Hurley K; Robson ME; Lacbawan F; Slavin TP; Myers ER; Rezende LF; Swisher EM, 2017, 'Traceback: A proposed framework to increase identification and genetic counseling of BRCA1 and BRCA2 mutation carriers through family-based outreach', Journal of Clinical Oncology, 35, pp. 2329 - 2337, http://dx.doi.org/10.1200/JCO.2016.70.3439
    Journal articles | 2017
    Sandler CX; Goldstein D; Horsfield S; Bennett BK; Friedlander M; Bastick PA; Lewis CR; segelov E; Boyle FM; Chin MT; webber K; Barry BK; Lloyd AR, 2017, 'Randomized evaluation of cognitive-behavioral therapy and graded exercise therapy for post-cancer fatigue.', Journal of Pain and Symptom Management, 54, pp. 74 - 84, http://dx.doi.org/10.1016/j.jpainsymman.2017.03.015
    Journal articles | 2017
    Scerri TS; Quaglieri A; Cai C; Zernant J; Matsunami N; Baird L; Scheppke L; Bonelli R; Yannuzzi LA; Friedlander M; MacTel Project Consortium ; Egan CA; Fruttiger M; Leppert M; Allikmets R; Bahlo M, 2017, 'Genome-wide analyses identify common variants associated with macular telangiectasia type 2.', Nat Genet, 49, pp. 559 - 567, http://dx.doi.org/10.1038/ng.3799
    Journal articles | 2017
    Sousa MS; Peate M; Jarvis S; Hickey M; Friedlander M, 2017, 'A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy', Therapeutic Advances in Medical Oncology, 9, pp. 269 - 285, http://dx.doi.org/10.1177/1758834016687260
    Journal articles | 2017
    Webber K; Friedlander M, 2017, 'Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer', Best Practice and Research: Clinical Obstetrics and Gynaecology, 41, pp. 126 - 138, http://dx.doi.org/10.1016/j.bpobgyn.2016.11.004
    Journal articles | 2017
    Wilson MK; Friedlander ML; Lheureux S; Small W; Poveda A; Pujade-Lauraine E; Karakasis K; Bacon M; Bowering V; Chawla T; Oza AM, 2017, 'Resisting RECISTV uniformity versus clinical validity', International Journal of Gynecological Cancer, 27, pp. 1619 - 1627, http://dx.doi.org/10.1097/IGC.0000000000001062
    Journal articles | 2017
    Wilson MK; Pujade-Lauraine E; Aoki D; Mirza MR; Lorusso D; Oza AM; du Bois A; Vergote I; Reuss A; Bacon M; Friedlander M; Gallardo-Rincon D; Joly F; Chang SJ; Ferrero AM; Edmondson RJ; Wimberger P; Maenpaa J; Gaffney D; Zang R; Okamoto A; Stuart G; Ochiai K, 2017, 'Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: Recurrent disease', Annals of Oncology, 28, pp. 727 - 732, http://dx.doi.org/10.1093/annonc/mdw663
    Journal articles | 2017
    2017, 'A systematic evaluation of compliance and reporting of patient-reported outcome endpoints in ovarian cancer randomised controlled trials: Implications for generalisability and clinical practice', Journal of Patient-Reported Outcomes, 1, http://dx.doi.org/10.1186/s41687-017-0008-3
    Journal articles | 2017
    2017, 'Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: Phase III SOLO2 trial (ENGOT Ov-21)', Annals of Oncology, 28, pp. v331 - v331, http://dx.doi.org/10.1093/annonc/mdx372.002
    Journal articles | 2017
    2017, 'Erratum to: The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols (Quality of Life Research, (2016), 25, 10, (2457-2465), 10.1007/s11136-016-1339-x)', Quality of Life Research, 26, pp. 2249 - 2250, http://dx.doi.org/10.1007/s11136-017-1578-5
    Journal articles | 2017
    2017, 'Factors Associated With Deciding Between Risk-Reducing Salpingo-oophorectomy and Ovarian Cancer Screening Among High-Risk Women Enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group Study', Obstetrical & Gynecological Survey, 72, pp. 336 - 337, http://dx.doi.org/10.1097/ogx.0000000000000451
    Journal articles | 2017
    2017, 'Is objective response rate (ORR) a valid primary endpoint in phase 2 trials (Ph2t) of immune checkpoint inhibitors (ICI) for advanced solid cancers?', Annals of Oncology, 28, pp. v411 - v411, http://dx.doi.org/10.1093/annonc/mdx376.023
    Journal articles | 2017
    2017, 'Phase I study of olaparib (O), in combination with oral cyclophosphamide (C), in patients (pts) with metastatic triple negative breast cancer (TNBC) and recurrent high grade serous ovarian cancer (OVCA).', Journal of Clinical Oncology, 35, pp. 1104 - 1104, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.1104
    Journal articles | 2017
    2017, 'Preliminary results from a subset of patients (pts) with advanced ovarian cancer (OC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb)', Annals of Oncology, 28, pp. v130 - v130, http://dx.doi.org/10.1093/annonc/mdx367.023
    Journal articles | 2016
    Anuradha S; Donovan PJ; Webb PM; Brand AH; Goh J; Friedlander M; Oehler MK; Quinn M; Steer C; Jordan SJ, 2016, 'Variations in adjuvant chemotherapy and survival in women with epithelial ovarian cancer - A population-based study', Acta Oncologica, 55, pp. 226 - 233, http://dx.doi.org/10.3109/0284186X.2015.1054950
    Journal articles | 2016
    Domchek SM; Aghajanian C; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmaña J; Mitchell G; Fried G; Stemmer SM; Hubert A; Rosengarten O; Loman N; Robertson JD; Mann H; Kaufman B, 2016, 'Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy', Gynecologic Oncology, 140, pp. 199 - 203, http://dx.doi.org/10.1016/j.ygyno.2015.12.020
    Journal articles | 2016
    Ferraro D; Goldstein D; O'Connell RL; Zalcberg JR; Sjoquist KM; Tebbutt NC; Grimison P; McLachlan S; Lipton LL; Vasey P; Gebski VJ; Aiken C; Cronk M; Ng S; Karapetis CS; Shannon J; Do V; Marschner I; Friedlander M; Gurney H; Simes J; Hague W; O’Connell R; Gorzeman M; Pike R; Miranda K; Waring P; Lau D; Fox S; Liu Y; Wood T; Cocks C; Simmons K; McCourt J; Jefford M; Hobinchet A; Mirco B; Sagong J; Dudukovic S; Aghmesheh M; Parker S; Segelov E; Ratnayake L; Ranieri N; Varma S; Page J; Heyer E; Abdi E; Chorlton C; Wilkinson L; Marshall I, 2016, 'TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer', Cancer Chemotherapy and Pharmacology, 78, pp. 361 - 367, http://dx.doi.org/10.1007/s00280-016-3089-4
    Journal articles | 2016
    Friedlander M; Banerjee S; Mileshkin L; Scott C; Shannon C; Goh J, 2016, 'Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer', Asia-Pacific Journal of Clinical Oncology, 12, pp. 323 - 331, http://dx.doi.org/10.1111/ajco.12636
    Journal articles | 2016
    Friedlander M; Mercieca-Bebber RL; King MT, 2016, 'Patient-reported outcomes (PRO) in ovarian cancer clinical trials-lost opportunities and lessons learned', Annals of Oncology, 27, pp. i66 - i71, http://dx.doi.org/10.1093/annonc/mdw080
    Journal articles | 2016
    Friedlander ML; Russell K; Millis S; Gatalica Z; Bender R; Voss A, 2016, 'Molecular profiling of clear cell ovarian cancers: Identifying potential treatment targets for clinical trials', International Journal of Gynecological Cancer, 26, pp. 648 - 654, http://dx.doi.org/10.1097/IGC.0000000000000677
    Journal articles | 2016
    Harter P; Johnson T; Berton-Rigaud D; Park SY; Friedlander M; Del Campo JM; Shimada M; Forget F; Mirza MR; Colombo N; Zamagni C; Chan JK; Imhof M; Herzog TJ; O'Donnell D; Heitz F; King K; Stinnett S; Barrett C; Jobanputra M; Xu CF; Du Bois A, 2016, 'BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study', Gynecologic Oncology, 140, pp. 443 - 449, http://dx.doi.org/10.1016/j.ygyno.2015.12.027
    Journal articles | 2016
    Herzog TJ; Spetzler D; Xiao N; Burnett K; Maney T; Voss A; Reddy S; Burger R; Krivak T; Powell M; Friedlander M; McGuire W, 2016, 'Impact of molecular profiling on overall survival of patients with advanced ovarian cancer', Oncotarget, 7, pp. 19840 - 19849, http://dx.doi.org/10.18632/oncotarget.7835
    Journal articles | 2016
    Lawrence N; Martin A; Toner G; Stockler M; Buizen L; Thomson D; Gebski V; Friedlander M; Yeung A; Wong N; Gurney H; Rosenthal M; Singhal N; Kichenadasse G; Wong S; Lewis C; Vasey P; Grimison P, 2016, 'Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)', Annals of Oncology, 27, pp. 2302 - 2303, http://dx.doi.org/10.1093/annonc/mdw313
    Journal articles | 2016
    Ledermann JA; Embleton AC; Raja F; Perren TJ; Jayson GC; Rustin GJS; Kaye SB; Hirte H; Eisenhauer E; Vaughan M; Friedlander M; González-Martín A; Stark D; Clark E; Farrelly L; Swart AM; Cook A; Kaplan RS; Parmar MKB, 2016, 'Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): A randomised, double-blind, placebo-controlled phase 3 trial', The Lancet, 387, pp. 1066 - 1074, http://dx.doi.org/10.1016/S0140-6736(15)01167-8
    Journal articles | 2016
    Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Bennett B; Parry D; Spencer S; Mann H; Matulonis U, 2016, 'Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer', British Journal of Cancer, 115, pp. 1313 - 1320, http://dx.doi.org/10.1038/bjc.2016.348
    Journal articles | 2016
    Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U, 2016, 'Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial', The Lancet Oncology, 17, pp. 1579 - 1589, http://dx.doi.org/10.1016/S1470-2045(16)30376-X
    Journal articles | 2016
    Lehane C; Ho F; Thompson SR; Links D; Lewis C; Smee R; Parasyn A; Friedlander M; Williams J; Crowe P, 2016, 'Neoadjuvant chemoradiation (modified Eilber protocol) versus adjuvant radiotherapy in the treatment of extremity soft tissue sarcoma', Journal of Medical Imaging and Radiation Oncology, 60, pp. 539 - 544, http://dx.doi.org/10.1111/1754-9485.12442
    Journal articles | 2016
    Lundqvist A; van Hoef V; Zhang X; Wennerberg E; Lorent J; Witt K; Sanz LM; Liang S; Murray S; Larsson O; Kiessling R; Mao Y; Sidhom J-W; Bessell CA; Havel J; Schneck J; Chan TA; Sachsenmeier E; Woods D; Berglund A; Ramakrishnan R; Sodre A; Weber J; Zappasodi R; Li Y; Qi J; Wong P; Sirard C; Postow M; Newman W; Koon H; Velcheti V; Callahan MK; Wolchok JD; Merghoub T; Lum LG; Choi M; Thakur A; Deol A; Dyson G; Shields A; Haymaker C; Uemura M; Murthy R; James M; Wang D; Brevard J; Monaghan C; Swann S; Geib J; Cornfeld M; Chunduru S; Agrawal S; Yee C; Wargo J; Patel SP; Amaria R; Tawbi H; Glitza I; Woodman S; Hwu W-J; Davies MA; Hwu P; Overwijk WW; Bernatchez C; Diab A; Massarelli E; Segal NH; Ribrag V; Melero I; Gangadhar TC; Urba W; Schadendorf D; Ferris RL; Houot R; Morschhauser F; Logan T; Luke JJ; Sharfman W; Barlesi F; Ott PA; Mansi L; Kummar S; Salles G; Carpio C; Meier R; Krishnan S; McDonald D; Maurer M; Gu X; Neely J; Suryawanshi S; Levy R; Khushalani N; Wu J; Zhang J; Basher F; Rubinstein M; Bucsek M; Qiao G; MacDonald C; Hylander B; Repasky E; Chatterjee S; Daenthanasanmak A; Chakraborty P; Toth K; Meek M; Garrett-Mayer E; Nishimura M; Paulos C; Beeson C; Yu X; Mehrotra S; Zhao F; Evans K; Xiao C; Holtzhausen A; Hanks BA; Scharping N; Menk AV; Moreci R; Whetstone R; Dadey R; Watkins S; Ferris R; Delgoffe GM; Peled J; Devlin S; Staffas A; Lumish M; Rodriguez KP; Ahr K; Perales M; Giralt S; Taur Y; Pamer E; van den Brink MRM; Jenq R; Annels N; Pandha H; Simpson G; Mostafid H; Harrington K; Melcher A; Grose M; Davies B; Au G; Karpathy R; Shafren D; Ricca J; Merghoub T; Wolchok JD; Zamarin D; Batista L; Marliot F; Vasaturo A; Carpentier S; Poggionovo C; Frayssinet V; Fieschi J; Van den Eynde M; Pagès F; Galon J; Hermitte F; Smith SG; Nguyen K; Ravindranathan S; Koppolu B; Zaharoff D; Schvartsman G; Bassett R; McQuade JL; Haydu LE; Davies MA; Tawbi H; Glitza I; Kline D; Chen X; Fosco D; Kline J; Overacre A; Chikina M; Brunazzi E; Shayan G; Horne W; Kolls J; Ferris RL; Delgoffe GM; Bruno TC; Workman C; Vignali D; Adusumilli PS; Ansa-Addo EA; Li Z; Gerry A; Sanderson JP; Howe K; Docta R; Gao Q; Bagg EAL; Tribble N; Maroto M; Betts G; Bath N; Melchiori L; Lowther DE; Ramachandran I; Kari G; Basu S; Binder-Scholl G; Chagin K; Pandite L; Holdich T; Amado R; Zhang H; Glod J; Bernstein D; Jakobsen B; Mackall C; Wong R; Silk JD; Adams K; Hamilton G; Bennett AD; Brett S; Jing J; Quattrini A; Saini M; Wiedermann G; Gerry A; Jakobsen B; Binder-Scholl G; Brewer J; Duong M; Lu A; Chang P; Mahendravada A; Shinners N; Slawin K; Spencer DM; Foster AE; Bayle JH; Bergamaschi C; Ng SSM; Nagy B; Jensen S; Hu X; Alicea C; Fox B; Felber B; Pavlakis G; Chacon J; Yamamoto T; Garrabrant T; Cortina L; Powell DJ; Donia M; Kjeldsen JW; Andersen R; Westergaard MCW; Bianchi V; Legut M; Attaf M; Dolton G; Szomolay B; Ott S; Lyngaa R; Hadrup SR; Sewell AK; Svane IM; Fan A; Kumai T; Celis E; Frank I; Stramer A; Blaskovich MA; Wardell S; Fardis M; Bender J; Lotze MT; Goff SL; Zacharakis N; Assadipour Y; Prickett TD; Gartner JJ; Somerville R; Black M; Xu H; Chinnasamy H; Kriley I; Lu L; Wunderlich J; Robbins PF; Rosenberg S; Feldman SA; Trebska-McGowan K; Kriley I; Malekzadeh P; Payabyab E; Sherry R; Rosenberg S; Goff SL; Gokuldass A; Blaskovich MA; Kopits C; Rabinovich B; Lotze MT; Green DS; Kamenyeva O; Zoon KC; Annunziata CM; Hammill J; Helsen C; Aarts C; Bramson J; Harada Y; Yonemitsu Y; Helsen C; Hammill J; Mwawasi K; Denisova G; Bramson J; Giri R; Jin B; Campbell T; Draper LM; Stevanovic S; Yu Z; Weissbrich B; Restifo NP; Trimble CL; Rosenberg S; Hinrichs CS; Tsang K; Fantini M; Hodge JW; Fujii R; Fernando I; Jochems C; Heery C; Gulley J; Soon-Shiong P; Schlom J; Jing W; Gershan J; Blitzer G; Weber J; McOlash L; Johnson BD; Kiany S; Gangxiong H; Kleinerman ES; Klichinsky M; Ruella M; Shestova O; Kenderian S; Kim M; Scholler J; June CH; Gill S; Moogk D; Zhong S; Yu Z; Liadi I; Rittase W; Fang V; Dougherty J; Perez-Garcia A; Osman I; Zhu C; Varadarajan N; Restifo NP; Frey A; Krogsgaard M; Landi D; Fousek K; Mukherjee M; Shree A; Joseph S; Bielamowicz K; Byrd T; Ahmed N; Hegde M; Lee S; Byrd D; Thompson J; Bhatia S; Tykodi S; Delismon J; Chu L; Abdul-Alim S; Ohanian A; DeVito AM; Riddell S; Margolin K; Magalhaes I; Mattsson J; Uhlin M; Nemoto S; Villarroel PP; Nakagawa R; Mule JJ; Mailloux AW; Mata M; Nguyen P; Gerken C; DeRenzo C; Spencer DM; Gottschalk S; Mathieu M; Pelletier S; Stagg J; Turcotte S; Minutolo N; Sharma P; Tsourkas A; Powell DJ; Mockel-Tenbrinck N; Mauer D; Drechsel K; Barth C; Freese K; Kolrep U; Schult S; Assenmacher M; Kaiser A; Mullinax J; Hall M; Le J; Kodumudi K; Royster E; Richards A; Gonzalez R; Sarnaik A; Pilon-Thomas S; Nielsen M; Krarup-Hansen A; Hovgaard D; Petersen MM; Loya AC; Junker N; Svane IM; Rivas C; Parihar R; Gottschalk S; Rooney CM; Qin H; Nguyen S; Su P; Burk C; Duncan B; Kim B-H; Kohler ME; Fry T; Rao AA; Teyssier N; Pfeil J; Sgourakis N; Salama S; Haussler D; Richman SA; Nunez-Cruz S; Gershenson Z; Mourelatos Z; Barrett D; Grupp S; Milone M; Rodriguez-Garcia A; Robinson MK; Adams GP; Powell DJ; Santos J; Havunen R; Siurala M; Cervera-Carrascón V; Parviainen S; Antilla M; Hemminki A; Sethuraman J; Santiago L; Chen JQ; Dai Z; Wardell S; Bender J; Lotze MT; Sha H; Su S; Ding N; Liu B; Stevanovic S; Pasetto A; Helman SR; Gartner JJ; Prickett TD; Robbins PF; Rosenberg SA; Hinrichs CS; Bhatia S; Burgess M; Zhang H; Lee T; Klingemann H; Soon-Shiong P; Nghiem P; Kirkwood JM; Rossi JM; Sherman M; Xue A; Shen Y-W; Navale L; Rosenberg SA; Kochenderfer JN; Bot A; Veerapathran A; Gokuldass A; Stramer A; Sethuraman J; Blaskovich MA; Wiener D; Frank I; Santiago L; Rabinovich B; Fardis M; Bender J; Lotze MT; Waller EK; Li J-M; Petersen C; Blazar BR; Li J; Giver CR; Wang Z; Grossenbacher SK; Sturgill I; Canter RJ; Murphy WJ; Zhang C; Burger MC; Jennewein L; Waldmann A; Mittelbronn M; Tonn T; Steinbach JP; Wels WS; Williams JB; Zha Y; Gajewski TF; Williams LC; Krenciute G; Kalra M; Louis C; Gottschalk S; Xin G; Schauder D; Jiang A; Joshi N; Cui W; Zeng X; Menk AV; Scharping N; Delgoffe GM; Zhao Z; Hamieh M; Eyquem J; Gunset G; Bander N; Sadelain M; Askmyr D; Abolhalaj M; Lundberg K; Greiff L; Lindstedt M; Angell HK; Kim K-M; Kim S-T; Kim S; Sharpe AD; Ogden J; Davenport A; Hodgson DR; Barrett C; Lee J; Kilgour E; Hanson J; Caspell R; Karulin A; Lehmann P; Ansari T; Schiller A; Sundararaman S; Lehmann P; Hanson J; Roen D; Karulin A; Lehmann P; Ayers M; Levitan D; Arreaza G; Liu F; Mogg R; Bang Y-J; O’Neil B; Cristescu R; Friedlander P; Wassman K; Kyi C; Oh W; Bhardwaj N; Bornschlegl S; Gustafson MP; Gastineau DA; Parney IF; Dietz AB; Carvajal-Hausdorf D; Mani N; Velcheti V; Schalper K; Rimm D; Chang S; Levy R; Kurland J; Krishnan S; Ahlers CM; Jure-Kunkel M; Cohen L; Maecker H; Kohrt H; Chen S; Crabill G; Pritchard T; McMiller T; Pardoll D; Pan F; Topalian S; Danaher P; Warren S; Dennis L; White AM; D’Amico L; Geller M; Disis ML; Beechem J; Odunsi K; Fling S; Derakhshandeh R; Webb TJ; Dubois S; Conlon K; Bryant B; Hsu J; Beltran N; Müller J; Waldmann T; Duhen R; Duhen T; Thompson L; Montler R; Weinberg A; Kates M; Early B; Yusko E; Schreiber TH; Bivalacqua TJ; Ayers M; Lunceford J; Nebozhyn M; Murphy E; Loboda A; Kaufman DR; Albright A; Cheng J; Kang SP; Shankaran V; Piha-Paul SA; Yearley J; Seiwert T; Ribas A; McClanahan TK; Cristescu R; Mogg R; Ayers M; Albright A; Murphy E; Yearley J; Sher X; Liu XQ; Nebozhyn M; Lunceford J; Joe A; Cheng J; Plimack E; Ott PA; McClanahan TK; Loboda A; Kaufman DR; Forrest-Hay A; Guyre CA; Narumiya K; Delcommenne M; Hirsch HA; Deshpande A; Reeves J; Shu J; Zi T; Michaelson J; Law D; Trehu E; Sathyanaryanan S; Hodkinson BP; Hutnick NA; Schaffer ME; Gormley M; Hulett T; Jensen S; Ballesteros-Merino C; Dubay C; Afentoulis M; Reddy A; David L; Fox B; Jayant K; Agrawal S; Agrawal R; Jeyakumar G; Kim S; Kim H; Silski C; Suisham S; Heath E; Vaishampayan U; Vandeven N; Viller NN; O’Connor A; Chen H; Bossen B; Sievers E; Uger R; Nghiem P; Johnson L; Kao H-F; Hsiao C-F; Lai S-C; Wang C-W; Ko J-Y; Lou P-J; Lee T-J; Liu T-W; Hong R-L; Kearney SJ; Black JC; Landis BJ; Koegler S; Hirsch B; Gianani R; Kim J; He M-X; Zhang B; Su N; Luo Y; Ma X-J; Park E; Kim DW; Copploa D; Kothari N; doo Chang Y; Kim R; Kim N; Lye M; Wan E; Kim N; Lye M; Wan E; Kim N; Lye M; Wan E; Knaus HA; Berglund S; Hackl H; Karp JE; Gojo I; Luznik L; Hong HS; Koch SD; Scheel B; Gnad-Vogt U; Kallen K-J; Wiegand V; Backert L; Kohlbacher O; Hoerr I; Fotin-Mleczek M; Billingsley JM; Koguchi Y; Conrad V; Miller W; Gonzalez I; Poplonski T; Meeuwsen T; Howells-Ferreira A; Rattray R; Campbell M; Bifulco C; Dubay C; Bahjat K; Curti B; Urba W; Vetsika E-K; Kallergi G; Aggouraki D; Lyristi Z; Katsarlinos P; Koinis F; Georgoulias V; Kotsakis A; Martin NT; Aeffner F; Kearney SJ; Black JC; Cerkovnik L; Pratte L; Kim R; Hirsch B; Krueger J; Gianani R; Martínez-Usatorre A; Jandus C; Donda A; Carretero-Iglesia L; Speiser DE; Zehn D; Rufer N; Romero P; Panda A; Mehnert J; Hirshfield KM; Riedlinger G; Damare S; Saunders T; Sokol L; Stein M; Poplin E; Rodriguez-Rodriguez L; Silk A; Chan N; Frankel M; Kane M; Malhotra J; Aisner J; Kaufman HL; Ali S; Ross J; White E; Bhanot G; Ganesan S; Monette A; Bergeron D; Amor AB; Meunier L; Caron C; Morou A; Kaufmann D; Liberman M; Jurisica I; Mes-Masson A-M; Hamzaoui K; Lapointe R; Mongan A; Ku Y-C; Tom W; Sun Y; Pankov A; Looney T; Au-Young J; Hyland F; Conroy J; Morrison C; Glenn S; Burgher B; Ji H; Gardner M; Mongan A; Omilian AR; Conroy J; Bshara W; Angela O; Burgher B; Ji H; Glenn S; Morrison C; Mongan A; Obeid JM; Erdag G; Smolkin ME; Deacon DH; Patterson JW; Chen L; Bullock TN; Slingluff CL; Obeid JM; Erdag G; Deacon DH; Slingluff CL; Bullock TN; Loffredo JT; Vuyyuru R; Beyer S; Spires VM; Fox M; Ehrmann JM; Taylor KA; Korman AJ; Graziano RF; Page D; Sanchez K; Ballesteros-Merino C; Martel M; Bifulco C; Urba W; Fox B; Patel SP; De Macedo MP; Qin Y; Reuben A; Spencer C; Guindani M; Bassett R; Wargo J; Racolta A; Kelly B; Jones T; Polaske N; Theiss N; Robida M; Meridew J; Habensus I; Zhang L; Pestic-Dragovich L; Tang L; Sullivan RJ; Logan T; Khushalani N; Margolin K; Koon H; Olencki T; Hutson T; Curti B; Roder J; Blackmon S; Roder H; Stewart J; Amin A; Ernstoff MS; Clark JI; Atkins MB; Kaufman HL; Sosman J; Weber J; McDermott DF; Weber J; Kluger H; Halaban R; Snzol M; Roder H; Roder J; Asmellash S; Steingrimsson A; Blackmon S; Sullivan RJ; Wang C; Roman K; Clement A; Downing S; Hoyt C; Harder N; Schmidt G; Schoenmeyer R; Brieu N; Yigitsoy M; Madonna G; Botti G; Grimaldi A; Ascierto PA; Huss R; Athelogou M; Hessel H; Harder N; Buchner A; Schmidt G; Stief C; Huss R; Binnig G; Kirchner T; Sellappan S; Thyparambil S; Schwartz S; Cecchi F; Nguyen A; Vaske C; Hembrough T; Spacek J; Vocka M; Zavadova E; Skalova H; Dundr P; Petruzelka L; Francis N; Tilman RT; Hartmann A; Netikova I; Ballesteros-Merino C; Stump J; Tufman A; Berger F; Neuberger M; Hatz R; Lindner M; Sanborn RE; Handy J; Fox B; Bifulco C; Huber RM; Winter H; Reu S; Sun C; Xiao W; Tian Z; Arora K; Desai N; Kulkarni A; Rajurkar M; Rivera M; Deshpande V; Ting D; Tsai K; Nosrati A; Goldinger S; Hamid O; Algazi A; Tumeh P; Hwang J; Liu J; Chen L; Dummer R; Rosenblum M; Daud A; Tsao T-S; Ashworth-Sharpe J; Johnson D; Bhaumik S; Bieniarz C; Couto J; Farrell M; Ghaffari M; Habensus I; Hubbard A; Jones T; Kelly B; Kosmeder J; Lee C; Marner E; Meridew J; Polaske N; Racolta A; Uribe D; Zhang H; Zhang J; Zhang W; Zhu Y; Morrison L; Pestic-Dragovich L; Tang L; Tsujikawa T; Borkar RN; Azimi V; Kumar S; Thibault G; Mori M; El Rassi E; Clayburgh DR; Kulesz-Martin MF; Flint PW; Coussens LM; Villabona L; Masucci GV; Geiss G; Birditt B; Mei Q; Huang A; White AM; Eagan MA; Ignacio E; Elliott N; Dunaway D; Dennis L; Warren S; Beechem J; Dunaway D; Jung J; Merritt C; Sprague I; Webster P; Liang Y; Warren S; Beechem J; Wenthe J; Enblad G; Karlsson H; Essand M; Savoldo B; Dotti G; Höglund M; Brenner MK; Hagberg H; Loskog A; Bernett MJ; Moore GL; Hedvat M; Bonzon C; Chu S; Rashid R; Avery KN; Muchhal U; Desjarlais J; Hedvat M; Bernett MJ; Moore GL; Bonzon C; Rashid R; Chu S; Avery KN; Muchhal U; Desjarlais J; Kraman M; Kmiecik K; Allen N; Faroudi M; Zimarino C; Wydro M; Doody J; Srinivasa SP; Govindappa N; Reddy P; Dubey A; Periyasamy S; Adekandi M; Dey C; Joy M; van Loo PF; Veninga H; Shamsili S; Throsby M; Dolstra H; Bakker L; Alva A; Gschwendt J; Loriot Y; Bellmunt J; Feng D; Poehlein C; Powles T; Antonarakis ES; Drake CG; Wu H; Poehlein C; De Bono J; Bannerji R; Byrd J; Gregory G; Opat S; Shortt J; Yee AJ; Raje N; Thompson S; Balakumaran A; Kumar S; Rini BI; Choueiri TK; Mariani M; Albiges L; Haanen JB; Atkins MB; Larkin J; Schmidinger M; Magazzù D; di Pietro A; Motzer RJ; Borch TH; Andersen R; Kongsted P; Pedersen M; Nielsen M; Met Ö; Donia M; Svane IM; Boudadi K; Wang H; Vasselli J; Baughman JE; Wigginton J; Abdallah R; Ross A; Drake CG; Antonarakis ES; Canter RJ; Park J; Wang Z; Grossenbacher S; Luna JI; Withers S; Culp W; Chen M; Monjazeb A; Kent MS; Murphy WJ; Chandran S; Somerville R; Wunderlich J; Danforth D; Yang J; Sherry R; Klebanoff C; Goff S; Paria B; Sabesan A; Srivastava A; Rosenberg SA; Kammula U; Curti B; Richards J; Faries M; Andtbacka RHI; Grose M; Shafren D; Diaz LA; Le DT; Yoshino T; André T; Bendell J; Koshiji M; Zhang Y; Kang SP; Lam B; Jäger D; Bauer TM; Wang JS; Lee JK; Manji GA; Kudchadkar R; Kauh JS; Tang S; Laing N; Falchook G; Garon EB; Halmos B; Rina H; Leighl N; Lee SS; Walsh W; Dragnev K; Piperdi B; Rodriguez LP-A; Shinwari N; Wei Z; Gustafson MP; Maas ML; Deeds M; Armstrong A; Bornschlegl S; Peterson T; Steinmetz S; Gastineau DA; Parney IF; Dietz AB; Herzog T; Backes FJ; Copeland L; Del Pilar Estevez Diz M; Hare TW; Huh W; Kim B-G; Moore KM; Oaknin A; Small W; Tewari KS; Monk BJ; Kamat AM; Bellmunt J; Choueiri TK; Nam K; De Santis M; Dreicer R; Hahn NM; Perini R; Siefker-Radtke A; Sonpavde G; de Wit R; Witjes JA; Keefe S; Bajorin D; Kline J; Armand P; Kuruvilla J; Moskowitz C; Hamadani M; Ribrag V; Zinzani PL; Chlosta S; Thompson S; Balakumaran A; Bartlett N; Kyi C; Sabado R; Saenger Y; William L; Donovan MJ; Sacris E; Mandeli J; Salazar AM; Friedlander P; Bhardwaj N; Powderly J; Brody J; Nemunaitis J; Emens L; Luke JJ; Patnaik A; McCaffery I; Miller R; Laport G; Coveler AL; Smith DC; Grilley-Olson JE; Gajewski TF; Goel S; Gardai SJ; Law C-L; Means G; Manley T; Curti B; Marrone KA; Rosner G; Anagnostou V; Riemer J; Wakefield J; Zanhow C; Baylin S; Gitlitz B; Brahmer J; McDermott DF; Signoretti S; Li W; Schloss C; Michot J-M; Armand P; Ding W; Ribrag V; Christian B; Balakumaran A; Marinello P; Chlosta S; Zhang Y; Shipp M; Zinzani PL; Najjar YG; Lin ; Butterfield LH; Tarhini AA; Davar D; Zarour H; Rush E; Sander C; Kirkwood JM; Fu S; Bauer T; Molineaux C; Bennett MK; Orford KW; Papadopoulos KP; Padda SK; Shah SA; Colevas AD; Narayanan S; Fisher GA; Supan D; Wakelee HA; Aoki R; Pegram MD; Villalobos VM; Liu J; Takimoto CH; Chao M; Volkmer J-P; Majeti R; Weissman IL; Sikic BI; Page D; Yu W; Conlin A; Ruzich J; Lewis S; Acheson A; Kemmer K; Perlewitz K; Moxon NM; Mellinger S; Bifulco C; Martel M; Koguchi Y; Fox B; Urba W; McArthur H; Pedersen M; Westergaard MCW; Borch TH; Nielsen M; Kongsted P; Juhler-Nøttrup T; Donia M; Svane IM; Desai J; Markman B; Sandhu S; Gan H; Friedlander ML; Tran B; Meniawy T; Lundy J; Colyer D; Ameratunga M; Norris C; Yang J; Li K; Wang L; Luo L; Qin Z; Mu S; Tan X; Song J; Millward M; Katz MHG; Bauer TW; Varadhachary GR; Acquavella N; Merchant N; Petroni G; Slingluff CL; Rahma OE; Rini BI; Powles T; Chen M; Song Y; Puhlmann M; Atkins MB; Sathyanaryanan S; Hirsch HA; Shu J; Deshpande A; Khattri A; Reeves J; Zi T; Brisson R; Harvey C; Michaelson J; Law D; Seiwert T; Shah J; Mateos MV; Matsumoto M; Blacklock H; Rocafiguera AO; Goldschmidt H; Iida S; Yehuda DB; Ocio E; Rodríguez-Otero P; Jagannath S; Lonial S; Kher U; Marinello P; San-Miguel J; Shah J; Lonial S; de Oliveira MR; Yimer H; Mateos MV; Rifkin R; Schjesvold F; Ocio E; Rodríguez-Otero P; San-Miguel J; Ghori R; Marinello P; Jagannath S; Spreafico A; Lee V; Ngan RKC; To KF; Ahn MJ; Ng QS; Hong R-L; Lin J-C; Swaby RF; Gause C; Saraf S; Chan ATC; Lam E; Tannir NM; Meric-Bernstam F; Vaishampayan U; Orford KW; Molineaux C; Gross M; MacKinnon A; Whiting S; Voss M; Yu EY; Wu H; Schloss C; Albertini MR; Ranheim EA; Hank JA; Zuleger C; McFarland T; Collins J; Clements E; Weber S; Weigel T; Neuman H; Hartig G; Mahvi D; Henry M; Gan J; Yang R; Carmichael L; Kim K; Gillies SD; Sondel PM; Subbiah V; Murthy R; Noffsinger L; Hendricks K; Bosch M; Lee JM; Lee M-H; Garon EB; Goldman JW; Baratelli FE; Schaue D; Wang G; Rosen F; Yanagawa J; Walser TC; Lin YQ; Adams S; Marincola FM; Tumeh PC; Abtin F; Suh R; Reckamp K; Wallace WD; Zeng G; Elashoff DA; Sharma S; Dubinett SM; Bhardwaj N; Friedlander P; Pavlick AC; Ernstoff MS; Gastman B; Hanks B; Albertini MR; Luke JJ; Keler T; Davis T; Vitale LA; Sharon E; Danaher P; Morishima C; Cheever M; Fling S; Heery CR; Kim JW; Lamping E; Marte J; McMahon S; Cordes L; Fakhrejahani F; Madan R; Tsang K; Jochems C; Salazar R; Zhang M; Helwig C; Schlom J; Gulley JL; Li R; Amrhein J; Cohen Z; Champagne M; Kamat A; Aznar MA; Labiano S; Diaz-Lagares A; Esteller M; Sandoval J; Melero I; Barbee SD; Bellovin DI; Timmer JC; Wondyfraw N; Johnson S; Park J; Chen A; Mkrtichyan M; Razai AS; Jones KS; Hata CY; Gonzalez D; Deveraux Q; Eckelman BP; Borges L; Bhardwaj R; Puri RK; Suzuki A; Leland P; Joshi BH; Bartkowiak T; Jaiswal A; Ager C; Ai M; Budhani P; Chin R; Hong D; Curran M; Hastings WD; Pinzon-Ortiz M; Murakami M; Dobson JR; Quinn D; Wagner JP; Rong X; Shaw P; Dammassa E; Guan W; Dranoff G; Cao A; Fulton RB; Leonardo S; Fraser K; Kangas TO; Ottoson N; Bose N; Huhn RD; Graff J; Lowe J; Gorden K; Uhlik M; Vitale LA; O’Neill T; Widger J; Crocker A; He L-Z; Weidlick J; Sundarapandiyan K; Ramakrishna V; Storey J; Thomas LJ; Goldstein J; Marsh HC; Keler T; Grailer J; Gilden J; Stecha P; Garvin D; Hartnett J; Fan F; Cong M; Cheng Z-JJ; Hinner MJ; Aiba R-SB; Schlosser C; Jaquin T; Allersdorfer A; Berger S; Wiedenmann A; Matschiner G; Schüler J; Moebius U; Rothe C; Shane OA; Horton B; Spranger S; Gajewski TF; Moreira D; Adamus T; Zhao X; Swiderski P; Pal S; Kortylewski M; Kosmides A; Necochea K; Schneck J; Mahoney KM; Shukla SA; Patsoukis N; Chaudhri A; Pham H; Hua P; Bu X; Zhu B; Hacohen N; Wu CJ; Fritsch E; Boussiotis VA; Freeman GJ; Moran AE; Polesso F; Lukaesko L; Weinberg A; Rådestad E; Egevad L; Mattsson J; Sundberg B; Henningsohn L; Levitsky V; Uhlin M; Rafelson W; Reagan JL; Fast L; Sasikumar P; Sudarshan N; Ramachandra R; Gowda N; Samiulla D; Chandrasekhar T; Adurthi S; Mani J; Nair R; Dhudashia A; Gowda N; Ramachandra M; Sankin A; Gartrell B; Cumberbatch K; Huang H; Stern J; Schoenberg M; Zang X; Swanson R; Kornacker M; Evans L; Rickel E; Wolfson M; Valsesia-Wittmann S; Shekarian T; Simard F; Nailo R; Dutour A; Jallas A-C; Caux C; Marabelle A, 2016, '31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one', Journal for ImmunoTherapy of Cancer, 4, http://dx.doi.org/10.1186/s40425-016-0172-7
    Journal articles | 2016
    Mateo J; Moreno V; Gupta A; Kaye SB; Dean E; Middleton MR; Friedlander M; Gourley C; Plummer R; Rustin G; Sessa C; Leunen K; Ledermann J; Swaisland H; Fielding A; Bannister W; Nicum S; Molife LR, 2016, 'An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib', Targeted Oncology, 11, pp. 401 - 415, http://dx.doi.org/10.1007/s11523-016-0435-8
    Journal articles | 2016
    Matulonis UA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Parry D; Grinsted L; Ledermann JA, 2016, 'Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy', Cancer, 122, pp. 1844 - 1852, http://dx.doi.org/10.1002/cncr.29995
    Journal articles | 2016
    Mercieca-Bebber R; Friedlander M; Kok PS; Calvert M; Kyte D; Stockler M; King MT, 2016, 'The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols', Quality of Life Research, 25, pp. 2457 - 2465, http://dx.doi.org/10.1007/s11136-016-1339-x
    Journal articles | 2016
    Pelttari LM; Khan S; Vuorela M; Kiiski JI; Vilske S; Nevanlinna V; Ranta S; Schleutker J; Winqvist R; Kallioniemi A; Dörk T; Bogdanova NV; Figueroa J; Pharoah PDP; Schmidt MK; Dunning AM; García-Closas M; Bolla MK; Dennis J; Michailidou K; Wang Q; Hopper JL; Southey MC; Rosenberg EH; Fasching PA; Beckmann MW; Peto J; Dos-Santos-silva I; Sawyer EJ; Tomlinson I; Burwinkel B; Surowy H; Guénel P; Truong T; Bojesen SE; Nordestgaard BG; Benitez J; González-Neira A; Neuhausen SL; Anton-Culver H; Brenner H; Arndt V; Meindl A; Schmutzler RK; Brauch H; Brüning T; Lindblom A; Margolin S; Mannermaa A; Hartikainen JM; Chenevix-Trench G; Van Dyck L; Janssen H; Chang-Claude J; Rudolph A; Radice P; Peterlongo P; Hallberg E; Olson JE; Giles GG; Milne RL; Haiman CA; Schumacher F; Simard J; Dumont M; Kristensen V; Borresen-Dale AL; Zheng W; Beeghly-Fadiel A; Grip M; Andrulis IL; Glendon G; Devilee P; Seynaeve C; Hooning MJ; Collée M; Cox A; Cross SS; Shah M; Luben RN; Hamann U; Torres D; Jakubowska A; Lubinski J; Couch FJ; Yannoukakos D; Orr N; Swerdlow A; Darabi H; Li J; Czene K; Hall P; Easton DF; Mattson J; Blomqvist C; Aittomäki K; Nevanlinna H; Aghmesheh M; Amor D; Andrews L, 2016, 'RAD51B in familial breast cancer', PLoS ONE, 11, http://dx.doi.org/10.1371/journal.pone.0153788
    Journal articles | 2016
    Phillips KA; Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Stern C; Hopper JL; Fisher R; Kannemeyer G; Picken S; Smith CD; Kelsey TW; Anderson RA, 2016, 'Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations', Human Reproduction, 31, pp. 1126 - 1132, http://dx.doi.org/10.1093/humrep/dew044
    Journal articles | 2016
    Phillips KA; Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Stern C; Hopper JL; Fisher R; Kannemeyer G; Picken S; Smith CD; Kelsey TW; Anderson RA, 2016, 'Anti-müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations', Obstetrical and Gynecological Survey, 71, pp. 474 - 475, http://dx.doi.org/10.1097/01.ogx.0000489566.21546.e2
    Journal articles | 2016
    Price MA; Butow PN; Bell ML; deFazio A; Friedlander M; Fardell JE; Protani MM; Webb PM; AOCS—Quality of Life Study Investigators on behalf , 2016, 'Helplessness/hopelessness, minimization and optimism predict survival in women with invasive ovarian cancer: a role for targeted support during initial treatment decision-making?', Supportive Care in Cancer, 24, pp. 2627 - 2634, http://dx.doi.org/10.1007/s00520-015-3070-5
    Journal articles | 2016
    Pulford DJ; Harter P; Floquet A; Barrett C; Suh DH; Friedlander M; Arranz JA; Hasegawa K; Tada H; Vuylsteke P; Mirza MR; Donadello N; Scambia G; Johnson T; Cox C; Chan JK; Imhof M; Herzog TJ; Calvert P; Wimberger P; Berton-Rigaud D; Lim MC; Elser G; Xu CF; Du Bois A, 2016, 'Communicating BRCA research results to patients enrolled in international clinical trials: Lessons learnt from the AGO-OVAR 16 study', BMC Medical Ethics, 17, http://dx.doi.org/10.1186/s12910-016-0144-y
    Journal articles | 2016
    Roncolato FT; Chatfield M; Houghton B; Toner G; Stockler M; Thomson D; Friedlander M; Gurney H; Rosenthal M; Grimison P, 2016, 'The effect of pulmonary function testing on bleomycin dosing in germ cell tumours', Internal Medicine Journal, 46, pp. 893 - 898, http://dx.doi.org/10.1111/imj.13158
    Journal articles | 2016
    Thewes B; Prins J; Friedlander M, 2016, '70-Gene signature in early-stage breast cancer', New England Journal of Medicine, 375, pp. 2199 - 2200, http://dx.doi.org/10.1056/NEJMc1612048
    Journal articles | 2016
    Zeng C; Guo X; Long J; Kuchenbaecker KB; Droit A; Michailidou K; Ghoussaini M; Kar S; Freeman A; Hopper JL; Milne RL; Bolla MK; Wang Q; Dennis J; Agata S; Ahmed S; Aittomäki K; Andrulis IL; Anton-Culver H; Antonenkova NN; Arason A; Arndt V; Arun BK; Arver B; Bacot F; Barrowdale D; Baynes C; Beeghly-Fadiel A; Benitez J; Bermisheva M; Blomqvist C; Blot WJ; Bogdanova NV; Bojesen SE; Bonanni B; Borresen-Dale AL; Brand JS; Brauch H; Brennan P; Brenner H; Broeks A; Brüning T; Burwinkel B; Buys SS; Cai Q; Caldes T; Campbell I; Carpenter J; Chang-Claude J; Choi JY; Claes KBM; Clarke C; Cox A; Cross SS; Czene K; Daly MB; de la Hoya M; De Leeneer K; Devilee P; Diez O; Domchek SM; Doody M; Dorfling CM; Dörk T; dos-Santos-Silva I; Dumont M; Dwek M; Dworniczak B; Egan K; Eilber U; Einbeigi Z; Ejlertsen B; Ellis S; Frost D; Lalloo F; Fasching PA; Figueroa J; Flyger H; Friedlander M; Friedman E; Gambino G; Gao YT; Garber J; García-Closas M; Gehrig A; Damiola F; Lesueur F; Mazoyer S; Stoppa-Lyonnet D; Giles GG; Godwin AK; Goldgar DE; González-Neira A; Greene MH; Guénel P; Haeberle L; Haiman CA; Hallberg E; Hamann U; Hansen TVO, 2016, 'Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus', Breast Cancer Research, 18, http://dx.doi.org/10.1186/s13058-016-0718-0
    Journal articles | 2016
    2016, 'The effect of pulmonary function testing on bleomycin dosing in germ cell tumours (vol 46, pg 893, 2016)', INTERNAL MEDICINE JOURNAL, 46, pp. 1459 - 1459, http://dx.doi.org/10.1111/imj.13259
    Journal articles | 2015
    Berek JS; Crum C; Friedlander M, 2015, 'Cancer of the ovary, fallopian tube, and peritoneum', International Journal of Gynecology and Obstetrics, 131, pp. S111 - S122, http://dx.doi.org/10.1016/j.ijgo.2015.06.007
    Journal articles | 2015
    Domchek SM; Kaufman B; Friedlander M, 2015, 'Reply to M.G. McNamara et al and M.S. Copur et al', Journal of Clinical Oncology, 33, pp. 2583 - 2584, http://dx.doi.org/10.1200/JCO.2015.61.8298
    Journal articles | 2015
    Floquet A; Vergote I; Colombo N; Fiane B; Monk BJ; Reinthaller A; Calvert P; Herzog TJ; Meier W; Kim JW; Campo JM D; Friedlander M; Pisano C; Isonishin S; Crescenzo RJ; Barrett C; Wang K; Mitrica I; Bois AD, 2015, 'Progression-free survival by local investigator versus independent central review: Comparative analysis of the AGO-OVAR16 Trial', Gynecologic Oncology, 136, pp. 37 - 42, http://dx.doi.org/10.1016/j.ygyno.2014.11.074
    Journal articles | 2015
    Harrison M; Friedlander M, 2015, 'Over half of all gynaecologic cancers are rare: Barriers and challenges to improving outcomes', Cancer Forum, 39, pp. 20 - 24
    Journal articles | 2015
    Harter P; Johnson T; Berton-Rigaud D; Park SY; Friedlander M; del Campo JM; Shimada M; Forget F; Mirza MR; Colombo N; Zamagni C; Chan JK; Imhof M; Herzog TJ; O'Donnell D; Heitz F; King K; Stinnett S; Barrett C; Jobanputra M; Xu CF; du Bois A, 2015, 'BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study', Gynecologic Oncology, http://dx.doi.org/10.1016/j.ygyno.2015.12.027
    Journal articles | 2015
    Inglis H; Boyle FM; Friedlander ML; Watson SL, 2015, 'Dry eyes and AIs: If you don't ask you won't find out', Breast, 24, pp. 694 - 698, http://dx.doi.org/10.1016/j.breast.2015.08.008
    Journal articles | 2015
    Kaufman B; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmaña J; Mitchell G; Fried G; Stemmer SM; Hubert A; Rosengarten O; Steiner M; Loman N; Bowen K; Fielding A; Domchek SM, 2015, 'Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation', Journal of Clinical Oncology, 33, pp. 244 - 250, http://dx.doi.org/10.1200/JCO.2014.56.2728
    Journal articles | 2015
    Kondrashova O; Love CJ; Lunke S; Hsu AL; Bowtell D; Chenevix-Trench G; Green A; Webb P; DeFazio A; Gertig D; Traficante N; Fereday S; Moore S; Hung J; Harrap K; Sadkowsky T; Pandeya N; Malt M; Mellon A; Robertson R; Vanden Bergh T; Jones M; Mackenzie P; Maidens J; Nattress K; Chiew YE; Stenlake A; Sullivan H; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Ferguson K; Martin K; Martyn A; Ranieri B; White J; Jayde V; Mamers P; Bowes L; Galletta L; Giles D; Hendley J; Alsop K; Schmidt T; Shirley H; Ball C; Young C; Viduka S; Tran H; Bilic S; Glavinas L; Brooks J; Stuart-Harris R; Kirsten F; Rutovitz J; Clingan P; Glasgow A; Proietto A; Braye S; Otton G; Shannon J; Bonaventura T; Stewart J; Begbie S; Friedlander M; Bell D; Baron-Hay S; Ferrier A; Gard G; Nevell D; Pavlakis N; Valmadre S; Young B; Camaris C; Crouch R; Edwards L; Hacker N; Marsden D; Robertson G; Beale P; Beith J; Carter J; Dalrymple C; Houghton R; Russell P; Links M; Grygiel J; Hill J; Brand A; Byth K; Jaworski R; Harnett P; Sharma R; Wain G; Ward B; Papadimos D; Crandon A, 2015, 'High-throughput amplicon-based copy number detection of 11 genes in formalin-fixed paraffin-embedded ovarian tumour samples by MLPA-seq', PLoS ONE, 10, http://dx.doi.org/10.1371/journal.pone.0143006
    Journal articles | 2015
    Ledermann J; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott CL; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Dougherty B; Orr M; Hodgson D; Barrett JC; Matulonis U, 2015, 'Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial', Obstetrical and Gynecological Survey, 69, pp. 594 - 596, http://dx.doi.org/10.1097/ogx.0000000000000107
    Journal articles | 2015
    Lee CK; Lord S; Grunewald T; Gebski V; Hardy-Bessard AC; Sehouli J; Woie K; Heywood M; Schauer C; Vergote I; Scambia G; Ferrero A; Harter P; Pujade-Lauraine E; Friedlander M, 2015, 'Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: Analysis of the CALYPSO trial', Gynecologic Oncology, 136, pp. 18 - 24, http://dx.doi.org/10.1016/j.ygyno.2014.09.017
    Journal articles | 2015
    Mizrahi D; Broderick C; Friedlander M; Ryan M; Harrison M; Pumpa K; Naumann F, 2015, 'An exercise intervention during chemotherapy for women with recurrent ovarian cancer: A feasibility study', International Journal of Gynecological Cancer, 25, pp. 985 - 992, http://dx.doi.org/10.1097/IGC.0000000000000460
    Journal articles | 2015
    Mizrahi D; Naumann F; Broderick C; Samara J; Ryan M; Friedlander M, 2015, 'Quantifying physical activity and the associated barriers for women with ovarian cancer', International Journal of Gynecological Cancer, 25, pp. 577 - 583, http://dx.doi.org/10.1097/IGC.0000000000000349
    Journal articles | 2015
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RHJ; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M, 2015, 'Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial', The Lancet Oncology, 16, pp. 87 - 97, http://dx.doi.org/10.1016/S1470-2045(14)71135-0
    Journal articles | 2015
    Patch AM; Christie EL; Etemadmoghadam D; Garsed DW; George J; Fereday S; Nones K; Cowin P; Alsop K; Bailey PJ; Kassahn KS; Newell F; Quinn M; Kazakoff S; Quek K; Wilhelm-Benartzi C; Curry E; Leong HS; Hamilton A; Mileshkin L; Au-Yeung G; Kennedy C; Hung J; Chiew YE; Harnett P; Friedlander M; Pyman J; Cordner S; O'Brien P; Leditschke J; Young G; Strachan K; Waring P; Azar W; Mitchell C; Traficante N; Hendley J; Thorne H; Shackleton M; Miller DK; Arnau GM; Tothill RW; Holloway TP; Semple T; Harliwong I; Nourse C; Nourbakhsh E; Manning S; Idrisoglu S; Bruxner TJC; Christ AN; Poudel B; Holmes O; Anderson M; Leonard C; Lonie A; Hall N; Wood S; Taylor DF; Xu Q; Fink JL; Waddell N; Drapkin R; Stronach E; Gabra H; Brown R; Jewell A; Nagaraj SH; Markham E; Wilson PJ; Ellul J; McNally O; Doyle MA; Vedururu R; Stewart C; Lengyel E; Pearson JV; Waddell N; DeFazio A; Grimmond SM; Bowtell DDL, 2015, 'Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer', Nature, 527, pp. 398, http://dx.doi.org/10.1038/nature15716
    Journal articles | 2015
    Patch AM; Christie EL; Etemadmoghadam D; Garsed DW; George J; Fereday S; Nones K; Cowin P; Alsop K; Bailey PJ; Kassahn KS; Newell F; Quinn MCJ; Kazakoff S; Quek K; Wilhelm-Benartzi C; Curry E; Leong HS; Hamilton A; Mileshkin L; Au-Yeung G; Kennedy C; Hung J; Chiew YE; Harnett P; Friedlander M; Pyman J; Cordner S; O'Brien P; Leditschke J; Young G; Strachan K; Waring P; Azar W; Mitchell C; Traficante N; Hendley J; Thorne H; Shackleton M; Miller DK; Arnau GM; Tothill RW; Holloway TP; Semple T; Harliwong I; Nourse C; Nourbakhsh E; Manning S; Idrisoglu S; Bruxner TJC; Christ AN; Poudel B; Holmes O; Anderson M; Leonard C; Lonie A; Hall N; Wood S; Taylor DF; Xu Q; Lynn Fink J; Waddell N; Drapkin R; Stronach E; Gabra H; Brown R; Jewell A; Nagaraj SH; Markham E; Wilson PJ; Ellul J; McNally O; Doyle MA; Vedururu R; Stewart C; Lengyel E; Pearson JV; Waddell N; Defazio A; Grimmond SM; Bowtell DDL, 2015, 'Whole-genome characterization of chemoresistant ovarian cancer', Nature, 521, pp. 489 - 494, http://dx.doi.org/10.1038/nature14410
    Journal articles | 2015
    Peculis LD; Ius Y; Campion M; Friedlander M; Hacker N, 2015, 'Stage IB2 adenosquamous cervical cancer diagnosed at 19-weeks' gestation', Australian and New Zealand Journal of Obstetrics and Gynaecology, 55, pp. 94 - 97, http://dx.doi.org/10.1111/ajo.12281
    Journal articles | 2015
    Peterlongo P; Chang-Claude J; Moysich KB; Rudolph A; Schmutzler RK; Simard J; Soucy P; Eeles RA; Easton DF; Hamann U; Wilkening S; Chen B; Rookus MA; Schmidt MK; Van Der Baan FH; Spurdle AB; Walker LC; Lose F; Maia AT; Montagna M; Matricardi L; Lubinski J; Jakubowska A; Garcia EB G; Olopade OI; Nussbaum RL; Nathanson KL; Domchek SM; Rebbeck TR; Arun BK; Karlan BY; Orsulic S; Lester J; Chung WK; Miron A; Southey MC; Goldgar DE; Buys SS; Janavicius R; Dorfling CM; Van Rensburg EJ; Ding YC; Neuhausen SL; Hansen TV O; Gerdes AM; Ejlertsen B; Jønson L; Osorio A; Martínez-Bouzas C; Benitez J; Conway EE; Blazer KR; Weitzel JN; Manoukian S; Peissel B; Zaffaroni D; Scuvera G; Barile M; Ficarazzi F; Mariette F; Fortuzzi S; Viel A; Giannini G; Papi L; Martayan A; Tibiletti MG; Radice P; Vratimos A; Fostira F; Garber JE; Donaldson A; Brewer C; Foo C; Evans DG R; Frost D; Eccles D; Brady A; Cook J; Tischkowitz M; Adlard J; Barwell J; Walker L; Izatt L; Side LE; Kennedy MJ; Rogers MT; Porteous ME; Morrison PJ; Platte R; Davidson R; Hodgson SV; Ellis S; Cole T; Godwin AK; Claes K; Van Maerken T; Meindl A; Gehrig A; Sutter C; Engel C, 2015, 'Candidate genetic modifiers for breast and ovarian cancer risk inBRCA1andBRCA2 mutation carriers', Cancer Epidemiology Biomarkers and Prevention, 24, pp. 308 - 316, http://dx.doi.org/10.1158/1055-9965.EPI-14-0532
    Journal articles | 2015
    Scurry J; Hacker NF; Barlow E; Friedlander M; Jackson M, 2015, 'Is quantification of lymphovascular space invasion useful in stage 1B2 cervical carcinomas?', Journal of Obstetrics and Gynaecology, 35, pp. 377 - 381, http://dx.doi.org/10.3109/01443615.2014.958448
    Journal articles | 2015
    Sobral-Leite M; Wesseling J; Smit VT H B M; Nevanlinna H; van Miltenburg MH; Sanders J; Hofland I; Blows FM; Coulson P; Patrycja G; Schellens JH M; Fagerholm R; Heikkilä P; Aittomäki K; Blomqvist C; Provenzano E; Ali HR; Figueroa J; Sherman M; Lissowska J; Mannermaa A; Kataja V; Kosma VM; Hartikainen JM; Phillips KA; Couch FJ; Olson JE; Vachon C; Visscher D; Brenner H; Butterbach K; Arndt V; Holleczek B; Hooning MJ; Hollestelle A; Martens JW M; van Deurzen CH M; van de Water B; Broeks A; Chang-Claude J; Chenevix-Trench G; Easton DF; Pharoah PD P; García-Closas M; de Graauw M; Schmidt MK; Aghmesheh M; Amor D; Andrews L; Antill Y; Armitage S; Arnold L; Balleine R; Bankier A; Bastick P; Beesley J; Beilby J; Bennett B; Bennett I; Berry G; Blackburn A; Bogwitz M; Brennan M; Brown M; Buckley M; Burgess M; Burke J; Butow P; Byron K; Callen D; Campbell I; Chauhan D; Chauhan M; Christian A; Clarke C; Colley A; Cotton D; Crook A; Cui J; Culling B; Cummings M; Dawson SJ; de Fazio A; Delatycki M; Dickson R; Dixon J; Dobrovic A; Dudding T; Edkins T; Edwards S; Eisenbruch M; Farshid G; Fawcett S; Fellows A; Fenton G; Field M; Firgaira F; Flanagan J; Fleming J; Fong P, 2015, 'Annexin A1 expression in a pooled breast cancer series: Association with tumor subtypes and prognosis', BMC Medicine, 13, http://dx.doi.org/10.1186/s12916-015-0392-6
    Journal articles | 2015
    Webber K; King MT; Friedlander ML; Webb P, 2015, 'TRAJECTORIES OF PERSISTENT SYMPTOMS AFTER COMPLETION OF PRIMARY TREATMENT FOR OVARIAN CANCER', INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 25, pp. 613 - 613, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000377145701188&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Journal articles | 2015
    Webber K; Sommeijer D; Mileshkin LR; Blagden SP; McAlpine JN; Coleman RL; Herzog TJ; Witte G; Baugh E; Silberman A; Friedlander ML, 2015, 'OBESITY, PHYSICAL INACTIVITY AND SYMPTOMS AFTER OVARIAN CANCER TREATMENT: RESULTS FROM AN INTERNATIONAL INTERNET-BASED SURVEY', INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 25, pp. 42 - 43, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000377145700023&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Journal articles | 2015
    Wilson MK; Collyar D; Chingos DT; Friedlander M; Ho TW; Karakasis K; Kaye S; Parmar MKB; Sydes MR; Tannock IF; Oza AM, 2015, 'Outcomes and endpoints in cancer trials: Bridging the divide', The Lancet Oncology, 16, pp. e43 - e52, http://dx.doi.org/10.1016/S1470-2045(14)70380-8
    Journal articles | 2015
    2015, 'TOPS: A randomised controlled trial of a multidisciplinary intervention for post-cancer fatigue.', Journal of Clinical Oncology, 33, pp. 9571 - 9571, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.9571
    Journal articles | 2014
    Amant F; Floquet A; Friedlander M; Kristensen G; Mahner S; Nam EJ; Powell MA; Ray-Coquard I; Siddiqui N; Sykes P; Westermann AM; Seddon B, 2014, 'Gynecologic Cancer InterGroup (GCIG) Consensus Review for Endometrial Stromal Sarcoma', International Journal of Gynecological Cancer, 24, pp. S67 - S72, http://dx.doi.org/10.1097/IGC.0000000000000205
    Journal articles | 2014
    Anuradha S; Webb PM; Blomfield P; Brand AH; Friedlander M; Leung Y; Obermair A; Oehler MK; Quinn M; Steer C; Jordan SJ, 2014, 'Survival of Australian women with invasive epithelial ovarian cancer: A populationbased study', Medical Journal of Australia, 201, pp. 283 - 288, http://dx.doi.org/10.5694/mja14.00132
    Journal articles | 2014
    Brown J; Friedlander M; Backes FJ; Harter P; O'Connor DM; De La Motte Rouge T; Lorusso D; Maenpaa J; Kim JW; Tenney ME; Seckl MJ, 2014, 'Gynecologic cancer intergroup (GCIG) consensus review for ovarian germ cell tumors', International Journal of Gynecological Cancer, 24, pp. S48 - S54, http://dx.doi.org/10.1097/IGC.0000000000000223
    Journal articles | 2014
    Butow PN; Price MA; Bell ML; Webb PM; Defazio A; Friedlander M, 2014, 'Caring for women with ovarian cancer in the last year of life: A longitudinal study of caregiver quality of life, distress and unmet needs', Gynecologic Oncology, 132, pp. 690 - 697, http://dx.doi.org/10.1016/j.ygyno.2014.01.002
    Journal articles | 2014
    Davis A; Tinker AV; Friedlander M, 2014, '"platinum resistant" ovarian cancer: What is it, who to treat and how to measure benefit?', Gynecologic Oncology, 133, pp. 624 - 631, http://dx.doi.org/10.1016/j.ygyno.2014.02.038
    Journal articles | 2014
    Du Bois A; Floquet A; Kim JW; Rau J; Del Campo JM; Friedlander M; Pignata S; Fujiwara K; Vergote I; Colombo N; Mirza MR; Monk BJ; Kimmig R; Ray-Coquard I; Zang R; Diaz-Padilla I; Baumann KH; Mouret-Reynier MA; Kim JH; Kurzeder C; Lesoin A; Vasey P; Marth C; Canzler U; Scambia G; Shimada M; Calvert P; Pujade-Lauraine E; Kim BG; Herzog TJ; Mitrica I; Schade-Brittinger C; Wang Q; Crescenzo R; Harter P, 2014, 'Incorporation of pazopanib in maintenance therapy of ovarian cancer', Journal of Clinical Oncology, 32, pp. 3374 - 3381, http://dx.doi.org/10.1200/JCO.2014.55.7348
    Journal articles | 2014
    Friedlander ML; Covens A; Glasspool RM; Hilpert F; Kristensen G; Kwon S; Selle F; Small W; Witteveen E; Russell P, 2014, 'Gynecologic cancer intergroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract', International Journal of Gynecological Cancer, 24, pp. S78 - S82, http://dx.doi.org/10.1097/IGC.0000000000000239
    Journal articles | 2014
    Friedlander ML; Stockler M; O'Connell R; Voysey M; Oza A; Gillies K; Donovan H; Martyn J; Sjoquist K; Butow P; King MT, 2014, 'Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer a reality check: Results of stage 1 of the gynecologic cancer intergroup symptom benefit study', International Journal of Gynecological Cancer, 24, pp. 857 - 864, http://dx.doi.org/10.1097/IGC.0000000000000147
    Journal articles | 2014
    Friedlander ML, 2014, 'Commentary on the clinical trial reported by: Tewari KS, Sill M, Long III HJ, et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: A phase III randomized trial of the Gynecologic Oncology Group. J Clin Oncol 2013;(suppl; abstr 3)', Chinese Clinical Oncology, 3, http://dx.doi.org/10.3978/j.issn.2304-3865.2013.11.01
    Journal articles | 2014
    Gao B; Russell A; Beesley J; Chen XQ; Healey S; Henderson M; Wong M; Emmanuel C; Galletta L; Johnatty SE; Bowtell D; Haber M; Norris M; Harnett P; Chenevix-Trench G; Balleine RL; Defazio A; Gertig D; Green A; Webb P; Hung J; Moore S; Traficante N; Fereday S; Harrap K; Sadkowsky T; Pandeya N; Stuart-Harris R; Kirsten F; Rutovitz J; Clingan P; Glasgow A; Proietto A; Braye S; Otton G; Shannon J; Bonaventura T; Stewart J; Begbie S; Friedlander M; Bell D; Baron-Hay S; Ferrier A; Gard G; Nevell D; Pavlakis N; Valmadre S; Young B; Camaris C; Crouch R; Edwards L; Hacker N; Marsden D; Robertson G; Beale P; Beith J; Carter J; Dalrymple C; Hamilton A; Houghton R; Russell P; Links M; Grygiel J; Hill J; Brand A; Byth K; Jaworski R; Sharma R; Achen A; Wain G; Ward B; Papadimos D; Crandon A; Cummings M; Horwood K; Obermair A; Perrin L; Wyld D; Nicklin J; Davy M; Oehler MK; Hall C; Dodd T; Healy T; Pittman K; Henderson D; Miller J; Pierdes J; Blomfield P; Challis D; McIntosh R; Parker A; Brown B; Rome R; Allen D; Grant P; Hyde S; Laurie R; Robbie M; Healy D, 2014, 'Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer', Scientific Reports, 4, http://dx.doi.org/10.1038/srep04669
    Journal articles | 2014
    Grimison PS; Stockler MR; Chatfield M; Thomson DB; Gebski V; Friedlander M; Boland AL; Houghton B; Gurney H; Rosenthal M; Singhal N; Kichenadasse G; Wong SS; Lewis CR; Vasey PA; Toner GC, 2014, 'Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)', Annals of Oncology, 25, pp. 143 - 148, http://dx.doi.org/10.1093/annonc/mdt369
    Journal articles | 2014
    Hasegawa K; Nagao S; Yasuda M; Millan D; Viswanathan AN; Glasspool RM; Devouassoux-Shisheboran M; Covens A; Lorusso D; Kurzeder C; Kim JW; Gladieff L; Bryce J; Friedlander M; Fujiwara K, 2014, 'Gynecologic cancer intergroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix', International Journal of Gynecological Cancer, 24, pp. S90 - S95, http://dx.doi.org/10.1097/IGC.0000000000000297
    Journal articles | 2014
    Joly F; McAlpine J; Nout R; Åvall-Lundqvist E; Shash E; Friedlander M, 2014, 'Quality of life and patient-reported outcomes in endometrial cancer clinical trials: A call for action!', International Journal of Gynecological Cancer, 24, pp. 1693 - 1699, http://dx.doi.org/10.1097/IGC.0000000000000299
    Journal articles | 2014
    King MT; Stockler MR; Butow P; O'Connell R; Voysey M; Oza AM; Gillies K; Donovan HS; Mercieca-Bebber R; Martyn J; Sjoquist K; Friedlander ML, 2014, 'Development of the measure of ovarian symptoms and Treatment concerns aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer', International Journal of Gynecological Cancer, 24, pp. 865 - 873, http://dx.doi.org/10.1097/IGC.0000000000000167
    Journal articles | 2014
    Ledermann J; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott CL; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Dougherty B; Orr M; Hodgson D; Barrett JC; Matulonis U, 2014, 'Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial', The Lancet Oncology, 15, pp. 852 - 861, http://dx.doi.org/10.1016/S1470-2045(14)70228-1
    Journal articles | 2014
    Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote IB; Rustin GJS; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei DE; Fielding A; Spencer S; Bennett B; Parry D; Matulonis U, 2014, 'Health-Related Quality of Life (Hrqol) During Olaparib Maintenance Therapy in Patients with Platinum-Sensitive Relapsed Serous Ovarian Cancer (Psr Soc) and a Brca Mutation (Brcam)', Annals of Oncology, 25, pp. iv308 - iv308, http://dx.doi.org/10.1093/annonc/mdu338.11
    Journal articles | 2014
    Ledermann JA; Luvero D; Shafer A; O'Connor D; Mangili G; Friedlander M; Pfisterer J; Mirza MR; Kim JW; Alexandre J; Oza A; Brown J, 2014, 'Gynecologic cancer intergroup (GCIG) Consensus review for mucinous ovarian carcinoma', International Journal of Gynecological Cancer, 24, pp. S14 - S19, http://dx.doi.org/10.1097/IGC.0000000000000296
    Journal articles | 2014
    Long A; Toner G; Stockler MR; Thomson DB; Gebski V; Yip S; King M; Friedlander M; Quinn DI; Singhal N; Roncolato F; Grimison P, 2014, 'Anzup 1302: a Randomised Phase 3 Trial of Accelerated Versus Standard Bep Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumours (P3Bep)', Annals of Oncology, 25, pp. iv303 - iv303, http://dx.doi.org/10.1093/annonc/mdu337.65
    Journal articles | 2014
    McAlpine JN; Greimel E; Brotto LA; Nout RA; Shash E; Åvall-Lundqvist E; Friedlander ML; Joly F, 2014, 'Quality of life research in endometrial cancer what is needed to advance progress in this disease site? Methodological considerations from the Gynecologic cancer InterGroup Symptom Benefit Working Group brainstorming session, leiden 2012', International Journal of Gynecological Cancer, 24, pp. 1686 - 1692, http://dx.doi.org/10.1097/IGC.0000000000000245
    Journal articles | 2014
    Meiser B; Price MA; Butow PN; Rahman B; Tucker K; Cheah B; Bickerstaffe A; Hopper J; Phillips KA; Bennett B; Tennant C; Milne RL; Weideman P; Stanhope L; Picken S; Friedlander ML; Goldgar D, 2014, 'Misperceptions of ovarian cancer risk in women at increased risk for hereditary ovarian cancer', Familial Cancer, 13, pp. 153 - 162, http://dx.doi.org/10.1007/s10689-013-9687-y
    Journal articles | 2014
    Mileshkin LR; Narayan K; Moore KN; Rischin D; King M; Kolodziej I; Martyn J; Friedlander M; Quinn M; Small W; Thomas G; Fyles AW; Gebski V; Stockler MR, 2014, 'A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: Outback (ANZGOG0902/GOG0274/RTOG1174).', Journal of Clinical Oncology, 32, pp. TPS5632 - TPS5632, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.tps5632
    Journal articles | 2014
    Murray JE; Pickering HR; Lin CS-Y; Goldstein D; Friedlander ML; Kiernan MC; Krishnan AV, 2014, '6. Functional impact of neuropathy in patients receiving oxaliplatin chemotherapy', Clinical Neurophysiology, 125, pp. e3 - e3, http://dx.doi.org/10.1016/j.clinph.2013.10.028
    Journal articles | 2014
    Park SB; Kwok JB; Loy CT; Friedlander ML; Lin CSY; Krishnan AV; Lewis CR; Kiernan MC, 2014, 'Paclitaxel-induced neuropathy: Potential association of MAPT and GSK3B genotypes', BMC Cancer, 14, http://dx.doi.org/10.1186/1471-2407-14-993
    Journal articles | 2014
    Peculis LD; Ius Y; Campion M; Friedlander M; Hacker N, 2014, 'Stage IB2 adenosquamous cervical cancer diagnosed at 19-weeks gestation', Australian and New Zealand Journal of Obstetrics and Gynaecology, http://dx.doi.org/10.1111/ajo.12281
    Journal articles | 2014
    Reed NS; Gomez-Garcia E; Gallardo-Rincon D; Barrette B; Baumann K; Friedlander M; Kichenadasse G; Kim JW; Lorusso D; Mirza MR; Ray-Coquard I, 2014, 'Gynecologic cancer InterGroup (GCIG) consensus review for carcinoid tumors of the ovary', International Journal of Gynecological Cancer, 24, pp. S35 - S41, http://dx.doi.org/10.1097/IGC.0000000000000265
    Journal articles | 2014
    Reed NS; Pautier P; Ã…vall-Lundqvist E; Choi CH; Du Bois A; Friedlander M; Fyles A; Kichenadasse G; Provencher DM; Ray-Coquard I, 2014, 'Gynecologic cancer interGroup (GCIG) consensus review for ovarian small cell cancers', International Journal of Gynecological Cancer, 24, pp. S30 - S34, http://dx.doi.org/10.1097/IGC.0000000000000293
    Journal articles | 2014
    Sousa M; Meiser B; Hickey M; Jarvis S; Lombard J; Chirgwin J; Segelov E; Lewis C; Friedlander M, 2014, 'PEGASUS - PREVALENCE AND SEVERITY OF GENITOURINARY SYMPTOMS AND IMPACT ON SEXUAL FUNCTION AND QOL IN POSTMENOPAUSAL WOMEN RECEIVING ENDOCRINE THERAPY FOR EARLY BREAST CANCER', INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 24, pp. 1041 - 1042, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966501317&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Journal articles | 2014
    Stockler MR; Hilpert F; Friedlander M; King MT; Wenzel L; Lee CK; Joly F; De Gregorio N; Arranz JA; Mirza MR; Sorio R; Freudensprung U; Sneller V; Hales G; Pujade-Lauraine E, 2014, 'Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer', Journal of Clinical Oncology, 32, pp. 1309 - 1316, http://dx.doi.org/10.1200/JCO.2013.51.4240
    Journal articles | 2014
    Webber K; Sommeijer D; Mileshkin L; Friedlander ML, 2014, 'OVQUEST: LIVING AFTER THE DIAGNOSIS AND TREATMENT OF OVARIAN CANCER. PRELIMINARY RESULTS FROM AN INTERNET-BASED SURVEY', INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 24, pp. 252 - 252, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500197&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Journal articles | 2014
    2014, 'Analysis of intermediate clinical endpoints from a Phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC)', Gynecologic Oncology, 133, pp. 54 - 55, http://dx.doi.org/10.1016/j.ygyno.2014.03.152
    Journal articles | 2014
    2014, 'Cutaneous adverse effects of hormonal adjuvant therapy for breast cancer: A case of localised urticarial vasculitis following anastrozole therapy and a review of the literature', Australasian Journal of Dermatology, 55, pp. 282 - 285, http://dx.doi.org/10.1111/ajd.12110
    Journal articles | 2014
    2014, 'Erhaltungstherapie mit Olaparib nach platinhaltiger Re-induktion bei platinsensitivem serösem Ovarialkarzinomrezidiv: eine Placebo-kontrollierte Phase II Studie', Geburtshilfe und Frauenheilkunde, 74, http://dx.doi.org/10.1055/s-0034-1388545
    Journal articles | 2014
    2014, 'Pazopanib Versus Placebo in Women Without Progression After First-Line Chemotherapy for Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (Aeoc): Second Interim Overall Survival Analysis from the Ago-Ovar16 Trial', Annals of Oncology, 25, pp. iv307 - iv307, http://dx.doi.org/10.1093/annonc/mdu338.6
    Journal articles | 2013
    Ang JE; Gourley C; Powell CB; High H; Shapira-Frommer R; Castonguay V; De Greve J; Atkinson T; Yap TA; Sandhu S; Banerjee S; Chen LM; Friedlander ML; Kaufman B; Oza AM; Matulonis U; Barber LJ; Kozarewa I; Fenwick K; Assiotis I; Campbell J; Chen L; De Bono JS; Gore ME; Lord CJ; Ashworth A; Kaye SB, 2013, 'Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: A multi-institutional study', Clinical Cancer Research, 19, pp. 5485 - 5493, http://dx.doi.org/10.1158/1078-0432.CCR-13-1262
    Journal articles | 2013
    Baumbusch LO; Helland A; Wang Y; Liestøl K; Schaner ME; Holm R; Etemadmoghadam D; Alsop K; Brown P; Mitchell G; Fereday S; DeFazio A; Bowtell DD L; Kristensen GB; Lingjærde OC; Børresen-Dale AL, 2013, 'High Levels of Genomic Aberrations in Serous Ovarian Cancers Are Associated with Better Survival', PLoS ONE, 8, http://dx.doi.org/10.1371/journal.pone.0054356
    Journal articles | 2013
    Blinman P; Gainford C; Donoghoe M; Martyn J; Blomfield P; Grant P; Kichenadasse G; Vaughan M; Brand A; Shannon C; Gebski V; Stockler M; Friedlander M, 2013, 'Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: An ANZGOG study', Journal of Gynecologic Oncology, 24, pp. 359 - 366, http://dx.doi.org/10.3802/jgo.2013.24.4.359
    Journal articles | 2013
    Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Weideman PC; Birch KE; Hopper JL; Phillips KA, 2013, 'Do BRCA1 and BRCA2 mutation carriers have earlier natural menopause than their noncarrier relatives? Results from the Kathleen Cuningham foundation consortium for research into familial breast cancer', Journal of Clinical Oncology, 31, pp. 3920 - 3925, http://dx.doi.org/10.1200/JCO.2013.49.3007
    Journal articles | 2013
    Collins IM; Milne RL; Weideman PC; McLachlan SA; Friedlander ML; Cuningham K; Hopper JL; Phillips KA, 2013, 'Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers', Medical Journal of Australia, 199, pp. 680 - 683, http://dx.doi.org/10.5694/mja13.10848
    Journal articles | 2013
    Couch FJ; Wang X; McGuffog L; Lee A; Olswold C; Kuchenbaecker KB; Soucy P; Fredericksen Z; Barrowdale D; Dennis J; Gaudet MM; Dicks E; Kosel M; Healey S; Sinilnikova OM; Lee A; Bacot F; Vincent D; Hogervorst FBL; Peock S; Stoppa-Lyonnet D; Jakubowska A; Radice P; Schmutzler RK; Domchek SM; Piedmonte M; Singer CF; Friedman E; Thomassen M; Hansen TVO; Neuhausen SL; Szabo CI; Blanco I; Greene MH; Karlan BY; Garber J; Phelan CM; Weitzel JN; Montagna M; Olah E; Andrulis IL; Godwin AK; Yannoukakos D; Goldgar DE; Caldes T; Nevanlinna H; Osorio A; Terry MB; Daly MB; van Rensburg EJ; Hamann U; Ramus SJ; Ewart Toland A; Caligo MA; Olopade OI; Tung N; Claes K; Beattie MS; Southey MC; Imyanitov EN; Tischkowitz M; Janavicius R; John EM; Kwong A; Diez O; Balmaña J; Barkardottir RB; Arun BK; Rennert G; Teo SH; Ganz PA; Campbell I; van der Hout AH; van Deurzen CHM; Seynaeve C; Gómez Garcia EB; van Leeuwen FE; Meijers-Heijboer HEJ; Gille JJP; Ausems MGEM; Blok MJ; Ligtenberg MJL; Rookus MA; Devilee P; Verhoef S; van Os TAM; Wijnen JT; Frost D; Ellis S; Fineberg E; Platte R; Evans DG; Izatt L; Eeles RA; Adlard J; Eccles DM; Cook J; Brewer C; Douglas F; Hodgson S, 2013, 'Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk', PLoS Genetics, 9, http://dx.doi.org/10.1371/journal.pgen.1003212
    Journal articles | 2013
    Friedlander ML; King MT, 2013, 'Patient-reported outcomes in ovarian cancer clinical trials', Annals of Oncology, 24, http://dx.doi.org/10.1093/annonc/mdt474
    Journal articles | 2013
    Friedlander ML; Stockler MR; Butow P; King MT; McAlpine J; Tinker A; Ledermann JA, 2013, 'Clinical trials of palliative chemotherapy in platinum-resistant or -refractory ovarian cancer: Time to think differently?', Journal of Clinical Oncology, 31, pp. 2362, http://dx.doi.org/10.1200/JCO.2012.47.7927
    Journal articles | 2013
    Gleeson MA; Meiser B; Barlow-Stewart K; Trainer A; Tucker K; Watts KJ; Friedlander M; Kasparian NA, 2013, 'Communication and information needs of women diagnosed with ovarian cancer regarding treatment-focused genetic testing', Oncology Nursing Forum, 40, pp. 275 - 283, http://dx.doi.org/10.1188/13.ONF.40-03AP
    Journal articles | 2013
    Hacker NF; Barlow EL; Scurry J; Gebski V; Farrell R; Robertson G; Friedlander ML; Jackson M, 2013, 'Primary surgical management with tailored adjuvant radiation for stage IB2 cervical cancer', Obstetrics and Gynecology, 121, pp. 765 - 772, http://dx.doi.org/10.1097/AOG.0b013e3182887836
    Journal articles | 2013
    Jordan S; Steer C; DeFazio A; Quinn M; Obermair A; Friedlander M; Francis J; O'Brien S; Goss G; Wyld D; Webb P, 2013, 'Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer - A population-based study', Gynecologic Oncology, 129, pp. 310 - 317, http://dx.doi.org/10.1016/j.ygyno.2013.02.007
    Journal articles | 2013
    Juraskova I; Jarvis SK; Mok K; Peate M; Meiser B; Cheah BC; Mireskandari S; Friedlander M, 2013, 'The acceptability, feasibility and efficacy (Phase I/II study) of the OVERcome (Olive oil, Vaginal Exercise and moisturizeR) intervention to improve dyspareunia and alleviate sexual problems in women with breast cancer.', Journal of Sexual Medicine, EPUB ahead of print, pp. 2549 - 2558, http://dx.doi.org/10.1111/jsm.12156
    Journal articles | 2013
    Kaufman B; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmaña J; Mitchell G; Fried G; Bowen K; Fielding A; Domchek SM, 2013, 'Olaparib monotherapy in patients with advanced cancer and a germ-line BRCA1/2 mutation: An open-label phase II study.', Journal of Clinical Oncology, 31, pp. 11024 - 11024, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.11024
    Journal articles | 2013
    Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin GJS; Scott CL; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Macpherson E; Dougherty B; Jürgensmeier JM; Orr M; Matulonis U, 2013, 'Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm).', Journal of Clinical Oncology, 31, pp. 5505 - 5505, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.5505
    Journal articles | 2013
    Lee CK; Simes RJ; Brown C; Gebski V; Pfisterer J; Swart AM; Berton-Rigaud D; Plante M; Skeie-Jensen T; Vergote I; Schauer C; Pisano C; Parma G; Baumann K; Ledermann JA; Pujade-Lauraine E; Bentley J; Kristensen G; Belau A; Nankivell M; Canzler U; Lord SJ; Kurzeder C; Friedlander M, 2013, 'A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer', Annals of Oncology, 24, pp. 937 - 943, http://dx.doi.org/10.1093/annonc/mds538
    Journal articles | 2013
    Luk WY; Friedlander M, 2013, 'A fibroid or cancer? A rare case of mixed choriocarcinoma and epithelioid trophoblastic tumour.', Case Rep Obstet Gynecol, 2013, pp. 492754, http://dx.doi.org/10.1155/2013/492754
    Journal articles | 2013
    Nagle CM; Olsen CM; Ibiebele TI; Spurdle AB; Webb PM, 2013, 'Glycemic index, glycemic load and endometrial cancer risk: results from the Australian National Endometrial Cancer study and an updated systematic review and meta-analysis', EUROPEAN JOURNAL OF NUTRITION, 52, pp. 705 - 715, http://dx.doi.org/10.1007/s00394-012-0376-7
    Journal articles | 2013
    Olsen CM; Nagle CM; Whiteman DC; Ness R; Pearce CL; Pike MC; Rossing MA; Terry KL; Wu AH; Group S; Risch HA; Yu H; Doherty JA; Chang-Claude J; Hein R; Nickels S; Wang-Gohrke S; Goodman MT; Carney ME; Matsuno RK; Lurie G; Moysich K; Kjaer SK; Jensen A; Hogdall E; Goode EL; Fridley BL; Vierkant RA; Larson MC; Schildkraut J; Hoyo C; Moorman P; Weber RP; Cramer DW; Vitonis AF; Bandera EV; Olson SH; Rodriguez-Rodriguez L; King M; Brinton LA; Yang H; Garcia-Closas M; Lissowska J; Anton-Culver H; Ziogas A; Gayther SA; Ramus SJ; Menon U; Gentry-Maharaj A; Webb PM, 2013, 'Obesity and risk of ovarian cancer subtypes: Evidence from the Ovarian Cancer Association Consortium', Endocrine-Related Cancer, 20, pp. 251 - 262, http://dx.doi.org/10.1530/ERC-12-0395
    Journal articles | 2013
    Park SB; Goldstein D; Krishnan AV; Lin CS Y; Friedlander ML; Cassidy J; Koltzenburg M; Kiernan MC, 2013, 'Chemotherapy-induced peripheral neurotoxicity: A critical analysis', CA Cancer Journal for Clinicians, http://dx.doi.org/10.1002/caac.21204
    Journal articles | 2013
    Park SB; Goldstein D; Krishnan AV; Lin CSY; Friedlander ML; Cassidy J; Koltzenburg M; Kiernan MC, 2013, 'Chemotherapy-induced peripheral neurotoxicity: A critical analysis', CA Cancer Journal for Clinicians, 63, pp. 419 - 437, http://dx.doi.org/10.3322/caac.21204
    Journal articles | 2013
    Permuth-Wey J; Lawrenson K; Shen HC; Velkova A; Tyrer JP; Chen Z; Lin HY; Ann Chen Y; Tsai YY; Qu X; Ramus SJ; Karevan R; Lee J; Lee N; Larson MC; Aben KK; Anton-Culver H; Antonenkova N; Antoniou AC; Armasu SM; Bacot F; Baglietto L; Bandera EV; Barnholtz-Sloan J; Beckmann MW; Birrer MJ; Bloom G; Bogdanova N; Brinton LA; Brooks-Wilson A; Brown R; Butzow R; Cai Q; Campbell I; Chang-Claude J; Chanock S; Chenevix-Trench G; Cheng JQ; Cicek MS; Coetzee GA; Cook LS; Couch FJ; Cramer DW; Cunningham JM; Dansonka-Mieszkowska A; Despierre E; Doherty JA; Dörk T; Du Bois A; Dürst M; Easton DF; Eccles D; Edwards R; Ekici AB; Fasching PA; Fenstermacher DA; Flanagan JM; Garcia-Closas M; Gentry-Maharaj A; Giles GG; Glasspool RM; Gonzalez-Bosquet J; Goodman MT; Gore M; Górski B; Gronwald J; Hall P; Halle MK; Harter P; Heitz F; Hillemanns P; Hoatlin M; Høgdall CK; Høgdall E; Hosono S; Jakubowska A; Jensen A; Jim H; Kalli KR; Karlan BY; Kaye SB; Kelemen LE; Kiemeney LA; Kikkawa F; Konecny GE; Krakstad C; Krüger Kjaer S; Kupryjanczyk J; Lambrechts D; Lambrechts S; Lancaster JM; Le ND; Leminen A; Levine DA; Liang D; Kiong Lim B; Lin J; Lissowska J; Lu KH; Lubiński J, 2013, 'Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31', Nature Communications, 4, http://dx.doi.org/10.1038/ncomms2613
    Journal articles | 2013
    Phillips KA; Milne RL; Rookus MA; Daly MB; Antoniou AC; Peock S; Frost D; Easton DF; Ellis S; Friedlander ML; Buys SS; Andrieu N; Noguès C; Stoppa-Lyonnet D; Bonadona V; Pujol P; McLachlan SA; John EM; Hooning MJ; Seynaeve C; Tollenaar RAEM; Goldgar DE; Terry MB; Caldes T; Weideman PC; Andrulis IL; Singer CF; Birch K; Simard J; Southey MC; Olsson HL; Jakubowska A; Olah E; Gerdes AM; Foretova L; Hopper JL, 2013, 'Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers', Journal of Clinical Oncology, 31, pp. 3091 - 3099, http://dx.doi.org/10.1200/JCO.2012.47.8313
    Journal articles | 2013
    Price MA; Bell ML; Sommeijer DW; Friedlander M; Stockler MR; Defazio A; Webb PM; Butow PN, 2013, 'Physical symptoms, coping styles and quality of life in recurrent ovarian cancer: A prospective population-based study over the last year of life', Gynecologic Oncology, 130, pp. 162 - 168, http://dx.doi.org/10.1016/j.ygyno.2013.03.031
    Journal articles | 2013
    Price MA; Butow PN; Bell ML; Webb PM; deFazio A; Friedlander M; Fardell JE, 2013, 'PSYCHOSOCIAL PREDICTORS OF SURVIVAL IN WOMEN WITH INVASIVE OVARIAN CANCER: A POPULATION-BASED PROSPECTIVE STUDY', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 9, pp. 91 - 91, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800106&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Journal articles | 2013
    Shen H; Fridley BL; Song H; Lawrenson K; Cunningham JM; Ramus SJ; Cicek MS; Tyrer J; Stram D; Larson MC; Köbel M; Ziogas A; Zheng W; Yang HP; Wu AH; Wozniak EL; Ling Woo Y; Winterhoff B; Wik E; Whittemore AS; Wentzensen N; Palmieri Weber R; Vitonis AF; Vincent D; Vierkant RA; Vergote I; Van Den Berg D; Van Altena AM; Tworoger SS; Thompson PJ; Tessier DC; Terry KL; Teo SH; Templeman C; Stram DO; Southey MC; Sieh W; Siddiqui N; Shvetsov YB; Shu XO; Shridhar V; Wang-Gohrke S; Severi G; Schwaab I; Salvesen HB; Rzepecka IK; Runnebaum IB; Anne Rossing M; Rodriguez-Rodriguez L; Risch HA; Renner SP; Poole EM; Pike MC; Phelan CM; Pelttari LM; Pejovic T; Paul J; Orlow I; Zawiah Omar S; Olson SH; Odunsi K; Nickels S; Nevanlinna H; Ness RB; Narod SA; Nakanishi T; Moysich KB; Monteiro ANA; Moes-Sosnowska J; Modugno F; Menon U; McLaughlin JR; McGuire V; Matsuo K; Mat Adenan NA; Massuger LFAG; Lurie G; Lundvall L; Lubiński J; Lissowska J; Levine DA; Leminen A; Lee AW; Le ND; Lambrechts S; Lambrechts D; Kupryjanczyk J; Krakstad C; Konecny GE; Krüger Kjaer S; Kiemeney LA; Kelemen LE; Keeney GL; Karlan BY; Karevan R; Kalli KR; Kajiyama H; Ji BT; Jensen A; Jakubowska A, 2013, 'Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer', Nature Communications, 4, http://dx.doi.org/10.1038/ncomms2629
    Journal articles | 2013
    Sjoquist KM; Friedlander ML; O'Connell RL; Voysey M; King MT; Stockler MR; Oza AM; Gillies K; Martyn JK; Butow PN, 2013, 'Hope, quality of life, and benefit from treatment in women having chemotherapy for platinum-resistant/refractory recurrent ovarian cancer: The gynecologic cancer intergroup symptom benefit study', Oncologist, 18, pp. 1221 - 1228, http://dx.doi.org/10.1634/theoncologist.2013-0175
    Journal articles | 2013
    Sommeijer DW; Sjoquist KM; Friedlander M, 2013, 'Hormonal treatment in recurrent and metastatic gynaecological cancers: A review of the current literature', Current Oncology Reports, 15, pp. 541 - 548, http://dx.doi.org/10.1007/s11912-013-0343-3
    Journal articles | 2013
    Thewes B; Bell ML; Butow P; Beith J; Boyle F; Friedlander M; McLachlan SA, 2013, 'Psychological morbidity and stress but not social factors influence level of fear of cancer recurrence in young women with early breast cancer: Results of a cross-sectional study', Psycho-Oncology, 22, pp. 2797 - 2806, http://dx.doi.org/10.1002/pon.3348
    Journal articles | 2013
    2013, 'Health-related quality of life (HRQoL) results from the AURELIA trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (OC).', Journal of Clinical Oncology, 31, pp. 5542 - 5542, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.5542
    Journal articles | 2013
    2013, 'PARAGON: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynecologic neoplasms: ANZGOG 0903.', Journal of Clinical Oncology, 31, pp. TPS5614 - TPS5614, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.tps5614
    Journal articles | 2013
    2013, 'Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer (AOC): Results of an international intergroup trial (AGO-OVAR16).', Journal of Clinical Oncology, 31, pp. LBA5503 - LBA5503, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.lba5503
    Journal articles | 2013
    2013, 'The unmet needs of cancer survivors and their preferences for discussing them with oncologists and general practitioners (GPs).', Journal of Clinical Oncology, 31, pp. 9602 - 9602, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.9602
    Journal articles | 2013
    2013, 'Using decision aids for improving treatment-choices for women with breast cancer.', Breast Cancer Management, 2, pp. 23 - 31, http://dx.doi.org/10.2217/bmt.12.61
    Journal articles | 2012
    Alsop K; Fereday S; Meldrum C; DeFazio A; Emmanuel C; George J; Dobrovic A; Birrer MJ; Webb PM; Stewart C; Friedlander M; Fox S; Bowtell D; Mitchell G, 2012, 'BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: A report from the Australian ovarian cancer study group', Journal of Clinical Oncology, 30, pp. 2654 - 2663, http://dx.doi.org/10.1200/JCO.2011.39.8545
    Journal articles | 2012
    Bennett BK; Lloyd AR; Webber K; Friedlander M; Goldstein D, 2012, 'Predictors of resilience in women treated for breast cancer: A prospective study.', Journal of Clinical Oncology, 30, pp. 9044 - 9044, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.9044
    Journal articles | 2012
    Berek JS; Crum C; Friedlander M, 2012, 'Cancer of the ovary, fallopian tube, and peritoneum', International Journal of Gynecology and Obstetrics, 119, http://dx.doi.org/10.1016/S0020-7292(12)60025-3
    Journal articles | 2012
    Goldstein D; Bennett BK; Webber K; Boyle F; De Souza P; Wilcken NRC; Scott E; Toppler R; Murie P; O''Malley L; Mccourt J; Friedlander M; Hickie IB; Lloyd AR, 2012, 'Cancer-related fatigue in women with breast cancer: outcomes of a 5 year prospective cohort study.', Journal of Clinical Oncology, 30, pp. 1805 - 1812, http://dx.doi.org/10.1200/JCO.2011.34.6148
    Journal articles | 2012
    Goodwin PJ; Phillips KA; West DW; Ennis M; Hopper JL; John EM; O'Malley FP; Milne RL; Andrulis IL; Friedlander ML; Southey MC; Apicella C; Giles GG; Longacre TA, 2012, 'Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: An international prospective breast cancer family registry population-based cohort study', Journal of Clinical Oncology, 30, pp. 19 - 26, http://dx.doi.org/10.1200/JCO.2010.33.0068
    Journal articles | 2012
    Kaye SB; Lubinski J; Matulonis U; Ang JE; Gourley C; Karlan BY; Amnon A; Bell-McGuinn KM; Chen LM; Friedlander M; Safra T; Vergote I; Wickens M; Lowe ES; Carmichael J; Kaufman B, 2012, 'Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer', Journal of Clinical Oncology, 30, pp. 372 - 379, http://dx.doi.org/10.1200/JCO.2011.36.9215
    Journal articles | 2012
    Kirchhoff T; Offit K; Gaudet MM; Pharoah PDP; Easton DF; Antoniou AC; Mcguffog L; Humphreys MK; Dunning AM; Bojesen SE; Nordestgaard BG; Flyger H; Kang D; Yoo KY; Noh DY; Ahn SH; Dork T; Schürmann P; Karstens JH; Hillemanns P; Couch FJ; Olson J; Vachon C; Wang X; Cox A; Brock I; Elliott G; Reed MWR; Burwinkel B; Meindl A; Brauch H; Justenhoven C; Hamann U; Ko YD; Fischer HP; Brüning T; Pesch B; Harth V; Rabstein S; Broeks A; Schmidt MK; Van 't Veer LJ; Braaf LM; Johnson N; Fletcher O; Gibson L; Peto J; Turnbull C; Seal S; Renwick A; Rahman N; Wu PE; Yu JC; Hsiung CN; Shen CY; Southey MC; Hopper JL; Hammet F; van Dorpe T; Dieudonne AS; Hatse S; Lambrechts D; Andrulis IL; Bogdanova N; Antonenkova N; Rogov JI; Prokofieva D; Bermisheva M; Khusnutdinova E; van Asperen CJ; Tollenaar RAEM; Hooning MJ; Devilee P; Margolin S; Lindblom A; Milne RL; Arias JI; Pilar Zamora M; Benítez J; Severi G; Baglietto L; Giles GG; Chenevix-Trench G; Spurdle AB; Beesley J; Chen X; Holland H; Healey S; Wang-Gohrke S; Chang-Claude J; Mannermaa A; Kosma VM; Kauppinen J; Kataja V; Agnarsson BA; Caligo MA; Godwin AK; Nevanlinna H; Heikkinen T; Fredericksen Z, 2012, 'Breast cancer risk and 6q22.33: Combined results from breast cancer association consortium and consortium of investigators on modifiers of brca1/2', PLoS ONE, 7, http://dx.doi.org/10.1371/journal.pone.0035706
    Journal articles | 2012
    Ledermann J; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Macpherson E; Watkins C; Carmichael J; Matulonis U, 2012, 'Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer', New England Journal of Medicine, 366, pp. 1382 - 1392, http://dx.doi.org/10.1056/NEJMoa1105535
    Journal articles | 2012
    Mileshkin LR; Narayan K; Moore KN; Rischin D; Trimble EL; Stockler MR; King M; Kolodziej I; Martyn J; Friedlander M; Quinn M; Shrivastava SK; Small W; Thomas G; Craighead PS; Gebski V, 2012, 'A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The OUTBACK TRIAL.', Journal of Clinical Oncology, 30, pp. TPS5116 - TPS5116, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.tps5116
    Journal articles | 2012
    Oza AM; Cibula D; Oaknin A; Poole CJ; Mathijssen RHJ; Sonke GS; Colombo N; Špacek J; Vuylsteke P; Hirte HW; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Tchakov I; Friedlander M, 2012, 'Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study.', Journal of Clinical Oncology, 30, pp. 5001 - 5001, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.5001
    Journal articles | 2012
    Ribi K; Aldridge J; Phillips K-A; Thompson A; Harvey V; Thuerlimann B; Cardoso F; Pagani O; Coates AS; Goldhirsch A; Price KN; Gelber RD; Bernhard J, 2012, 'Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer', BRITISH JOURNAL OF CANCER, 106, pp. 1618 - 1625, http://dx.doi.org/10.1038/bjc.2012.156
    Journal articles | 2012
    Sallo FB; Peto T; Egan C; Wolf-Schnurrbusch UE K; Clemons TE; Gillies MC; Pauleikhoff D; Rubin GS; Chew EY; Bird AC; Sahel JA; Guymer R; Soubrane G; Gaudric A; Schwartz S; Constable I; Cooney M; Singerman L; Friedlander M; Moisseiev J; Rosen R; Murphy R; Holz F; Comer G; Blodi B; Do D; Brucker A; Narayanan R; Wolf S; Rosenfeld P; Bernstein PS; Miller JW, 2012, 'The IS/OS junction layer in the natural history of type 2 idiopathic macular telangiectasia', Investigative Ophthalmology and Visual Science, 53, pp. 7889 - 7895, http://dx.doi.org/10.1167/iovs.12-10765
    Journal articles | 2012
    Watts KJ; Meiser B; Mitchell GF; Kirk J; Saunders C; Peate M; Duffy J; Kelly PJ; Gleeson MA; Barlow-Stewart K; Rahman B; Friedlander M; Tucker K; TFGT CG, 2012, 'How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer', BMC Cancer, 12, http://dx.doi.org/10.1186/1471-2407-12-320
    Journal articles | 2012
    2012, 'Accelerated BEP for metastatic germ cell tumors: Combined analysis of Australian and U.K. phase I/II trials.', Journal of Clinical Oncology, 30, pp. 4531 - 4531, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.4531
    Journal articles | 2012
    2012, 'Association of tamoxifen use and reduced risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers', Hereditary Cancer in Clinical Practice, 10, pp. A11 - A11, http://dx.doi.org/10.1186/1897-4287-10-s2-a11
    Journal articles | 2012
    2012, 'LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin', Cancer Research, 72, pp. 4060 - 4073, http://dx.doi.org/10.1158/0008-5472.CAN-12-0203
    Journal articles | 2012
    2012, 'Pathological diagnosis of ovarian cancer', Hereditary Cancer in Clinical Practice, 10, pp. A82 - A82, http://dx.doi.org/10.1186/1897-4287-10-s2-a82
    Journal articles | 2012
    2012, 'Progression-free survival (PFS) as a surrogate end point for overall survival (OS) in first-line treatment of advanced epithelial ovarian cancer (EOC).', Journal of Clinical Oncology, 30, pp. 5081 - 5081, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.5081
    Journal articles | 2012
    2012, 'Safety and efficacy results from two randomized expansions of a phase I study of a tablet formulation of the PARP inhibitor, olaparib, in ovarian and breast cancer patients with BRCA1/2 mutations.', Journal of Clinical Oncology, 30, pp. 3048 - 3048, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.3048
    Journal articles | 2012
    2012, 'Use of chemotherapy (CT) in BRCA1/2-deficient ovarian cancer (BDOC) patients (pts) with poly-ADP-ribose polymerase inhibitor (PARPi) resistance: A multi-institutional study.', Journal of Clinical Oncology, 30, pp. 5022 - 5022, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.5022
    Journal articles | 2011
    Anglesio M; Kulbe H; Friedlander M; Rischin D; Lemech C; Power J; Coward J; Cowin P; House CM; Chakravarty P; Gorringe K; Campbell I; George J, 2011, 'IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.', Clinical Cancer Research, 17, pp. 2538 - 2548, http://dx.doi.org/10.1158/1078-0432.CCR-10-3314
    Journal articles | 2011
    Bowtell DD L; Friedlander M; Quinn M; Mitchell G, 2011, 'A response to the forgotten fallopian tube', Nature Reviews Cancer, 11, http://dx.doi.org/10.1038/nrc2946-c2
    Journal articles | 2011
    Friedlander M; Trimble E; Tinker A; Alberts D; Avall-lundqvist E; Brady M; Harter P; Pignata S; Pujade-lauraine E; Sehouli J; Vergote I; Beale P; Bekkers R; Calvert P; Copeland LM; Glasspool R; Gonzalez-martin A; Katsaros D; Kim JW; Miller B; Provencher D; Rubinstein L; Atri M; Zeimet A; Bacon M; Kitchener H; Stuart GW, 2011, 'Clinical trials in recurrent ovarian cancer.', International Journal of Gynecological Cancer, 21, pp. 771 - 775, http://dx.doi.org/10.1097/IGC.0b013e31821bb8aa
    Journal articles | 2011
    Griffiths G, 2011, 'International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial', JOURNAL OF CLINICAL ONCOLOGY, 29, pp. 2171 - 2177, http://dx.doi.org/10.1200/JCO.2010.32.3139
    Journal articles | 2011
    Grimison PS; Thomson DB; Stockler MR; Chatfield MD; Friedlander M; Gebski V; Boland AL; Houghton BB; Gurney H; Rosenthal M; Singhal N; Kichenadasse G; Wong SS; Lewis CR; Vasey PA; Toner GC, 2011, 'Accelerated BEP for advanced germ cell tumors: An Australian multicenter phase I/II trial.', JOURNAL OF CLINICAL ONCOLOGY, 29, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.4561
    Journal articles | 2011
    Helland A; Anglesio MS; George J; Cowin PA; Johnstone CN; House CM; Sheppard KE; Etemadmoghadam D; Melnyk N; Rustgi AK; Phillips WA; Johnsen H; Holm R; Kristensen GB; Birrer MJ; Pearson RB; Børresen-Dale AL; Huntsman DG; deFazio A; Creighton CJ; Smyth GK; Bowtell DDL, 2011, 'Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers', PLoS ONE, 6, http://dx.doi.org/10.1371/journal.pone.0018064
    Journal articles | 2011
    Juraskova I; Jarvis S; Mok K; Peate M; Meiser B; Mireskandari S; Friedlander M, 2011, 'OVERcome: An intervention study to improve sexual function in women with breast cancer.', J Clin Oncol, 29, pp. 9066, http://www.ncbi.nlm.nih.gov/pubmed/28021576
    Journal articles | 2011
    Lee CK; Simes RJ; Brown C; Lord S; Wagner U; Plante M; Vergote I; Pisano C; Parma G; Burgess AJ; Bourgeois H; Högberg T; Bentley JD; Angleitner-boubenizek L; Ferrero A; Richter B; Hirte H; Gebski V; Pfisterer J; Pujade-lauraine E; Friedlander M, 2011, 'Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer.', British Journal of Cancer, 105, pp. 1144 - 1150, http://dx.doi.org/10.1038/bjc.2011.364
    Journal articles | 2011
    Park SB; Lin CS-Y; Krishnan AV; Friedlander M; Lewis C; Kiernan MC, 2011, 'Early Progressive and Sustained Dysfunction of Sensory Axons Underlies Paclitaxel-induced Neuropathy', Muscle and Nerve, 43, pp. 367 - 374, http://dx.doi.org/10.1002/mus.21874
    Journal articles | 2011
    Park SB; Lin CS-Y; Krishnan AV; Goldstein D; Friedlander M; Kiernan MC, 2011, 'Dose effects of Oxaliplatin on persistent and transient na+ conductances and the development of neurotoxicity', PLoS One, 6, pp. 1 - 7, http://dx.doi.org/10.1371/journal.pone.0018469
    Journal articles | 2011
    Park SB; Lin CS-Y; Krishnan AV; Goldstein D; Friedlander M; Kiernan MC, 2011, 'Long-term neuropathy after Oxaliplatin treatment: Challenging the dictum of reversibility', Oncologist, 16, pp. 708 - 716, http://dx.doi.org/10.1634/theoncologist.2010-0248
    Journal articles | 2011
    Peate M; Meiser B; Friedlander M; Zorbas H; Rovelli S; Sansom-daly U; Sangster J; Hadzi-Pavlovic D; Hickey MS, 2011, 'It’s now or never: fertility-related knowledge, decision-making preferences, and treatment intentions in young women with breast cancer. An Australian Fertility Decision Aid Collaborative Group Study.', Journal of Clinical Oncology, 29, pp. 1670 - 1677, http://dx.doi.org/10.1200/JCO.2010.31.2462
    Journal articles | 2011
    Perren TJ; Swart AM; Pfisterer J; Ledermann JA; Pujade-Lauraine E; Kristensen G; Carey MS; Beale P; Cervantes A; Kurzeder C; du Bois A; Sehouli J; Kimmig R; Staehle A; Collinson F; Essapen S; Gourley C; Lortholary A; Selle F; Mirza MR; Leminen A; Plante M; Stark D; Qian W; Parmar MKB; Oza AM, 2011, 'A Phase 3 Trial of Bevacizumab in Ovarian Cancer', NEW ENGLAND JOURNAL OF MEDICINE, 365, pp. 2484 - 2496, http://dx.doi.org/10.1056/NEJMoa1103799
    Journal articles | 2011
    Regan MM; Neven P; Giobbie-Hurder A; Goldhirsch A; Ejlertsen B; Mauriac L; Forbes JF; Smith I; Lang I; Wardley A; Rabaglio M; Price KN; Gelber RD; Coates AS; Thuerlimann B, 2011, 'Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up', LANCET ONCOLOGY, 12, pp. 1101 - 1108, http://dx.doi.org/10.1016/S1470-2045(11)70270-4
    Journal articles | 2011
    Regan MM; Price KN; Giobbie-Hurder A; Thuerlimann B; Gelber RD, 2011, 'Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer', BREAST CANCER RESEARCH, 13, http://dx.doi.org/10.1186/bcr2837
    Journal articles | 2011
    Rustin G; Vergote I; Eisenhauer E; Pujade-lauraine E; Quinn M; Thigpen T; Du bois A; Kristensen G; Jakobsen A; Sagae S; Greven K; Parmar M; Friedlander M; Cervantes A; Vermorken J, 2011, 'Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 Agreed by the gynecological cancer intergroup (GCIG)', International Journal of Gynecological Cancer, 21, pp. 419 - 423, http://dx.doi.org/10.1097/IGC.0b013e3182070f17
    Journal articles | 2011
    Sjoquist KM; Martyn J; Edmondson RJ; Friedlander ML, 2011, 'The role of hormonal therapy in gynecological cancers - Current status and future directions', International Journal of Gynecological Cancer, 21, pp. 1328 - 1333, http://dx.doi.org/10.1097/IGC.0b013e31821d6021
    Journal articles | 2011
    Vaughan S; Coward J; Bast R; Berchuck A; Berek JS; Brenton JD; Coukos G; Crum CC; Drapkin R; Etemadmoghadam D; Friedlander M; Gabra H; Kaye S; Lord CJ; Lengyel E; Levine DA; McNeish IA; Menon U; Mills G; Nephew KP; Oza AM; Sood A; Stronach EA; Walczak H; Bowtell D; Balkwill FR, 2011, 'Rethinking ovarian cancer: recommendations for improving outcomes.', Nature Reviews Cancer, 11, pp. 719 - 725, http://dx.doi.org/10.1038/nrc3144
    Journal articles | 2011
    Watts KJ; Meiser B; Conlon H; Rovelli S; Tiller K; Zorbas H; Lewis C; Neil G; Friedlander M, 2011, 'Development and evaluation of a new specialist breast care nurse role for women with metastatic breast cancer', Oncology Nursing Forum, 38, pp. 627 - 631
    Journal articles | 2011
    Webber K; Mok K; Bennett BK; Juraskova I; Goldstein D; Friedlander M; Lloyd AR; FOLCAN study group , 2011, 'Cancer-related fatigue and sexual functioning in women with early breast cancer: Is there a link?', J Clin Oncol, 29, pp. 9072, http://www.ncbi.nlm.nih.gov/pubmed/28021533
    Journal articles | 2011
    Webber K; Mok K; Bennett BK; Lloyd AR; Friedlander M; Juraskova I; Goldstein D, 2011, 'If I Am in the Mood, I Enjoy It: an exploration of cancer-related fatigue and sexual functioning in women with breast cancer', Oncologist, 16, pp. 1333 - 1344, http://dx.doi.org/10.1634/theoncologist.2011-0100
    Journal articles | 2011
    2011, 'A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer', Breast Cancer Research and Treatment, 129, pp. 467 - 476, http://dx.doi.org/10.1007/s10549-011-1471-9
    Journal articles | 2011
    2011, 'A specialist breast care nurse role for women with metastatic breast cancer: Enhancing supportive care', Oncology Nursing Forum, 38, pp. 627 - 631, http://dx.doi.org/10.1188/11.ONF.627-631
    Journal articles | 2011
    2011, 'Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer.', Familial Cancer, 10, pp. 505 - 514, http://dx.doi.org/10.1007/s10689-011-9435-0
    Journal articles | 2011
    2011, 'CART-WHEEL.org can facilitate research into rare gynecological tumors.', International Journal of Gynecological Cancer, 21, pp. 1517 - 1519
    Journal articles | 2011
    2011, 'Carboplatin dosing in ovarian cancer: problems and pitfalls.', International Journal of Gynecological Cancer, 21, pp. 1213 - 1218, http://dx.doi.org/10.1097/IGC.0b013e31822127ad
    Journal articles | 2011
    2011, 'Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer', British Journal of Cancer, 105, pp. 360 - 365, http://dx.doi.org/10.1038/bjc.2011.256
    Journal articles | 2011
    2011, 'Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer.', Journal of CLIN ONCOL, 29, pp. 4224 - 4226, http://dx.doi.org/10.1200/JCO.2011.36.8134
    Journal articles | 2011
    2011, 'Development and pilot testing of a fertility decision aid for young women diagnosed with early breast cancer', The breast journal, 17, pp. 112 - 114, http://dx.doi.org/10.1111/j.1524-4741.2010.01033.x
    Journal articles | 2011
    2011, 'Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer.', Journal of the National Cancer Institute, 103, pp. 1338 - 1342, http://dx.doi.org/10.1093/jnci/djr282
    Journal articles | 2011
    2011, 'Neuroprotection for oxaliplatin-induced neurotoxicity: what happened to objective assessment?', Journal of clinical oncology - official journal of the American Society of Clinical Oncology, 29, pp. e553 - e554e, http://dx.doi.org/10.1200/JCO.2011.34.8227
    Journal articles | 2011
    2011, 'Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive families.', Breast Cancer Research and Treatment, 130, pp. 1057 - 1061, http://dx.doi.org/10.1007/s10549-011-1733-6
    Journal articles | 2011
    2011, 'The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions.', Asia-Pacific Journal of Clinical Oncology, 7, pp. 197 - 211, http://dx.doi.org/10.1111/j.1743-7563.2011.01430.x
    Journal articles | 2011
    2011, 'Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy', Experimental Neurology, 227, pp. 120 - 127, http://dx.doi.org/10.1016/j.expneurol.2010.10.002
    Journal articles | 2010
    Audeh M; Carmichael J; Penson R; Friedlander M, 2010, 'Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proff-of-concept trial.', The Lancet, 24, pp. 245 - 251
    Journal articles | 2010
    Audeh MW; Carmichael J; Penson RT; Friedlander M; Powell B; Bell-McGuinn KM; Scott C; Weitzel JN; Oaknin A; Loman N; Lu K; Schmutzler RK; Matulonis U; Wickens M; Tutt A, 2010, 'Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial', The Lancet, 376, pp. 245 - 251, http://dx.doi.org/10.1016/S0140-6736(10)60893-8
    Journal articles | 2010
    Duffy S; Jackson TL; Lansdown M; Philips K; Wells M; Clack G; Bianco AR, 2010, 'The ATAC adjuvant breast-cancer trial: Six-year results of the endometrial subprotocol', JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 30, pp. 596 - 604, http://dx.doi.org/10.3109/01443615.2010.492433
    Journal articles | 2010
    Friedlander M, 2010, 'Optimally debulked stage III ovarian cancer: intraperitoneal or intravenous chemotherapy?', International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 20, http://dx.doi.org/10.1111/igc.0b013e3181f60d26
    Journal articles | 2010
    Gainford M; Tinker A; Carter J; Petru E; Nicklin J; Quinn MA; Hammond IG; Elit L; Lenhard M; Friedlander M, 2010, 'Malignant transformation within ovarian dermoid cysts:and audit of treatment received and patient outcomes', International Journal of Gynecological Cancer, 20, pp. 75 - 81
    Journal articles | 2010
    Gainford MC; Tinker A; Carter J; Petru E; Nicklin J; Quinn M; Hammond I; Elit L; Lenhard M; Friedlander M, 2010, 'Malignant transformation within ovarian dermoid cysts: An audit of treatment received and patient outcomes. An Australia New Zealand gynaecological oncology group (ANZGOG) and gynaecologic cancer intergroup (GCIG) study', International Journal of Gynecological Cancer, 20, pp. 75 - 81, http://dx.doi.org/10.1111/IGC.0b013e3181c7fccf
    Journal articles | 2010
    Kiely BE; Jenkins MA; McKinley JM; Friedlander ML; Weideman P; Milne RL; McLachlan SA; Hopper JL; Phillips KA, 2010, 'Erratum: Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the kathleen cuningham foundation consortium for research into familial breast cancer (kConFab) (Breast Cancer Res Treat (2010) (120) DOI: 10.1007/s10549-009-0497-8))', Breast Cancer Research and Treatment, 120, pp. 725 - 726, http://dx.doi.org/10.1007/s10549-009-0528-5
    Journal articles | 2010
    Mai PL; Friedlander M; Tucker K; Phillips KA; Hogg D; Jewett MAS; Lohynska R; Daugaard G; Richard S; Bonaïti-Pellié C; Heidenreich A; Albers P; Bodrogi I; Geczi L; Olah E; Daly PA; Guilford P; Fosså SD; Heimdal K; Liubchenko L; Tjulandin SA; Stoll H; Weber W; Easton DF; Dudakia D; Huddart R; Stratton MR; Einhorn L; Korde L; Nathanson KL; Bishop DT; Rapley EA; Greene MH, 2010, 'The international testicular cancer linkage consortium: A clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred', Urologic Oncology: Seminars and Original Investigations, 28, pp. 492 - 499, http://dx.doi.org/10.1016/j.urolonc.2008.10.004
    Journal articles | 2010
    Parmalee NL; Schubert C; Merriam JE; Allikmets K; Bird AC; Gillies MC; Peto T; Figueroa M; Friedlander M; Fruttiger M; Greenwood J; Moss SE; Smith LE H; Toomes C; Inglehearn CF; Allikmets R, 2010, 'Analysis of candidate genes for macular telangiectasia type 2', Molecular Vision, 16, pp. 2718 - 2726
    Journal articles | 2010
    Price M; Butow PN; Bullen T; Meiser B; McKinley J; Phillips KA, 2010, 'Predictors of breast cancer screening behaviors in women with a strong family history of the disease.', Breast Cancer Research and Treatment, 124, pp. 509 - 519, http://dx.doi.org/10.1007/s10549-010-0868-1
    Journal articles | 2010
    Trainer A; Meiser B; Watts KJ; Mitchell GF; Tucker K; Friedlander ML, 2010, 'Moving towards personalised medicine: Treatment- focused genetic testing of women newly diagnosed with ovarian cancer.', International Journal of Gynecological Cancer, 20, pp. 704 - 716, http://dx.doi.org/10.1111/IGC.0b013e3181dbd1a5
    Journal articles | 2010
    Trimble EL; Birrer MJ; Hoskins WJ; Marth C; Petryshyn R; Quinn M; Thomas GM; Kitchener HC, 2010, 'Current academic clinical trials in ovarian cancer: Gynecologic cancer intergroup and us national cancer institute clinical trials planning meeting, may 2009', International Journal of Gynecological Cancer, 20, pp. 1, http://dx.doi.org/10.1111/IGC.0b013e3181ee1c01
    Journal articles | 2010
    Tutt A; Robson M; Garber J; Domchek SM; Friedlander M; Audeh M; Weitzel J, 2010, 'Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-content trial', The Lancet, 24, pp. 235 - 244
    Journal articles | 2010
    Tutt A; Robson M; Garber JE; Domchek SM; Audeh MW; Weitzel JN; Friedlander M; Arun B; Loman N; Schmutzler RK; Wardley A; Mitchell G; Earl H; Wickens M; Carmichael J; Liedtke C, 2010, 'The future is 'PARP' - Phase-II-activity of PARP inhibitor among patients with BRCA-deficient breast cancer', Breast Care, 5, pp. 364 - 365, http://dx.doi.org/10.1159/000322170
    Journal articles | 2010
    Tutt A; Robson M; Garber JE; Domchek SM; Audeh MW; Weitzel JN; Friedlander M; Arun B; Loman N; Schmutzler RK; Wardley A; Mitchell G; Earl H; Wickens M; Carmichael J, 2010, 'Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial', The Lancet, 376, pp. 235 - 244, http://dx.doi.org/10.1016/S0140-6736(10)60892-6
    Journal articles | 2010
    Webber K; Goldstein D; Bennett BK; Boyle FM; De Souza PL; Wilcken N; Friedlander M; Lloyd AR, 2010, 'Influence of fatigue after breast cancer adjuvant theraphy on health care utilization and percieved needs', JOURNAL OF CLINICAL ONCOLOGY, 28, http://dx.doi.org/10.1200/jco.2010.28.15_suppl.9047
    Journal articles | 2010
    2010, '5. A novel biomarker of axonal dysfunction in oxaliplatin-induced neurotoxicity', Clinical Neurophysiology, 121, pp. e2 - e2, http://dx.doi.org/10.1016/j.clinph.2009.10.025
    Journal articles | 2010
    2010, 'A phase 11, open-label study evaluating pazopanib in patients with recurrent ovarian cancer', Gynecologic Oncology, 119, pp. 32 - 37, http://dx.doi.org/10.1016/j.ygyno.2010.05.033
    Journal articles | 2010
    2010, 'Assessing health-related quality of life in gynecologic oncology: a systematic review of questionnaires and their ability to detect clinically important differences and change', International Journal of Gynecological Cancer, 20, pp. 664 - 684, http://dx.doi.org/10.1111/IGC.0b013e3181dad379
    Journal articles | 2010
    2010, 'Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for research into familial breast cancer', Breast Cancer Research and Treatment, 120, pp. 715 - 723, http://dx.doi.org/10.1007/s10549-009-0497-8
    Journal articles | 2010
    2010, 'Optimally debulked stage 111 ovarian cancer: intraperitoneal or intravenous chemotherapy?', International Journal of Gynecological Cancer, 20, pp. S20 - S23, http://dx.doi.org/10.1111/IGC.0b013e3181f60d26
    Journal articles | 2009
    Audeh MW; Penson RT; Friedlander M; Powell B; Bell-McGuinn KM; Scott C; Weitzel JN; Carmichael J; Tutt A, 2009, 'Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer', Journal of Clinical Oncology, 27, pp. 5500 - 5500, http://dx.doi.org/10.1200/jco.2009.27.15_suppl.5500
    Journal articles | 2009
    Bookman MA; Brady MF; McGuire WP; Harper PG; Alberts DS; Friedlander M; Colombo N; Fowler JM; Argenta PA; De Geest K; Mutch DG; Burger RA; Swart AM; Trimble EL; Accario-Winslow C; Roth LM, 2009, 'Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A phase III trial of the gynecologic cancer intergroup', Journal of Clinical Oncology, 27, pp. 1419 - 1425, http://dx.doi.org/10.1200/JCO.2008.19.1684
    Journal articles | 2009
    Colleoni M; Sun Z; Martinelli G; Basser RL; Coates AS; Gelber RD; Green MD; Peccatori F; Cinieri S; Aebi S; Viale G; Price KN; Goldhirsch A, 2009, 'The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: Results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up', Annals of Oncology, 20, pp. 1344 - 1351, http://dx.doi.org/10.1093/annonc/mdp024
    Journal articles | 2009
    Field KM; Jenkins MA; Friedlander ML; McKinley JM; Price MA; Weideman P; Keogh LA; McLachlan SA; Lindeman GJ; Hopper JL; Butow PN; Phillips KA, 2009, 'Predictors of the use of complementary and alternative medicine (CAM) by women at high risk for breast cancer', European Journal of Cancer, 45, pp. 551 - 560, http://dx.doi.org/10.1016/j.ejca.2008.09.023
    Journal articles | 2009
    Friedlander M; Butow P; Stockler M; Gainford C; Martyn J; Oza A; Donovan HS; Miller B; King M, 2009, 'Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer.', International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 19 Suppl 2, http://dx.doi.org/10.1111/igc.0b013e3181bf7fb8
    Journal articles | 2009
    Mai PL; Chen BE; Tucker K; Friedlander M; Phillips KA; Hogg D; Jewett MA S; Bodrogi I; Geczi L; Olah E; Heimdal K; Fosså SD; Nathanson KL; Korde L; Easton DF; Dudakia D; Huddart R; Stratton MR; Bishop DT; Rapley EA; Greene MH, 2009, 'Younger age-at-diagnosis for familial malignant testicular germ cell tumor', Familial Cancer, 8, pp. 451 - 456, http://dx.doi.org/10.1007/s10689-009-9264-6
    Journal articles | 2009
    Mouridsen H; Giobbie-Hurder A; Goldhirsch A; Thuerlimann B; Paridaens R; Smith I; Mauriac L; Forbes JF; Price KN; Regan MM; Gelber RD; Coates AS, 2009, 'Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer', NEW ENGLAND JOURNAL OF MEDICINE, 361, pp. 766 - 776, http://dx.doi.org/10.1056/nejmoa0810818
    Journal articles | 2009
    Park SB; Goldstein D; Lin CS; Krishnan AV; Friedlander ML; Kiernan MC, 2009, 'Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity', Journal of clinical oncology - official journal of the American Society of Clinical Oncology, 27, pp. 1243 - 1249, http://dx.doi.org/10.1200/JCO.2008.19.3425
    Journal articles | 2009
    Park SB; Lin CS-Y; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC, 2009, 'Oxaliplatin-induced Lhermitte’s phenomenon as a manifestation of severe generalized nerve dysfunction', Oncology, 77, pp. 342 - 348, http://dx.doi.org/10.1159/000265940
    Journal articles | 2009
    Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC, 2009, 'Oxaliplatin-induced neurotoxicity: Changes in axonal excitability precede development of neuropathy', Brain, 132, pp. 2712 - 2723, http://dx.doi.org/10.1093/brain/awp219
    Journal articles | 2009
    Pearce CL; Near AM; Van Den Berg DJ; Ramus SJ; Gentry-Maharaj A; Menon U; Gayther SA; Anderson AR; Edlund CK; Wu AH; Chen X; Beesley J; Webb PM; Holt SK; Chen C; Doherty JA; Rossing MA; Whittemore AS; McGuire V; DiCioccio RA; Goodman MT; Lurie G; Carney ME; Wilkens LR; Ness RB; Moysich KB; Edwards R; Jennison E; Kjaer SK; Hogdall E; Hogdall CK; Goode EL; Sellers TA; Vierkant RA; Cunningham JC; Schildkraut JM; Berchuck A; Moorman PG; Iversen ES; Cramer DW; Terry KL; Vitonis AF; Titus-Ernstoff L; Song H; Pharoah PD P; Spurdle AB; Anton-Culver H; Ziogas A; Brewster W; Galitovskiy V; Chenevix-Trench G; Gertig D; Vanden Bergh T; Camaris C; Crouch R; Edwards L; Hacker N; Marsden D; Robertson G; DeFazio A; Hung J; Chiew YE; Stenlake A; Sullivan H; Brand A; Jaworski R; Harnett P; Wain G; Green A; Moore S; Harrap K; Sadkowsky T; Purdie D; Whiteman D; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Martin K; Ranieri B; White J; Mamers P; Healy D; Jobling T; Maniolitas T; McNealage J; Rogers P; Susil B; Veitch A; Constable J; Ping Tong S; Robinson I; Simpson I; Schmidt T; Shirley H; Viduka S; Tran H; Bilic S, 2009, 'Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium', British Journal of Cancer, 100, pp. 412 - 420, http://dx.doi.org/10.1038/sj.bjc.6604820
    Journal articles | 2009
    Peate ML; Meiser B; Hickey MS; Friedlander ML, 2009, 'The fertility-related concerns, needs and preferences of younger women with breast cancer: A systematic review', Breast Cancer Research and Treatment, 116, pp. 215 - 223, http://dx.doi.org/10.1007/s10549-009-0401-6
    Journal articles | 2009
    Phillips KA; Milne RL; West DJ; Goodwin P; Giles GG; Chang E; Figueiredo J; Friedlander ML; Keegan T; Glendon G; Apicella C; O Malley F; Southey MC; Andrulis I; John E; Hopper JL, 2009, 'Prediagnosis reproductive factors and all-cause mortality for women with breast cancer in the breast cancer family registry', Cancer epidemiology biomarkers and prevention, 18, pp. 1792 - 1797, http://dx.doi.org/10.1158/1055-9965.EPI-08-1014
    Journal articles | 2009
    Phillips KA; Milne RL; West DW; Goodwin PJ; Giles GG; Chang ET; Figueiredo JC; Friedlander ML; Keegan TH M; Glendon G; Apicella C; O'Malley F; Southey MC; Andrulis IL; John EM; Hopper JL, 2009, 'Article on Reproductive Factors and Mortality after Breast Cancer (vol 18, pg 1792, 2009)', CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 18, pp. 2345 - 2345, http://dx.doi.org/10.1158/1055-9965.EPI-18-8-CORI
    Journal articles | 2009
    Price MA; Zachariae R; Butow PN; deFazio A; Chauhan D; Espie CA; Friedlander M; Webb PM, 2009, 'Prevalence and predictors of insomnia in women with invasive ovarian cancer: Anxiety a major factor', European Journal of Cancer, 45, pp. 3262 - 3270, http://dx.doi.org/10.1016/j.ejca.2009.05.030
    Journal articles | 2009
    Rabaglio M; Sun Z; Price KN; Castiglione-Gertsch M; Hawle H; Thürlimann B; Mouridsen H; Campone M; Forbes JF; Paridaens RJ; Colleoni M; Pienkowski T; Nogaret JM; Láng I; Smith I; Gelber RD; Goldhirsch A; Coates AS, 2009, 'Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial', Annals of Oncology, 20, pp. 1489 - 1498, http://dx.doi.org/10.1093/annonc/mdp033
    Journal articles | 2009
    Tutt A; Robson M; Garber JE; Domchek S; Audeh MW; Weitzel JN; Friedlander M; Carmichael J, 2009, 'Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer', Journal of Clinical Oncology, 27, pp. CRA501 - CRA501, http://dx.doi.org/10.1200/jco.2009.27.18_suppl.cra501
    Journal articles | 2009
    2009, 'Breast cancer in young women and its impact on reproductive function', Human Reproduction Update, 15, pp. 323 - 339, http://dx.doi.org/10.1093/humupd/dmn064
    Journal articles | 2009
    2009, 'Contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)', Journal of Clinical Oncology, 27, pp. 1509 - 1509, http://dx.doi.org/10.1200/jco.2009.27.15_suppl.1509
    Journal articles | 2009
    2009, 'Family history of breast cancer and all-cause mortality after breast cancer diagnosis in the Breast Cancer Family Registry', Breast Cancer Research and Treatment, 117, pp. 167 - 176, http://dx.doi.org/10.1007/s10549-008-0255-3
    Journal articles | 2009
    2009, 'Improving Cancer Outcomes Through International Collaboration in Academic Cancer Treatment Trials', Journal of Clinical Oncology, 27, pp. 5109 - U194, http://dx.doi.org/10.1200/JCO.2009.22.5771
    Journal articles | 2009
    2009, 'Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer', Journal of Clinical Oncology, 27, pp. CRA501 - CRA501, http://dx.doi.org/10.1200/jco.2009.27.15_suppl.cra501
    Journal articles | 2009
    2009, 'Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer', Journal of Clinical Oncology, 27, pp. CRA501 - CRA501, http://dx.doi.org/10.1200/jco.2009.27.18s.cra501
    Journal articles | 2008
    Goldstein D; Bennett B; Cameron B; Boyle F; DeSouza P; Wilcken N; Friedlander M; Scott E; Hickie I; Lloyd AA M, 2008, 'A prospective cohort study of fatigue after adjuvant therapy for breast cancer: Association with hematologic, endocrine, and immune parameters', JOURNAL OF CLINICAL ONCOLOGY, 26, http://dx.doi.org/10.1200/jco.2008.26.15_suppl.9596
    Journal articles | 2008
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; Bowtell D; Chenevix-Trench G; Green A; Webb P; DeFazio A; Gertig D; Traficante N; Moore S; Hung J; Fereday S; Harrap K; Sadkowsky T; Mellon A; Robertson R; Vanden Bergh T; Jones M; Maidens J; Nattress K; Chiew YE; Stenlake A; Sullivan H; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Martin K; Ranieri B; White J; Jayde V; Bowes L; Mamers P; Schmidt T; Shirley H; Viduka S; Tran H; Bilic S; Glavinas L; Stuart-Harris R; Kirsten F; Rutovitz J; Clingan P; Glasgow A; Proietto A; Braye S; Otton G; Shannon J; Bonaventura T; Stewart J; Begbie S; Friedlander M; Bell D; Baron-Hay S; Ferrier A; Gard G; Nevell D; Pavlakis N; Young B; Camaris C; Crouch R; Edwards L; Hacker N; Marsden D; Robertson G; Beale P; Beith J; Carter J; Dalrymple C; Hamilton A; Houghton R; Russell P; Links M; Grygiel J; Hill J; Brand A; Byth K; Jaworski R; Harnett P; Sharma R; Wain G; Purdie D; Whiteman D; Ward B; Papadimos D; Crandon A; Cummings M; Horwood K; Obermair A; Perrin L; Wyld D; Nicklin J; Davy M; Oehler M; Hall C, 2008, 'Skewed X chromosome inactivation and breast and ovarian cancer status: Evidence for X-linked modifiers of BRCA1', Journal of the National Cancer Institute, 100, pp. 1519 - 1529, http://dx.doi.org/10.1093/jnci/djn345
    Journal articles | 2008
    Meiser B; Tucker K; Friedlander ML; Barlow-Stewart K; Lobb EA; Saunders C; Mitchell GF, 2008, 'Genetic counselling and testing for inherited gene mutations in newly diagnosed patients with breast cancer: a review of the existing literature and a proposed research agenda', Breast Cancer Research, 10, http://dx.doi.org/10.1186/bcr2194
    Journal articles | 2008
    Merritt MA; Green AC; Nagle CM; Webb PM; Bowtell D; Chenevix-Trench G; Green A; DeFazio A; Gertig D; Traficante N; Moore S; Hung J; Fereday S; Harrap K; Sadkowsky T; Mellon A; Robertson R; Vanden Bergh T; Maidens J; Nattress K; Chiew YE; Stenlake A; Sullivan H; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Martin K; Ranieri B; White J; Jayde V; Bowes L; Mamers P; Schmidt T; Shirley H; Viduka S; Tran H; Bilic S; Glavinas L; Proietto A; Braye S; Otton G; Bonaventura T; Stewart J; Friedlander M; Bell D; Baron-Hay S; Ferrier A; Gard G; Nevell D; Young B; Camaris C; Crouch R; Edwards L; Hacker N; Marsden D; Robertson G; Beale P; Beith J; Carter J; Dalrymple C; Hamilton A; Houghton R; Russell P; Brand A; Jaworski R; Harnett P; Wain G; Crandon A; Cummings M; Horwood K; Obermair A; Wyld D; Nicklin J; Perrin L; Ward B; Davy M; Hall C; Dodd T; Healy T; Pittman K; Henderson D; Hyde S; Miller J; Pierdes J; Blomfield P; Challis D; McIntosh R; Parker A; Brown B; Rome R; Allen D; Grant P; Laurie R; Robbie M; Healy D; Jobling T; Maniolitas T, 2008, 'Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer', International Journal of Cancer, 122, pp. 170 - 176, http://dx.doi.org/10.1002/ijc.23017
    Journal articles | 2008
    Mok K; Juraskova I; Friedlander M, 2008, 'The impact of aromatase inhibitors on sexual functioning: Current knowledge and future research directions', Breast, 17, pp. 436 - 440, http://dx.doi.org/10.1016/j.breast.2008.04.001
    Journal articles | 2008
    Nagle CM; Olsen CM; Webb PM; Jordan SJ; Whiteman DC; Green AC, 2008, 'Endometrioid and clear cell ovarian cancers - A comparative analysis of risk factors', EUROPEAN JOURNAL OF CANCER, 44, pp. 2477 - 2484, http://dx.doi.org/10.1016/j.ejca.2008.07.009
    Journal articles | 2008
    Olsen CM; Nagle CM; Whiteman DC; Purdie DM; Green AC; Webb PM; Bowtell D; Chenevix-Trench G; Green A; DeFazio A; Gertig D; Traficante N; Moore S; Hung J; Fereday S; Harrap K; Sadkowsky T; Mellon A; Robertson R; Vanden Bergh T; Maidens J; Nattress K; Chiew YE; Stenlake A; Sullivan H; Alexander B; Ashover P; Brown S; CorrGreenish T; Green L; Jackman L; Martin K; Ranieri B; White J; Jayde V; Bowes L; Mamers P; Schmidt T; Shirley H; Viduka S; Tran H; Bilic S; Glavinas L; Proietto A; Braye S; Otton G; Bonaventura T; Stewart J; Friedlander M; Bell D; Baron-Hay S; Ferrier A; Gard G; Nevell D; Young B; Camaris C; Crouch R; Edwards L; Hacker N; Marsden D; Robertson G; Beale P; Beith J; Carter J; Dalrymple C; Hamilton A; Houghton R; Russell P; Brand A; Jaworski R; Harnett P; Wain G; Crandon A; Cummings M; Horwood K; Obermair A; Wyld D; Nicklin J; Perrin L; Ward B; Davy M; Hall C; Dodd T; Healy T; Pittman K; Henderson D; Hyde S; Miller J; Pierdes J; Blomfield P; Challis D; McIntosh R; Parker A; Brown B; Rome R; Allen D; Grant P; Laurie R; Robbie M; Healy D, 2008, 'Body size and risk of epithelial ovarian and related cancers: A population-based case-control study', International Journal of Cancer, 123, pp. 450 - 456, http://dx.doi.org/10.1002/ijc.23509
    Journal articles | 2008
    Park SB; Krishnan AV; Lin CS; Goldstein D; Friedlander ML; Kiernan MC, 2008, 'Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies', Current Medicinal Chemistry: Cardiovascular and Hematological Agents, 15, pp. 3081 - 3094, http://dx.doi.org/10.2174/092986708786848569
    Journal articles | 2008
    Ramus SJ; Vierkant RA; Johnatty SE; Pike MC; Van Den Berg DJ; Wu AH; Pearce CL; Menon U; Gentry-Maharaj A; Gayther SA; DiCioccio RA; McGuire V; Whittemore AS; Song H; Easton DF; Pharoah PD P; Garcia-Closas M; Chanock S; Lissowska J; Brinton L; Terry KL; Cramer DW; Tworoger SS; Hankinson SE; Berchuck A; Moorman PG; Schildkraut JM; Cunningham JM; Liebow M; Kjaer SK; Hogdall E; Hogdall C; Blaakaer J; Ness RB; Moysich KB; Edwards RP; Carney ME; Lurie G; Goodman MT; Wang-Gohrke S; Kropp S; Chang-Claude J; Webb PM; Chen X; Beesley J; Chenevix-Trench G; Goode EL; Bowtell D; Green A; DeFazio A; Gertig D; Traficante N; Moore S; Hung J; Fereday S; Harrap K; Sadkowsky T; Mellon A; Robertson R; Vanden Bergh T; Maidens J; Nattress K; Chiew YE; Stenlake A; Sullivan H; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Martin K; Ranieri B; White J; Jayde V; Bowes VL; Mamers P; Schmidt T; Shirley H; Viduka S; Tran H; Bilic S; Glavinas L; Proietto A; Braye S; Otton G; Bonaventura T; Stewart J; Friedlander M; Bell D; Baron-Hay S; Ferrier A; Gard G; Nevell D; Young B; Camaris C; Crouch R; Edwards L; Hacker N; Marsden D, 2008, 'Consortium analysis of 7 candidate SNPs for ovarian cancer', International Journal of Cancer, 123, pp. 380 - 388, http://dx.doi.org/10.1002/ijc.23448
    Journal articles | 2008
    Ravaioli A; Monti F; Regan MM; Maffini F; Mastropasqua MG; Spataro V; Castiglione-Gertsch M; Panzini I; Gianni L; Goldhirsch A; Coates A; Price KN; Gusterson BA; Viale G, 2008, 'p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer', ANNALS OF ONCOLOGY, 19, pp. 660 - 668, http://dx.doi.org/10.1093/annonc/mdm547
    Journal articles | 2008
    Viale G; Giobbie-Hurder A; Regan MM; Coates AS; Mastropasqua MG; Dell'Orto P; Maiorano E; MacGrogan G; Braye SG; Oehlschlegel C; Neven P; Orosz Z; Olszewski WP; Knox F; Thuerlimann B; Price KN; Castiglione-Gertsch M; Gelber RD; Gusterson BA; Goldhirsch A, 2008, 'Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole', JOURNAL OF CLINICAL ONCOLOGY, 26, pp. 5569 - 5575, http://dx.doi.org/10.1200/JCO.2008.17.0829
    Journal articles | 2008
    2008, '457: Sensory nerve excitability in cancer patients treated with oxaliplatin', Journal of Clinical Neuroscience, 15, pp. 362 - 362, http://dx.doi.org/10.1016/j.jocn.2007.07.067
    Journal articles | 2008
    2008, 'Analysis of the DNDI gene in men with sporadic and familial testicular germ cell tumors', Genes Chromosomes and Cancer, 47, pp. 247 - 252, http://dx.doi.org/10.1002/gec.20526
    Journal articles | 2008
    2008, 'Cancer risk management practices of noncarriers within BRCA1/2 mutation - Positive families in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast cancer', Journal of Clinical Oncology, 26, pp. 225 - 232, http://dx.doi.org/10.1200/JCO.2007.11.0262
    Journal articles | 2008
    2008, 'OVERcome Study (Olive Oil Vaginal Exercise and Replens®)', Journal of Minimally Invasive Gynecology, 15, pp. 88S - 88S, http://dx.doi.org/10.1016/j.jmig.2008.09.336
    Journal articles | 2008
    2008, 'Oxaliplatin-induced chronic changes in sensory nerve excitability', Clinical Neurophysiology, 119, pp. e22 - e22, http://dx.doi.org/10.1016/j.clinph.2007.10.044
    Journal articles | 2008
    2008, 'Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency', International Journal of Cancer, 123, pp. 258 - 263, http://dx.doi.org/10.1002/ijc.23535
    Journal articles | 2007
    Beesley J; Jordan SJ; Spurdle AB; Song H; Ramus SJ; Kjaer SK; Hogdall E; DiCioccio RA; McGuire V; Whittemore AS; Gayther SA; Pharoah PD P; Webb PM; Chenevix-Trench G; Bowtell D; Green A; DeFazio A; Gertig D; Traficante N; Moore S; Hung J; Fereday S; Harrap K; Sadkowsky T; Mellon A; Robertson R; Vanden Bergh T; Maidens J; Nattress K; Chiew YE; Stenlake A; Sullivan H; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Martin K; Ranieri B; White J; Jayde V; Bowes L; Mamers P; Schmidt T; Shirley H; Viduka S; Tran H; Bilic S; Glavinas L; Proietto A; Braye S; Otton G; Bonaventura T; Stewart J; Friedlander M; Bell D; Baron-Hay S; Ferrier A; Gard G; Nevell D; Young B; Camaris C; Crouch R; Edwards L; Hacker N; Marsden D; Robertson G; Beale P; Beith J; Carter J; Dalrymple C; Hamilton A; Houghton R; Russell P; Brand A; Jaworski R; Harnett P; Wain G; Crandon A; Cummings M; Horwood K; Obermair A; Wyld D; Nicklin J; Perrin L; Ward B; Davy M; Hall C; Dodd T; Healy T; Pittman K; Henderson D; Hyde S; Miller J; Pierdes J; Blomfield P; Challis D; McIntosh R; Parker A, 2007, 'Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: Results from two Australian studies and an additional validation set', Cancer Epidemiology Biomarkers and Prevention, 16, pp. 2557 - 2565, http://dx.doi.org/10.1158/1055-9965.EPI-07-0542
    Journal articles | 2007
    Bennett BK; Goldstein D; Friedlander ML; Hickie IB; Lloyd AR, 2007, 'The experience of cancer-related fatigue and chronic fatigue syndrome: A qualitative and comparative study', Journal of Pain and Symptom Management, 34, pp. 126 - 135, http://dx.doi.org/10.1016/j.jpainsymman.2006.10.014
    Journal articles | 2007
    Bennett BK; Goldstein D; Lloyd AR O L A; Friedlander ML; Hickie IB, 2007, 'The experience of cancer-related fatigue and chronic fatigue syndrome: a qualitative and comparative study', Journal of Pain and Symptom Management, 34, pp. 126 - 135
    Journal articles | 2007
    Colleoni M; Gelber S; Simoncini E; Pagani O; Gelber RD; Price KN; Castiglione-Gertsch M; Coates AS; Goldhirsch A; Thürlimann B; Castiglione M; Collins JP; Cortés Funes H; Green M; Hiltbrunner A; Holmberg SB; Hossfeld DK; Láng I; Lindtner J; Paganetti F; Rudenstam CM; Stahel R; Senn HJ; Veronesi A; Egli G; Rabaglio M; Studer R; Ruepp B; Maibach R; Marbot E; Strausak M; Gelber R; Cole B; Regan M; Zahrieh D; Sun Z; Bernhard J; Hürny C; Gusterson B; Viale G; Blacher L; Celano J; Isley M; Hinkle R; Lippert S; Scott K; Crivellari D; Monfardini S; Galligioni E; Magri MD; Buonadonna A; Massarut S; Rossi C; Candiani E; Carbone A; Volpe R; Roncadin M; Arcicasa M; Coran F; Morassut S; Marini G; Marpicati P; Braga M; Grigolato P; Lucini L; Martinelli G; Orlando L; Nolè F; Torrisi R; De Pas T; de Braud F; Cinieri S; Peccatori F; Luini A; Orecchia R; Renne G; Costa A; Zurrida S; Veronesi P; Sacchini V; Galimberti V; Intra M; Veronesi U; Ravaioli A; Tassinari D; Oliverio G; Barbanti F; Rinaldi P; Pini E; Drudi G; Antimi M; Minelli M; Bellini V; Porzio R; Pernazza E; Santeusanio G; Spagnoli LG; Foladore S; Foghin L, 2007, 'Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: Results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93', Annals of Oncology, 18, pp. 1177 - 1184, http://dx.doi.org/10.1093/annonc/mdm091
    Journal articles | 2007
    Easton DF; Pooley KA; Dunning AM; Pharoah PD P; Thompson D; Ballinger DG; Struewing JP; Morrison J; Field H; Luben R; Wareham N; Ahmed S; Healey CS; Bowman R; Meyer KB; Haiman CA; Kolonel LK; Henderson BE; Le Marchand L; Brennan P; Sangrajrang S; Gaborieau V; Odefrey F; Shen CY; Wu PE; Wang HC; Eccles D; Evans DG; Peto J; Fletcher O; Johnson N; Seal S; Stratton MR; Rahman N; Chenevix-Trench G; Bojesen SE; Nordestgaard BG; Axelsson CK; Garcia-Closas M; Brinton L; Chanock S; Lissowska J; Peplonska B; Nevanlinna H; Fagerholm R; Eerola H; Kang D; Yoo KY; Noh DY; Ahn SH; Hunter DJ; Hankinson SE; Cox DG; Hall P; Wedren S; Liu J; Low YL; Bogdanova N; Schürmann P; Dörk T; Tollenaar RA E M; Jacobi CE; Devilee P; Klijn JG M; Sigurdson AJ; Doody MM; Alexander BH; Zhang J; Cox A; Brock IW; MacPherson G; Reed MW R; Couch FJ; Goode EL; Olson JE; Meijers-Heijboer H; Van Den Ouweland A; Uitterlinden A; Rivadeneira F; Milne RL; Ribas G; Gonzalez-Neira A; Benitez J; Hopper JL; McCredie M; Southey M; Giles G; Schroen C; Justenhoven C; Brauch H; Hamann U; Ko YD; Spurdle AB; Beesley J; Chen X; Mannermaa A; Kosma VM; Kataja V; Hartikainen J; Day NE, 2007, 'Genome-wide association study identifies novel breast cancer susceptibility loci', Nature, 447, pp. 1087 - 1093, http://dx.doi.org/10.1038/nature05887
    Journal articles | 2007
    Friedlander M; Hancock KC; Benigno B; Rischin D; Messing M; Stringer CA; Tay EH; Kathman S; Matthys G; Lager JJ, 2007, 'Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: Initial results of a phase II study', Journal of Clinical Oncology, 25, pp. 5561 - 5561, http://dx.doi.org/10.1200/jco.2007.25.18_suppl.5561
    Journal articles | 2007
    Hogg R; Scurry JP; Kim SN; Friedlander ML; Hacker NF, 2007, 'Microinvasion links ovarian serous borderline tumour and grade 1 invasive carcinoma', Gynecologic Oncology, 106, pp. 44 - 51, http://dx.doi.org/10.1016/j.ygyno.2007.01.054
    Journal articles | 2007
    McKinley JM; Weideman PC; Jenkins MA; Friedlander ML; Hopper JL; McLachlan SA; Lindeman GJ; Phillips KA, 2007, 'Prostate screening uptake in Australian BRCA1 and BRCA2 carriers', Hereditary Cancer in Clinical Practice, 5, pp. 161 - 163
    Journal articles | 2007
    Olsen CM; Bain CJ; Jordan SJ; Nagle CM; Green AC; Whiteman DC; Webb PM; Bowtell D; Chenevix-Trench G; Green A; Defazio A; Gertig D; Traficante N; Moore S; Hung J; Fereday S; Harrap K; Sadkowsky T; Mellon A; Robertson R; Vanden Bergh T; Maidens J; Nattress K; Chiew YE; Stenlake A; Sullivan H; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Martin K; Ranieri B; White J; Jayde V; Bowes L; Mamers P; Schmidt T; Shirley H; Viduka S; Tran H; Bilic S; Glavinas L; Proietto A; Braye S; Otton G; Bonaventura T; Stewart J; Friedlander M; Bell D; Baron-Hay S; Ferrier A; Gard G; Nevell D; Young B; Camaris C; Crouch R; Edwards L; Hacker N; Marsden D; Robertson G; Beale P; Beith J; Carter J; Dalrymple C; Hamilton A; Houghton R; Russell P; Brand A; Jaworski R; Harnett P; Wain G; Crandon A; Cummings M; Horwood K; Obermair A; Wyld D; Nicklin J; Perrin L; Ward B; Davy M; Hall C; Dodd T; Healy T; Pittman K; Henderson D; Hyde S; Miller J; Pierdes J; Blomfield P; Challis D; McIntosh R; Parker A; Rome R; Allen D; Grant P; Laurie R; Robbie M; Healy D, 2007, 'Recreational physical activity and epithelial ovarian cancer: A case-control study, systematic review, and meta-analysis', Cancer Epidemiology Biomarkers and Prevention, 16, pp. 2321 - 2330, http://dx.doi.org/10.1158/1055-9965.EPI-07-0566
    Journal articles | 2007
    2007, 'Modification of leucovorin dose within a simplified FOLFOX regimen improves tolerability without compromising efficacy', Clinical Colorectal Cancer, 6, pp. 578 - 582, http://dx.doi.org/10.3816/CCC.2007.n.025
    Journal articles | 2007
    2007, 'Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer', International Journal of Gynecological Cancer, 17, pp. 350 - 358, http://dx.doi.org/10.1111/j.1525-1438.2007.00795.x
    Journal articles | 2006
    Duffy S; Jackson TL; Lansdown M; Philips K; Wells M; Pollard S; Clack G; Coibion M; Bianco AR; Adams J; Baum M; Buzdar A; Cella D; Coleman R; Constenla M; Cuzick J; Distler W; Dowset M; Eastell R; Fallowfield LJ; Forbes J; George WD; Gray J; Guastalla JP; Hellmund R; Hoctin-Boes G; Houghton J; Williams N; Howell A; Klijn JG M; Locker GY; Mackey J; Mansel RE; Nabholtz JM; Naglkalnai T; Nicolucci A; Nylen U; Sainsbury R; Sapunar F; Suarez-Mendez VJ; Tobias JS; Friedlander M; Richardson G; Makar A; Neven P; Mention J; Distler DW; Eiermann W; Mouritis M; Wamsteker ; Campos O; Candeias OR; Landers G; Llombart A; Menjon S; Repolle´s M; Lindahl B; Ingvar C; Bharbra K; Bjornsson S; Charnock F; Cutner A; De Bono M; Evans-Jones J; Glass M; Holt S; Jones A; Kremer ; O'Donovan P; Omara-Boto TA; Onwude J; Phillips K; Price J; Samtaney N; Seif M; Doe A; Foster E; Woolas R; Buyse M; Wale C; Margolese R; Body JJ, 2006, 'The ATAC ('Arimidex', tamoxifen, alone or in combination) adjuvant breast cancer trial: First results of the endometrial sub-protocol following 2 years of treatment', Human Reproduction, 21, pp. 545 - 553, http://dx.doi.org/10.1093/humrep/dei322
    Journal articles | 2006
    Goldstein D; Bennett BK; Friedlander ML; Davenport TA; Hickie IB; Lloyd AR, 2006, 'Fatigue states after cancer treatment occur both in association with, and independent of, mood disorder: a longitudinal study', BMC Cancer, 6, pp. 240 - 240, http://dx.doi.org/10.1186/1471-2407-6-240
    Journal articles | 2006
    Harrison ML; Hoskins P; Du Bois A; Quinn M; Rustin GJ S; Ledermann JA; Baron-Hay S; Friedlander ML, 2006, 'Small cell of the ovary, hypercalcemic type - Analysis of combined experience and recommendation for management. A GCIG study', Gynecologic Oncology, 100, pp. 233 - 238, http://dx.doi.org/10.1016/j.ygyno.2005.10.024
    Journal articles | 2006
    Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC, 2006, 'Oxaliplatin and axonal Na+ channel function in vivo', Clinical Cancer Research, 12, pp. 4481 - 4484, http://dx.doi.org/10.1158/1078-0432.CCR-06-0694
    Journal articles | 2006
    Lutty GA; Chan-Ling T; Phelps DL; Adamis AP; Berns KI; Chan CK; Cole CH; D'Amore PA; Das A; Deng WT; Dobson V; Flynn JT; Friedlander M; Fulton A; Good WV; Grant MB; Hansen R; Hauswirth WW; Hardy RJ; Hinton DR; Hughes S; McLeod DS; Palmer EA; Patz A; Penn JS; Raisler BJ; Repka MX; Saint-Geniez M; Shaw LC; Shima DT; Smith BT; Smith LE H; Tahija SG; Tasman W; Trese MT, 2006, 'Proceedings of the Third International Symposium on Retinopathy of Prematurity: An update on ROP from the lab to the nursery (November 2003, Anaheim, California)', Molecular Vision, 12, pp. 532 - 580
    Journal articles | 2006
    Phillips KA; Jenkins MA; Lindeman GJ; Mclachlan SA; Mckinley JM; Weideman PC; Hopper JL; Friedlander ML, 2006, 'Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: A prospective cohort study', Clinical Genetics, 70, pp. 198 - 206, http://dx.doi.org/10.1111/j.1399-0004.2006.00665.x
    Journal articles | 2006
    Tiller K; Meiser B; Gaff C; Kirk J; Dudding T; Phillips KA; Friedlander ML; Tucker K, 2006, 'A randomised controlled trial of a decision aid for women at increased risk of ovarian cancer', Medical Decision Making, 26, pp. 360 - 372, http://dx.doi.org/10.1177/0272989X06290486
    Journal articles | 2006
    2006, 'Addition of Gabapentin to a Modified FOLFOX Regimen Does Not Reduce Oxaliplatin-Induced Neurotoxicity', Clinical Colorectal Cancer, 6, pp. 146 - 151, http://dx.doi.org/10.3816/CCC.2006.n.032
    Journal articles | 2006
    2006, 'Cancer risk management practices of non-carriers within BRCA1/2 mutation positive families in the Kathleen Cunningham Consortium for Research into Familial Breast Cancer (kConFab)', Journal of Clinical Oncology, 24, pp. 1020 - 1020, http://dx.doi.org/10.1200/jco.2006.24.18_suppl.1020
    Journal articles | 2006
    2006, 'Chromosome 2q24.2 is lost in sporadic but not in BRCA1-associated ovarian carcinomas', Pathology, 38, pp. 145 - 151, http://dx.doi.org/10.1080/00313020600561526
    Journal articles | 2006
    2006, 'Genome-wide linkage screen for testicular germ cell tumour susceptibility loci', Human Molecular Genetics, 15, pp. 443 - 451, http://dx.doi.org/10.1093/hmg/ddi459
    Journal articles | 2006
    2006, 'Paraneoplastic mononeuritis multiplex in non-small-cell lung carcinoma', Journal of Clinical Neuroscience, 13, pp. 595 - 598, http://dx.doi.org/10.1016/j.jocn.2005.06.006
    Journal articles | 2006
    2006, 'Risk management practices of Australasian BRCA1 and BRCA2 mutation carriers', European Journal of Cancer Supplements, 4, pp. 71 - 71, http://dx.doi.org/10.1016/s1359-6349(06)80114-x
    Journal articles | 2005
    Kaern J; Aghmesheh M; Nesland JM; Danielsen HE; Sandstad B; Friedlander M; Tropé C, 2005, 'Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors?', International Journal of Gynecological Cancer, 15, pp. 1014 - 1022, http://dx.doi.org/10.1111/j.1525-1438.2005.00185.x
    Journal articles | 2005
    Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC, 2005, 'Oxaliplatin-induced neurotoxicity and the development of neuropathy', Muscle and Nerve, 32, pp. 51 - 60, http://dx.doi.org/10.1002/mus.20340
    Journal articles | 2005
    Loi S; Milne RL; Friedlander ML; McCredie MRE; Giles GG; Hopper JL; Phillips KA, 2005, 'Obesity and outcomes in premenopausal and postmenopausal breast cancer', Cancer Epidemiology Biomarkers and Prevention, 14, pp. 1686 - 1691, http://dx.doi.org/10.1158/1055-9965.EPI-05-0042
    Journal articles | 2005
    Phillips KA; Milne RL; Buys S; Friedlander ML; Ward JH; McCredie MR E; Giles GG; Hopper JL, 2005, 'Agreement between self-reported breast cancer treatment and medical records in a population-based Breast Cancer Family Registry', Journal of Clinical Oncology, 23, pp. 4679 - 4686, http://dx.doi.org/10.1200/JCO.2005.03.002
    Journal articles | 2005
    Thewes B; Meiser B; Duric V; Stockler M; Taylor AJ; Stuart-Harris R; Links MR; Wilcken NW; McLachlan S; Phillips KA; Beith J; Boyle FM; Friedlander ML, 2005, 'What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?', Lancet Oncology, 6, pp. 581 - 588, http://dx.doi.org/10.1016/S1470-2045(05)70254-0
    Journal articles | 2005
    Thewes B; Meiser B; Taylor AJ; Phillips KA; Pendlebury S; Capp A; Dalley D; Goldstein D; Baber R; Friedlander ML, 2005, 'Fertility - and Menoapuse-Related Information Needs of Younger Women With a Diagnosis of Early Breast Cancer', Journal of Clinical Oncology, 23, pp. 5155 - 5165, http://dx.doi.org/10.1200/JCO.2005.07.773
    Journal articles | 2005
    Tiller K; Meiser B; Gould L; Tucker K; Dudding T; Friedlander ML; Andrews L; Franklin J, 2005, 'Knowledge of risk management strategies, and information and risk management preferences of women at increased risk for ovarian cancer', Psycho - Oncology, 14, pp. 249 - 261, http://dx.doi.org/10.1002/pon.840
    Journal articles | 2005
    2005, 'Addition of gabapentin (G) to a modified FOLFOX regimen does not reduce neurotoxicity in patients (pts) with advanced colorectal cancer (CRC)', Journal of Clinical Oncology, 23, pp. 3581 - 3581, http://dx.doi.org/10.1200/jco.2005.23.16_suppl.3581
    Journal articles | 2005
    2005, 'Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients', British Journal of Cancer, 92, pp. 832 - 837, http://dx.doi.org/10.1038/sj.bjc.6602426
    Journal articles | 2005
    2005, 'Expression of steroid hormone receptors in BRCA1-associated ovarian carcinomas', Gynecologic Oncology, 97, pp. 16 - 25, http://dx.doi.org/10.1016/j.ygyno.2004.12.030
    Journal articles | 2005
    2005, 'Predictors of participation in clinical and psychosocial follow-up of the kConFab breast cancer family cohort', Familial Cancer, 4, pp. 105 - 113, http://dx.doi.org/10.1007/s10689-004-6129-x
    Journal articles | 2005
    2005, 'The Y deletion gr/gr and susceptibility to testicular germ cell tumor', American Journal of Human Genetics, 77, pp. 1034 - 1043, http://dx.doi.org/10.1086/498455
    Journal articles | 2004
    Phillips KA; Milne RL; Friedlander ML; Jenkins MA; Mccredie M; Giles GG; Hopper JL, 2004, 'Prognosis of Premenopausal Breast Cancer and Childbirth Prior to Diagnosis', Journal of Clinical Oncology, 22, pp. 699 - 705, http://dx.doi.org/10.1200/JCO.2004.07.062
    Journal articles | 2004
    2004, 'BRCA1 mutation site may associate with nuclear DNA content in BRCA1-associated ovarian carcinomas', Journal of Clinical Oncology, 22, pp. 5040 - 5040, http://dx.doi.org/10.1200/jco.2004.22.90140.5040
    Journal articles | 2004
    2004, 'A Phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer', Gynecologic Oncology, 93, pp. 417 - 421, http://dx.doi.org/10.1016/j.ygyno.2004.01.037
    Journal articles | 2004
    2004, 'BRCA1 mutation site may associate with nuclear DNA content in BRCA1-associated ovarian carcinomas', Journal of Clinical Oncology, 22, pp. 5040 - 5040, http://dx.doi.org/10.1200/jco.2004.22.14_suppl.5040
    Journal articles | 2004
    2004, 'Biology of Epithelial Ovarian cancer: Implications for Screening Women at High Genetic Risk', Journal of Clinical Oncology, 22, pp. 1315 - 1327, http://dx.doi.org/10.1200/JCO.2004.07.179
    Journal articles | 2004
    2004, 'Blood level of phosphoglycerate kinase does not correlate with presenceor extent of tumor', International Journal of Biological Markers, 19, pp. 170 - 172
    Journal articles | 2004
    2004, 'No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers', Gynecologic Oncology, 95, pp. 430 - 436, http://dx.doi.org/10.1016/j.ygyno.2004.08.035
    Journal articles | 2004
    2004, 'Prevention of hepatotoxicity but loss of antimelanoma effect withcombined fotemustine and anti-oxidant treatment', Internal Medicine Journal, 34, pp. 298 - U2, http://dx.doi.org/10.1111/j.1444-0903.2004.00598.x
    Journal articles | 2004
    2004, 'Somatic mutations of KIT in familial testicular germ cell tumours', British Journal of Cancer, 90, pp. 2397 - 2401, http://dx.doi.org/10.1038/sj.bjc.6601880
    Journal articles | 2004
    2004, 'The feasibility of women at high risk for breast cancer participating in chemoprevention trials: An attitudinal study', Journal of Psychosocial Oncology, 22, pp. 31 - 45, http://dx.doi.org/10.1300/J077v22n04_02
    Journal articles | 2004
    2004, 'The impact of obesity on outcomes in a population-based cohort of women with early-onset breast cancer', Journal of Clinical Oncology, 22, pp. 9540 - 9540, http://dx.doi.org/10.1200/jco.2004.22.14_suppl.9540
    Journal articles | 2004
    2004, 'The impact of obesity on outcomes in a population-based cohort of women with early-onset breast cancer', Journal of Clinical Oncology, 22, pp. 9540 - 9540, http://dx.doi.org/10.1200/jco.2004.22.90140.9540
    Journal articles | 2004
    2004, 'Treatment of recurrent ovarian cancer', Chang Gung Medical Journal, 27, pp. 570 - 577, http://www.sciencedirect.com/science/article/B6WVB-4DVW7KP-2Y0/2/9a983bdc3c2e8ebecc9287dafa401635
    Journal articles | 2003
    Friedlander M; Hogg R; Phillips KA, 2003, 'Management of women at increased genetic risk of ovarian cancer', Cancer Forum, 27, pp. 151 - 156
    Journal articles | 2003
    Hogg R; Friedlander M, 2003, 'Role of systemic chemotherapy in metastatic cervical cancer', Expert Review of Anticancer Therapy, 3, pp. 234 - 240, http://dx.doi.org/10.1586/14737140.3.2.234
    Journal articles | 2003
    Scott CI; Iorgulescu DG; Thorne HJ; Henderson MA; Phillips KA; Sambrook J; Chenevix-Trench G; Friedlander M; Baxter N; Evans G; Waring P; Clouston D, 2003, 'Clinical, pathological and genetic features of women at high familial risk of breast cancer undergoing prophylactic mastectomy', Clinical Genetics, 64, pp. 111 - 121, http://dx.doi.org/10.1034/j.1399-0004.2003.00097.x
    Journal articles | 2003
    2003, 'A decision aid for women at increased risk for ovarian cancer', International Journal of Gynecologic Cancer, 13, pp. 15 - 22, http://dx.doi.org/10.1136/ijgc-00009577-200301000-00003
    Journal articles | 2003
    2003, 'A decision aid for women at increased risk for ovarian cancer', International Journal of Gynecological Cancer, 13, pp. 15 - 22, http://dx.doi.org/10.1046/j.1525-1438.2003.13018.x
    Journal articles | 2003
    2003, 'Carboplatin hypersentivity reactions: re-treatment with cisplatin desensitisation', Gynecologic Oncology, 89, pp. 112 - 115, http://dx.doi.org/10.1016/S0090-8258(03)00066-0
    Journal articles | 2003
    2003, 'Counting the costs of treatment: the reporductive and gynaecological consequences of adjuvant therapy in young women with breast cancer', Internal Medicine Journal, 33, pp. 372 - 379, http://dx.doi.org/10.1046/j.1445-5994.2003.00377.x
    Journal articles | 2003
    2003, 'Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a Defines personal and family history in an Ashkenazi Jewish woman LAMBDA', Breast Cancer Research, 5, pp. 206 - 216, http://dx.doi.org/10.1186/bcr644
    Journal articles | 2003
    2003, 'The fertility and menopause-related information needs of younger women with a diagnosis of breast cancer', Psycho - Oncology, 12, pp. 500 - 511, http://dx.doi.org/10.1002/pon.685
    Journal articles | 2002
    Friedlander ML, 2002, 'Guidelines for the treatment of recurrent and metastatic cervical cancer', Oncologist, 7, pp. 342 - 347
    Journal articles | 2002
    Hogg R; Friedlander M, 2002, 'Management of embryonal carcinoma of the ovary', CME Journal of Gynecologic Oncology, 7, pp. 234 - 237
    Journal articles | 2002
    Leary JA; Friedlander ML, 2002, 'The molecular genetics of epithelial ovarian cancer', Current Medical Literature Gynaecology and Obstetrics, 8, pp. 1 - 7
    Journal articles | 2002
    Meiser B; Butow P; Friedlander ML; Barratt AJ; Schnieden V, 2002, 'Psychological impact of genetic testing in women from high risk breast cancer families', European Journal of Cancer, 38, pp. 2025 - 2031, http://dx.doi.org/10.1016/S0959-8049(02)00264-2
    Journal articles | 2002
    Tiller K; Meiser B; Butow P; Clifton M; Thewes B, 2002, 'Psychological Impact of Prophylactic Oophorectomy in Women at Increased Risk of Developing Ovarian Cancer: A Prospective Study', Gynecologic Oncology, 86, pp. 212 - 219, http://dx.doi.org/10.1006/gyno.2002.6737
    Journal articles | 2001
    Ackland SP; Anton A; Breitbach GP; Colajori E; Tursi JM; Delfino C; Efremidis A; Ezzat A; Fittipaldo A; Kolaric K; Lopez M; Viaro D; Abdi E; Kotasek D; Beadle G; Friedlander M; Anton A; Aranda E; Murillo E; Nogueira M; Balli M; De Lena M; Lopez M; Luporini G; Micheletti E; Morrica B; Tordiglione M; Breitbach GP; Dornhoff W; Klinkenstein C; Villena C; Wilken H; Cervek J; Chacòn R; Estévez R; Mickiewicz E; Muro H; Damianov D; Donat D; Vuletic L; Gershanovich MN N; Ghilezan N; Hegg R; Jassem J; Pawlicki M; Ramlau C; Siedlecki P; Kocak I; Korec S; Muse IM; Nagykàlnai T; Perenyi L; Pinter T; Vallejos CS; Vogel C, 2001, 'Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: A randomized multinational study', Journal of Clinical Oncology, 19, pp. 943 - 953, http://dx.doi.org/10.1200/JCO.2001.19.4.943
    Journal articles | 2001
    Bahar AY; Taylor PC; Andrews L; Proos A; Tucker K; Burnett L; Friedlander ML; Buckley MF, 2001, 'Genetic Analysis of Breast, Ovarian and Colorectal Cancer in the Sydney Ashkenazi Jewish Population', Cancer, pp. 440 - 445
    Journal articles | 2001
    Bahar AY; Taylor PJ; Andrews L; Proos A; Burnett L; Tucker K; Friedlander M; Buckley MF, 2001, 'The frequency of founder mutations in the BRCA1, BRCA2, and APC genes in Australian Ashkenazi Jews: implications for the generality of U.S. population data', Cancer, 92, pp. 440 - 445, http://dx.doi.org/10.1002/1097-0142(20010715)92:2<440::AID-CNCR1340>3.0.CO;2-O
    Journal articles | 2001
    Evans VE; Vockler C; Friedlander ML; Walsh B; Willcox MD, 2001, 'Lacroglobin in Human Tears, a Potential Marker for Cancer', Clinical and Experimental Ophthalmology, pp. 161 - 163
    Journal articles | 2001
    Evans VE; Vockler C; Friedlander ML; Walsh B; Willcox MD, 2001, 'Lacryglobin in human tears, a potential marker for cancer', Clinical and Experimental Ophthalmology, 29, pp. 161 - 163, http://dx.doi.org/10.1046/j.1442-9071.2001.00408.x
    Journal articles | 2001
    Marx GM; Friedlander ML; Hacker NF, 2001, 'Cytotoxic drug treatment of vulval and vaginal cancer', CME Journal of Gynecologic Oncology, 6, pp. 67 - 72
    Journal articles | 2001
    Marx GM; Friedlander ML, 2001, 'Drug toxicity prevention and management', CME Journal of Gynecologic Oncology, 6, pp. 29 - 33
    Journal articles | 2001
    Yang JL; Friedlander ML, 2001, 'Effect of nifedipine in metastatic colon cancer with DNA mismatch repair gene defect', Lancet, 357, pp. 1767 - 1768, http://dx.doi.org/10.1016/S0140-6736(00)04892-3
    Journal articles | 2001
    Yang JL; Friedlander ML, 2001, 'Therapeutic Benefit of Nifedipine in Metastatic Colon Cancer with DNA Mismatch Repair Gene Defect: Clinical Observation and Supportive Laboratory Evidence', Lancet, pp. 1767 - 1768
    Journal articles | 2001
    2001, 'High Frequency of Allelic Imbalance at Regions of Chromosome 8p in Ovarian Carcinoma', Cancer, 129, pp. 23 - 29, http://dx.doi.org/10.1016/S0165-4608(01)00419-8
    Journal articles | 2000
    Bonevski B; Sanson-Fisher R; Girgis A; Burton L; Cook P; Boyes AW; Ackland S; Baker RW; Berry M; Biggs J, 2000, 'Evaluation of an instrument to assess the needs of patients with cancer', Cancer, 88, pp. 217 - 225, http://dx.doi.org/10.1002/(SICI)1097-0142(20000101)88:1<217::AID-CNCR29>3.0.CO;2-Y
    Journal articles | 2000
    Faulkner SW; Friedlander ML, 2000, 'Microsatellite instability in germ cell tumors of the testis and ovary', Gynecologic Oncology, 79, pp. 38 - 43, http://dx.doi.org/10.1006/gyno.2000.5906
    Journal articles | 2000
    Faulkner SW; Friedlander ML, 2000, 'Molecular genetic analysis of malignant ovarian germ cell tumors', Gynecologic Oncology, 77, pp. 283 - 288, http://dx.doi.org/10.1006/gyno.2000.5762
    Journal articles | 2000
    Faulkner SW; Leigh DA; Oosterhuis JW; Roelofs H; Looijenga LHJ; Friedlander ML, 2000, 'Allelic losses in carcinoma in situ and testicular germ cell tumours of adolescents and adults: Evidence suggestive of the linear progression model', British Journal of Cancer, 83, pp. 729 - 736, http://dx.doi.org/10.1054/bjoc.2000.1334
    Journal articles | 2000
    Meiser B; Butow P; Barratt A; Friedlander M; Kirk J; Gaff C; Haan E; Aittomäki K; Tucker K, 2000, 'Breast cancer screening uptake in women at increased risk of developing hereditary breast cancer', Breast Cancer Research and Treatment, 59, pp. 101 - 111, http://dx.doi.org/10.1023/A:1006330631832
    Journal articles | 2000
    Meiser B; Butow P; Friedlander M; Schnieden V; Gattas M; Kirk J; Suthers G; Haan E; Tucker K, 2000, 'Intention to undergo prophylactic bilateral mastectomy in women at increased risk of developing hereditary breast cancer', Journal of Clinical Oncology, 18, pp. 2250 - 2257, http://dx.doi.org/10.1200/JCO.2000.18.11.2250
    Journal articles | 2000
    Rapley EA; Crockford GP; Teare D; Biggs P; Seal S; Barfoot R; Edwards S; Hamoudi R; Heimdal K; Fosså SD; Tucker K; Donald J; Collins F; Friedlander M; Hogg D; Goss P; Heidenreich A; Ormiston W; Daly PA; Forman D; Oliver RT D; Leahy M; Huddart R; Cooper CS; Bodmer JG; Easton DF; Stratton MR; Bishop DT, 2000, 'Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours', Nature Genetics, 24, pp. 197 - 200, http://dx.doi.org/10.1038/72877
    Journal articles | 2000
    Sanson-Fisher R; Girgis A; Boyes A; Bonevski B; Burton L; Cook P; Ackland S; Baker R; Berry M; Biggs J; Bishop J; Bokey L; Burnard A; Clingan P; Cregan P; Dunn S; Friedlander M; Goulston K; Hacker N; Kearsley J; Langlands A; Levi J; Moylan E; Stewart J; Tattersall M, 2000, 'The unmet supportive care needs of patients with cancer', Cancer, 88, pp. 225 - 236, http://dx.doi.org/10.1002/(sici)1097-0142(20000101)88:1<226::aid-cncr30>3.0.co;2-p
    Journal articles | 2000
    Vergote I; Rustin GJ S; Eisenhauer EA; Kristensen GB; Pujade-Lauraine E; Parmar MK B; Friedlander M; Jakobsen A; Vermorken JB, 2000, 'Re: New guidelines to evaluate the response to treatment in solid tumors [ovarian cancer] [3]', Journal of the National Cancer Institute, 92, pp. 1534 - 1535
    Journal articles | 2000
    2000, 'Current management of Epithelial Ovarian Carcinoma: A Review', Seminars in Surgical Oncology, 19, pp. 11 - 19, http://dx.doi.org/10.1002/1098-2388(200007/08)19:1<11::AID-SSU3>3.0.CO;2-3
    Journal articles | 1999
    Friedlander ML, 1999, 'Multivariate prognostic models in ovarian cancer', CME Journal of Gynecologic Oncology, 4, pp. 256 - 258
    Journal articles | 1999
    Friedlander ML, 1999, 'Surgical stage, ascites, peritoneal cytology, tumour spillage, dense adherence', CME Journal of Gynecologic Oncology, 4, pp. 38 - 40
    Journal articles | 1999
    Meiser B; Butow P; Barratt A; Friedlander M; Gattas M; Kirk J; Suthers G; Walpole I; Tucker K, 1999, 'Attitudes toward prophylactic oophorectomy and screening utilization in women at increased risk of developing hereditary breast/ovarian cancer', Gynecologic Oncology, 75, pp. 122 - 129, http://dx.doi.org/10.1006/gyno.1999.5544
    Journal articles | 1999
    1999, 'Vinblastine pharmacokinetics in patients with non-small cell lung cancer given cisplatin', Cancer Investigation, 17, pp. 479 - 485, http://dx.doi.org/10.3109/07357909909032857
    Journal articles | 1998
    Friedlander M, 1998, 'A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer', Annals of Oncology, 9, pp. 1343 - 1345, http://dx.doi.org/10.1023/A:1008469212268
    Journal articles | 1998
    Friedlander ML, 1998, 'Prognostic factors and tumour markers in ovarian teratomas', CME Journal of Gynecologic Oncology, 3, pp. 177 - 180
    Journal articles | 1998
    Friedlander ML, 1998, 'Prognostic factors in ovarian cancer', Seminars in Oncology, 25, pp. 305 - 314
    Journal articles | 1998
    Kefford R; Tucker K; Friedlander M; Kirk J, 1998, 'Cancer in the family. Part 2.', Australian family physician, 27, pp. 40 - 44
    Journal articles | 1998
    Zalcberg J; Millward M; Bishop J; McKeage M; Zimet A; Toner G; Friedlander M; Barter C; Rischin D; Loret C; James R; Bougan N; Berille J, 1998, 'Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer', Journal of Clinical Oncology, 16, pp. 1948 - 1953, http://dx.doi.org/10.1200/JCO.1998.16.5.1948
    Journal articles | 1998
    1998, 'Influence of post operative treatment on survival in patients with uterine papillary serous carcinoma', Gynecologic Oncology, 71, pp. 344 - 347, http://dx.doi.org/10.1006/gyno.1998.5202
    Journal articles | 1998
    1998, 'Regulation and deregulation of G2 checkpoint proteins with cisplatin', Anticancer Research, 18, pp. 4057 - 4066
    Journal articles | 1997
    Beller E; Tattersall M; Lumley T; Levi J; Dalley D; Olver I; Page J; Abdi E; Wynne C; Friedlander M; Boadle D; Wheeler H; Margrie S; Simes RJ, 1997, 'Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: A randomised placebo-controlled trial', Annals of Oncology, 8, pp. 277 - 283, http://dx.doi.org/10.1023/A:1008291825695
    Journal articles | 1997
    Friedlander M; Tucker K, 1997, 'Hereditary ovarian cancer: genetic basic and management issues', Cancer Forum, 21, pp. 10 - 13
    Journal articles | 1997
    Friedlander M, 1997, 'A menopausal woman with a history of breast cancer: Should she receive HRT?', Modern Medicine of Australia, 40, pp. 164 - 165
    Journal articles | 1997
    Kefford R; Tucker K; Friedlander M; Kirk J, 1997, 'Cancer in the family. Guidelines for general practice.', Australian family physician, 26, pp. 545 - 549
    Journal articles | 1997
    Michael M; Bishop JF; Levi JA; Bell DR; Zalcberg JR; Friedlander ML; Olver LN; Smith JG; Toner GC, 1997, 'Australian multicentre phase II trial of paclitaxel in women with metastatic breast cancer and prior chemotherapy', Medical Journal of Australia, 166, pp. 520 - 523, http://dx.doi.org/10.5694/j.1326-5377.1997.tb123243.x
    Journal articles | 1997
    1997, 'Activity of Gemcitablne in stage 3 or 4 ovarian cancer: Patients previously treated with cisplatin (CP)-containing regimens', European Journal of Cancer, 33, pp. S120 - S121, http://dx.doi.org/10.1016/s0959-8049(97)85054-x
    Journal articles | 1997
    1997, 'Analysis of loss of heterozygosity and KRAS2 mutations in ovarian neoplasms: Clinicopathological correlations', Genes Chromosomes and Cancer, 18, pp. 75 - 83, http://dx.doi.org/10.1002/(SICI)1098-2264(199702)18:2<75::AID-GCC1>3.0.CO;2-Y
    Journal articles | 1996
    Kavallaris M; Leary JA; Barrett JA; Friedlander ML, 1996, 'MDR1 and multidrug resistance-associated protein (MRP) gene expression in epithelial ovarian tumors', Cancer Letters, 102, pp. 7 - 16, http://dx.doi.org/10.1016/0304-3835(96)04143-2
    Journal articles | 1996
    Kerr J; Leary JA; Hurst T; Shih YC; Antalis TM; Friedlander M; Crawford E; Khoo SK; Ward B; Chenevix-Trench G, 1996, 'Allelic loss on chromosome 7q in ovarian adenocarcinomas: Two critical regions and a rearrangement of the PLANH1 locus', Oncogene, 13, pp. 1815 - 1818
    Journal articles | 1996
    Millward MJ; Bishop JF; Friedlander M; Levi JA; Goldstein D; Olver IN; Smith JG; Toner GC; Rischin D; Bell DR, 1996, 'Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer', Journal of Clinical Oncology, 14, pp. 142 - 148, http://dx.doi.org/10.1200/JCO.1996.14.1.142
    Journal articles | 1996
    Zalcberg JR; Friedlander ML; Collopy BT; Barton M; Gray B, 1996, 'Erratum: Treatment principles in advanced colorectal cancer (Australian and New Zealand Journal of Surgery (1996) 66 (202-205))', Australian and New Zealand Journal of Surgery, 66, pp. 503
    Journal articles | 1996
    Zalcberg JR; Friedlander ML; Collopy BT; Barton M; Gray B, 1996, 'Treatment principles in advanced colorectal cancer (vol 66, pg 202, 1996)', AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 66, pp. 503 - 503, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1996UX20100021&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Journal articles | 1996
    Zalcberg JR; Friedlander ML; Collopy BT; Barton M; Gray B, 1996, 'Treatment principles in advanced colorectal cancer', Australian and New Zealand Journal of Surgery, 66, pp. 202 - 205, http://dx.doi.org/10.1111/j.1445-2197.1996.tb01164.x
    Journal articles | 1995
    De Souza PL; Friedlander ML, 1995, 'Humoral hypercalcemia associated with adenocarcinoma of the rectum: A case report and review of the literature', American Journal of Clinical Oncology: Cancer Clinical Trials, 18, pp. 126 - 129, http://dx.doi.org/10.1097/00000421-199504000-00006
    Journal articles | 1995
    Leary JA; Kerr J; Chenevix‐Trench G; Doris CP; Hurst T; Houghton CR S; Friedlanders ML, 1995, 'Increased expression of the nme1 gene is associated with metastasis in epithelial ovarian cancer', International Journal of Cancer, 64, pp. 189 - 195, http://dx.doi.org/10.1002/ijc.2910640308
    Journal articles | 1995
    Links M; Friedlander M, 1995, 'High-dose chemotherapy in gynaecological cancers: Does more mean better?', Current Opinion in Obstetrics and Gynecology, 7, pp. 49 - 52, http://dx.doi.org/10.1097/00001703-199507010-00010
    Journal articles | 1995
    Phillips KA; Fitzharris B; Friedlander M; McCrystal M; Olver I; Joughin J; Bishop J; Evans B; Smith J, 1995, 'Australasian multicentre phase II study of paclitaxel (Taxol) in relapsed ovarian cancer', Australian and New Zealand Journal of Medicine, 25, pp. 337 - 343, http://dx.doi.org/10.1111/j.1445-5994.1995.tb01899.x
    Journal articles | 1995
    Shannon JA; Donnellan MJ; Friedlander ML; Harnett PR, 1995, 'Persisting elevation of alphafetoprotein after chemotherapy for germ cell tumour-not always due to viable malignancy?', European Journal of Cancer, 31, pp. 1722, http://dx.doi.org/10.1016/0959-8049(95)00303-Z
    Journal articles | 1995
    1995, '1084 Interim results of a phase II trial of docetaxel in combination with cisplatin in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC)', European Journal of Cancer, 31, pp. S226 - S226, http://dx.doi.org/10.1016/0959-8049(95)96330-g
    Journal articles | 1995
    1995, 'High-dose chemotherapy in gynaecological cancers', Current Opinion in Obstetrics and Gynecology, 7, pp. 49 - 52, http://dx.doi.org/10.1097/00001703-199502000-00010
    Journal articles | 1995
    1995, 'Tamoxifen in patients with advanced epithelial ovarian cancer', International Journal of Gynecological Cancer, 5, pp. 301 - 305, http://dx.doi.org/10.1046/j.1525-1438.1995.05040301.x
    Journal articles | 1995
    1995, 'Uterine papillary serous carcinaoma: a clinical study', Cancer, 75, pp. 2239 - 2243, http://dx.doi.org/10.1002/1097-0142(19950501)75:9<2239::AID-CNCR2820750908>3.0.CO;2-7
    Journal articles | 1994
    Chenevix-Trench G; Kerr J; Friedlander M; Hurst T; Sanderson B; Coglan M; Ward B; Leary J; Khoo SK, 1994, 'Homozygous deletions on the short arm of chromosome 9 in ovarian adenocarcinoma cell lines and loss of heterozygosity in sporadic tumors', American Journal of Human Genetics, 55, pp. 143 - 149
    Journal articles | 1994
    De Souza P; Friedlander M; Wilde C; Kirsten F; Ryan M, 1994, 'Hypersensitivity reactions to etoposide: A report of three cases and review of the literature', American Journal of Clinical Oncology: Cancer Clinical Trials, 17, pp. 387 - 389, http://dx.doi.org/10.1097/00000421-199410000-00005
    Journal articles | 1994
    Mackintosh JF; Friedlander M; Lewis C; Goldstein D; Herrmann RP; Kearsley JH, 1994, 'Wanted: Guidelines for 'palliative' anti-cancer drug use [3]', Medical Journal of Australia, 161, pp. 638 - 639, http://dx.doi.org/10.5694/j.1326-5377.1994.tb127659.x
    Journal articles | 1994
    Mayordomo JI; Paz-Ares L; Diaz-Puente MT; Lianes P; Garcia-Prats MD; Cortes-Funes H; Segelov E; Friedlander M, 1994, 'Prognostic factors for women with ovarian germ cell tumors [2]', Journal of Clinical Oncology, 12, pp. 1737 - 1738, http://dx.doi.org/10.1200/JCO.1994.12.8.1737
    Journal articles | 1994
    Quinn M; Murray J; Friedlander M; Steigrad S; Khoo S; Marsden D; Hammond I; Jobling T, 1994, 'EMACO in High Risk Gestational Trophoblast Disease ‐ The Australian Experience', Australian and New Zealand Journal of Obstetrics and Gynaecology, 34, pp. 90 - 92, http://dx.doi.org/10.1111/j.1479-828X.1994.tb01047.x
    Journal articles | 1994
    SEGELOV E; FRIEDLANDER M, 1994, 'PROGNOSTIC FACTORS FOR WOMEN WITH OVARIAN GERM-CELL TUMORS - REPLY', JOURNAL OF CLINICAL ONCOLOGY, 12, pp. 1738 - 1738, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1994PA25700031&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Journal articles | 1994
    Segelov E; Campbell J; Ng M; Tattersall M; Rome R; Free K; Hacker N; Friedlander ML, 1994, 'Cisplatin-based chemotherapy for ovarian germ cell malignancies: The Australian experience', Journal of Clinical Oncology, 12, pp. 378 - 384, http://dx.doi.org/10.1200/JCO.1994.12.2.378
    Journal articles | 1994
    Segelov E; Stuart-Harris R; Bell D; Tattersall M; Hutton-Potts J; Friedlander M, 1994, 'A phase II study of carboplatin and cisplatin in advanced ovarian cancer', European Journal of Gynaecological Oncology, 15, pp. 277 - 282
    Journal articles | 1993
    Leary JA; Doris CP; Boltz EM; Houghton CR S; Kefford RF; Friedlander ML, 1993, 'Investigation of loss of heterozygosity at specific loci on chromosomes 3p, 6q, 11p, 17p and 17q in ovarian cancer 11p, 17p and 17q in ovarian cancer', International Journal of Gynecological Cancer, 3, pp. 293 - 298, http://dx.doi.org/10.1046/j.1525-1438.1993.03050293.x
    Journal articles | 1993
    Lewis CR; Segelov E; Goldstein D; Friedlander ML, 1993, 'Chemotherapy made easier.', Australian and New Zealand journal of medicine, 23, pp. 387 - 392, http://dx.doi.org/10.1111/j.1445-5994.1993.tb01440.x
    Journal articles | 1992
    Chenevix-Trench G; Leary J; Kerr J; Michel J; Kefford R; Hurst T; Parsons PG; Friedlander M; Khoo SK, 1992, 'Frequent loss of heterozygosity on chromosome 18 in ovarian adenocarcinoma which does not always include the DCC locus', Oncogene, 7, pp. 1059 - 1065
    Journal articles | 1992
    De Souza PL; Friedlander ML, 1992, 'Prognostic factors in ovarian cancer', Hematology/Oncology Clinics of North America, 6, pp. 761 - 781, http://dx.doi.org/10.1016/s0889-8588(18)30309-5
    Journal articles | 1992
    Friedlander M; De Souza P; Segelov E, 1992, 'Risk factors, epidemiology, screening, and prognostic factors in female genital cancer', Current Opinion in Oncology, 4, pp. 913 - 922, http://dx.doi.org/10.1097/00001622-199210000-00016
    Journal articles | 1992
    Leary JA; Edwards BG; Houghton CR S; Kefford RF; Friedlander ML, 1992, 'Amplification of HER-2/neu oncogene in human ovarian cancer', International Journal of Gynecological Cancer, 2, pp. 291 - 294, http://dx.doi.org/10.1046/j.1525-1438.1992.02060291.x
    Journal articles | 1992
    Levi JA; Wheeler HR; Friedlander M; Tattersall MH N; Kefford R; Dalley D, 1992, 'Dual sequential non-cross-resistant chemotherapy for advanced stage squamous cell carcinoma of the cervix', Gynecologic Oncology, 45, pp. 329 - 333, http://dx.doi.org/10.1016/0090-8258(92)90314-9
    Journal articles | 1991
    Cope C; Delbridge L; Philips E; Friedlander M, 1991, 'PROGNOSTIC SIGNIFICANCE OF NUCLEAR DNA CONTENT IN PHAEOCHROMOCYTOMA', Australian and New Zealand Journal of Surgery, 61, pp. 695 - 698, http://dx.doi.org/10.1111/j.1445-2197.1991.tb00323.x
    Journal articles | 1991
    Cope C; Rowe D; Delbridge L; Philips J; Friedlander M, 1991, 'Comparison of image analysis and flow cytometric determination of cellular DNA content', Journal of Clinical Pathology, 44, pp. 147 - 151, http://dx.doi.org/10.1136/jcp.44.2.147
    Journal articles | 1991
    Friedlander ML; Dembo AJ, 1991, 'Prognostic factors in ovarian cancer', Seminars in Oncology, 18, pp. 205 - 212
    Journal articles | 1991
    1991, 'CURRENT GENITOURINARY CANCER SURGERY', Australian and New Zealand Journal of Medicine, 21, pp. 492 - 492, http://dx.doi.org/10.1111/j.1445-5994.1991.tb01367.x
    Journal articles | 1990
    Bishop JF; Kefford R; Raghavan D; Zalcberg J; Stuart-Harris R; Ball D; Olver IN; Friedlander M; Bull C; Yuen K; Matthews JP; Zimet A, 1990, 'Etoposide, carboplatin, cyclophosphamide and vincristine in previously untreated patients with small-cell lung cancer', Cancer Chemotherapy and Pharmacology, 25, pp. 367 - 370, http://dx.doi.org/10.1007/BF00686239
    Journal articles | 1990
    Boltz EM; Harnett P; Kefford RF; Leary J; Houghton R; Friedlander ML, 1990, 'Demonstration of somatic rearrangements and genomic heterogeneity in human ovarian cancer by DNA fingerprinting', British Journal of Cancer, 62, pp. 23 - 27, http://dx.doi.org/10.1038/bjc.1990.222
    Journal articles | 1989
    Antonjuk DJ; Boadle DK; Cheung HT A; Friedlander ML; Gregory PM; Tattersall MH N, 1989, 'α-Monoamides of methotrexate as potential prodrugs', Arzneimittel-Forschung/Drug Research, 39, pp. 12 - 15
    Journal articles | 1989
    Bishop JF; Raghavan D; Olver IN; Reece P; Morris R; Friedlander ML, 1989, 'A phase I study of trimetrexate (NSC 352122) administered by 5-day continuous intravenous infusion', Cancer Chemotherapy and Pharmacology, 24, pp. 246 - 250, http://dx.doi.org/10.1007/BF00257627
    Journal articles | 1989
    Boltz EM; Kefford RF; Leary JA; Houghton CR; Friedlander ML, 1989, 'Amplification of c‐ras‐ki oncogene in human ovarian tumours', International Journal of Cancer, 43, pp. 428 - 430, http://dx.doi.org/10.1002/ijc.2910430314
    Journal articles | 1989
    Boyer M; Friedlander M; Bannatyne P; Atkinson K, 1989, 'Hypercalcemia in association with mucinous adenocarcinoma of the ovary: A case report', Gynecologic Oncology, 35, pp. 387 - 390, http://dx.doi.org/10.1016/0090-8258(89)90085-1
    Journal articles | 1989
    Dalrymple JC; Bannatyne P; Russell P; Solomon HJ; Tattersall MH N; Atkinson K; Carter J; Duval P; Elliott P; Friedlander M; Murray J; Coppleson M, 1989, 'Extraovarian peritoneal serous papillary carcinoma. A clinicopathologic study of 31 cases', Cancer, 64, pp. 110 - 115, http://dx.doi.org/10.1002/1097-0142(19890701)64:1<110::AID-CNCR2820640120>3.0.CO;2-5
    Journal articles | 1989
    Friedlander ML; Bell DR; Leary J; Davey RA, 1989, 'Comparison of Western blot analysis and immunocytochemical detection of P-glycoprotein in multidrug resistant cells', Journal of Clinical Pathology, 42, pp. 719 - 722, http://dx.doi.org/10.1136/jcp.42.7.719
    Journal articles | 1989
    Friedlander ML; Bell DR, 1989, 'Multidrug resistance: clinical findings and implications.', Cancer treatment and research, 42, pp. 63 - 77, http://dx.doi.org/10.1007/978-1-4613-1747-0_4
    Journal articles | 1989
    Friedlander ML; Quinn MA; Fortune D; Foo MS; Toppila M; Hudson CN; Russell P, 1989, 'The relationship of steroid receptor expression to nuclear DNA distribution and clinicopathological characteristics in epithelial ovarian tumors', Gynecologic Oncology, 32, pp. 184 - 190, http://dx.doi.org/10.1016/S0090-8258(89)80031-9
    Journal articles | 1988
    Friedlander M; Leary J; Russelli P, 1988, 'An evaluation of CA125, CA1 and peanut lectin immunoreactivity in epithelial ovarian neoplasms: Correlation with histopathological features, prognostic variables and patient outcome', Pathology, 20, pp. 38 - 44, http://dx.doi.org/10.3109/00313028809085194
    Journal articles | 1988
    Friedlander ML; Hedley DW; Swanson C; Russell P, 1988, 'Prediction of long-term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer', Journal of Clinical Oncology, 6, pp. 282 - 290, http://dx.doi.org/10.1200/JCO.1988.6.2.282
    Journal articles | 1988
    Solomon HJ; Atkinson KH; Coppleson JV M; Elliott PM; Houghton CR S; Murray J; Tattersall MH N; Friedlander ML; Green D, 1988, 'Ovarian carcinoma: Abdominopelvic irradiation following reexploration', Gynecologic Oncology, 31, pp. 396 - 401, http://dx.doi.org/10.1016/S0090-8258(88)80023-4
    Journal articles | 1987
    KIRSTEN F; ATKINSON KH; COPPLESON JV M; ELLIOTT PM; GREEN D; HOUGHTON R; MURRAY JC; RUSSELL P; SOLOMON HJ; FRIEDLANDER M; SWANSON CE; TATTERSALL MH N, 1987, 'Combination chemotherapy followed by surgery or radiotherapy in patients with locally advanced cervical cancer', BJOG: An International Journal of Obstetrics & Gynaecology, 94, pp. 583 - 588, http://dx.doi.org/10.1111/j.1471-0528.1987.tb03154.x
    Journal articles | 1987
    Trebeck CE; Friedlander ML; Russell P; Baird PJ, 1987, 'Brenner tumours of the ovary: A study of the histology, immunohistochemistry and cellular dna content in benign, borderline and malignant ovarian tumours', Pathology, 19, pp. 241 - 246, http://dx.doi.org/10.3109/00313028709066557
    Journal articles | 1986
    Zalcberg JR; Friedlander ML; Minden MD, 1986, 'Molecular evidence for the clonal origin of blast crisis in chronic myeloid leukaemia', British Journal of Cancer, 53, pp. 459 - 464, http://dx.doi.org/10.1038/bjc.1986.73
    Journal articles | 1985
    Eckstein RP; Russell P; Friedlander ML; Tattersall MH N; Bradfield A, 1985, 'Metastasizing placental site trophoblastic tumor: A case study', Human Pathology, 16, pp. 632 - 636, http://dx.doi.org/10.1016/S0046-8177(85)80114-3
    Journal articles | 1985
    Friedlander M; Foo MS; Quinn M, 1985, 'Relationship of steroid receptors and tumor ploidy in epithelial ovarian cancer', Proceedings of the American Association for Cancer Research, VOL. 26
    Journal articles | 1985
    Friedlander M; Zalcberg J; Patterson B; Minden M; Bergsagel DE, 1985, 'APPARENT T-CELL NEOPLASMS WITH IMMUNOGLOBULIN GENE REARRANGEMENTS', The Lancet, 326, pp. 670, http://dx.doi.org/10.1016/S0140-6736(85)90036-4
    Journal articles | 1985
    Friedlander ML; Russell P; Taylor IW; Tattersall MH N, 1985, 'Ovarian tumour xenografts in the study of the biology of human epithelial ovarian cancer', British Journal of Cancer, 51, pp. 319 - 333, http://dx.doi.org/10.1038/bjc.1985.44
    Journal articles | 1985
    Hedley DW; Friedlander ML; Taylor IW, 1985, 'Application of DNA flow cytometry to paraffin‐embedded archival material for the study of aneuploidy and its clinical significance', Cytometry, 6, pp. 327 - 333, http://dx.doi.org/10.1002/cyto.990060409
    Journal articles | 1985
    Taylor IW; Slowiaczek P; Friedlander ML; Tattersall MH N, 1985, 'Selective Toxicity of a New Lipophilic Antifolate, BW301U, for Methotrexate-resistant Cells with Reduced Drug Uptake', Cancer Research, 45, pp. 978 - 982
    Journal articles | 1984
    Friedlander ML; Atkinson K; Coppleson JV M; Elliot P; Green D; Houghton R; Solomon HJ; Russell P; Tattersall MH N, 1984, 'The integration of chemotherapy into the management of locally advanced cervical cancer: A pilot study', Gynecologic Oncology, 19, pp. 1 - 7, http://dx.doi.org/10.1016/0090-8258(84)90150-1
    Journal articles | 1984
    Friedlander ML; Hedley DW; Taylor IW, 1984, 'Clinical and biological significance of aneuploidy in human tumours', Journal of Clinical Pathology, 37, pp. 961 - 974, http://dx.doi.org/10.1136/jcp.37.9.961
    Journal articles | 1984
    Friedlander ML; Russell P; Taylor IW; Hedley DW; Tattersall MH N, 1984, 'Flow cytometric analysis of cellular DNA content as an adjunct to the diagnosis of ovarian tumours of borderline malignancy', Pathology, 16, pp. 301 - 306, http://dx.doi.org/10.3109/00313028409068541
    Journal articles | 1984
    Friedlander ML; Taylor IW; Russell P; Tattersall MH, 1984, 'Cellular DNA content—a stable feature in epithelial ovarian cancer', British Journal of Cancer, 49, pp. 173 - 179, http://dx.doi.org/10.1038/bjc.1984.29
    Journal articles | 1984
    Friedlander ML, 1984, 'Prognostic Variables in Epithelial Ovarian Cancer: A Review', Australian and New Zealand Journal of Obstetrics and Gynaecology, 24, pp. 256 - 261, http://dx.doi.org/10.1111/j.1479-828X.1984.tb01506.x
    Journal articles | 1984
    Hedley DW; Friedlander ML; Taylor IW; Rugg CA; Musgrove EA, 1984, 'DNA flow cytometry of paraffin‐embedded tissue', Cytometry, 5, pp. 660 - 660, http://dx.doi.org/10.1002/cyto.990050618
    Journal articles | 1984
    Hedley DW; Taylor IW; Coates AS; Tattersall MH N; Russell P; Friedlander ML, 1984, 'Influence of Cellular DNA Content on Survival in Advanced Ovarian Cancer', Cancer Research, 44, pp. 397 - 400
    Journal articles | 1983
    FRIEDLANDER ML; KEARSLEY JH; SIMS K; COATES A; HEDLEY D; RAGHAVAN D; FOX RM; TATTERSALL MH N, 1983, 'LORAZEPAM AS AN ADJUNCT TO ANTIEMETIC THERAPY WITH HALOPERIDOL IN PATIENTS RECEIVING CYTOTOXIC CHEMOTHERAPY', Australian and New Zealand Journal of Medicine, 13, pp. 53 - 56, http://dx.doi.org/10.1111/j.1445-5994.1983.tb04550.x
    Journal articles | 1983
    Friedlander M; Kaye SB; Sullivan A; Atkinson K; Elliott P; Coppleson M; Houghton R; Solomon J; Green D; Russell P; Hudson CN; Langlands AO; Tattersall MH N, 1983, 'Cervical carcinoma: A drug-responsive tumor-experience with combined cisplatin, vinblastine, and bleomycin therapy', Gynecologic Oncology, 16, pp. 275 - 281, http://dx.doi.org/10.1016/0090-8258(83)90102-6
    Journal articles | 1983
    Friedlander ML; Sims K; Kearsley JH, 1983, 'IMPAIRMENT OF RECALL IMPROVES TOLERANCE OF CYTOTOXIC CHEMOTHERAPY', The Lancet, 322, pp. 686, http://dx.doi.org/10.1016/S0140-6736(83)92568-0
    Journal articles | 1983
    Friedlander ML; Taylor IW; Russell P; Musgrove EA; Hedley DH; Tattersall MH N, 1983, 'Ploidy as a prognostic factor in ovarian cancer', International Journal of Gynecological Pathology, 2, pp. 55 - 63, http://dx.doi.org/10.1097/00004347-198301000-00005
    Journal articles | 1983
    Taylor IW; Musgrove EA; Friedlander ML; Foo MS; Hedley DW, 1983, 'The influence of age on the DNA ploidy levels of breast tumours', European Journal of Cancer and Clinical Oncology, 19, pp. 623 - 628, http://dx.doi.org/10.1016/0277-5379(83)90178-5
    Journal articles | 1983
    1983, 'Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry', Journal of Histochemistry and Cytochemistry, 31, pp. 1333 - 1335, http://dx.doi.org/10.1177/31.11.6619538
    Journal articles | 1982
    Friedlander ML; Halley JB W; Sinosich MJ; Coates A, 1982, 'Pulmonary Pseudotumours Following Chemotherapy for Endodermal Sinus Tumour of the Ovary', Australian and New Zealand Journal of Obstetrics and Gynaecology, 22, pp. 110 - 112, http://dx.doi.org/10.1111/j.1479-828X.1982.tb01417.x
    Journal articles | 1982
    Friedlander ML; Tattersall MH N, 1982, 'Counting the costs of cancer therapy', European Journal of Cancer and Clinical Oncology, 18, pp. 1237 - 1241, http://dx.doi.org/10.1016/0277-5379(82)90124-9
    Journal articles | 1982
    Raghavan D; Coates A; Friedlander M, 1982, 'Mitoxantrone (XAN): Progress in a phase ii trial in Sydney, Australia', Proceedings of the American Society of Clinical Oncology, Vol. 1
    Journal articles | 1982
    Tattersall MH; Friedlander ML, 1982, 'Cost considerations in cancer chemotherapy.', Australian health review : a publication of the Australian Hospital Association, 5, pp. 21 - 24
    Journal articles | 1981
    Friedlander M; Kearsley JH; Tattersall MH N, 1981, 'ORAL LORAZEPAM TO IMPROVE TOLERANCE OF CYTOTOXIC THERAPY', The Lancet, 317, pp. 1316 - 1317, http://dx.doi.org/10.1016/S0140-6736(81)92489-2
    Journal articles | 1981
    Friedlander M; Tattersall MH N, 1981, 'Postoperative radiotherapy in breast cancer', British Medical Journal (Clinical research ed.), 282, pp. 2133 - 2134, http://dx.doi.org/10.1136/bmj.282.6282.2133-d
    Journal articles | 1980
    Friedlander ML, 1980, 'AMINOGLUTETHIMIDE AND PROSTATIC CANCER', The Lancet, 316, pp. 1373, http://dx.doi.org/10.1016/S0140-6736(80)92440-X
  • Other | 2023
    2023, Data from Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians, , http://dx.doi.org/10.1158/1940-6207.c.6547304.v1
    Other | 2023
    2023, Data from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes, , http://dx.doi.org/10.1158/1078-0432.c.6532782
    Other | 2023
    2023, Data from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes, , http://dx.doi.org/10.1158/1078-0432.c.6532782.v1
    Other | 2023
    2023, Supplementary Data 1 from Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians, , http://dx.doi.org/10.1158/1940-6207.22533917
    Other | 2023
    2023, Supplementary Data 1 from Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians, , http://dx.doi.org/10.1158/1940-6207.22533917.v1
    Other | 2023
    2023, Supplementary Data 2 from Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians, , http://dx.doi.org/10.1158/1940-6207.22533914
    Other | 2023
    2023, Supplementary Data 2 from Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians, , http://dx.doi.org/10.1158/1940-6207.22533914.v1
    Other | 2023
    2023, Supplementary Data 3 from Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians, , http://dx.doi.org/10.1158/1940-6207.22533911
    Other | 2023
    2023, Supplementary Data 3 from Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians, , http://dx.doi.org/10.1158/1940-6207.22533911.v1
    Other | 2023
    2023, Supplementary Data 4 from Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians, , http://dx.doi.org/10.1158/1940-6207.22533908
    Other | 2023
    2023, Supplementary Data 4 from Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians, , http://dx.doi.org/10.1158/1940-6207.22533908.v1
    Other | 2023
    2023, Supplementary Figures S1-S13 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes, , http://dx.doi.org/10.1158/1078-0432.22488654
    Other | 2023
    2023, Supplementary Figures S1-S13 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes, , http://dx.doi.org/10.1158/1078-0432.22488654.v1
    Other | 2023
    2023, Supplementary Methods 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes, , http://dx.doi.org/10.1158/1078-0432.22488651
    Other | 2023
    2023, Supplementary Methods 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes, , http://dx.doi.org/10.1158/1078-0432.22488651.v1
    Other | 2023
    2023, Supplementary Tables S1-S11 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes, , http://dx.doi.org/10.1158/1078-0432.22488645
    Other | 2023
    2023, Supplementary Tables S1-S11 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes, , http://dx.doi.org/10.1158/1078-0432.22488645.v1
    Conference Abstracts | 2022
    Meagher NS; Hamilton PT; Anglesio MS; Harris HR; Konecny GE; Schildkraut JM; Talhouk A; Friedlander ML; Pearce CL; Pike MC; Kobel M; Doherty JA; Goode EL; Nelson BH; DeFazio A; Ramus SJ, 2022, 'Multi-modal immune profiling of mucinous ovarian carcinoma: analysis from the Ovarian Tumor Tissue Analysis/Multidisciplinary Ovarian Cancer Outcomes Group consortia', in JOURNAL OF IMMUNOLOGY, AMER ASSOC IMMUNOLOGISTS, Vol. 208, http://dx.doi.org/10.4049/jimmunol.208.Supp.179.04
    Conference Abstracts | 2022
    Mizrahi D; Goldstein D; Trinh T; Li T; Timmins HC; Harrison M; Marx GM; Hovey EJ; Lewis CR; Friedlander M; Park SB, 2022, 'Clinical Predictors And Levels Of Physical Activity Among Cancer Survivors Treated With Neurotoxic Chemotherapy', in MEDICINE & SCIENCE IN SPORTS & EXERCISE, LIPPINCOTT WILLIAMS & WILKINS, Vol. 54, pp. 322 - 322, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000888056601315&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2022
    2022, 'A multicenter phase II randomized trial of durvalumab (D) versus physician's choice chemotherapy (PCC) in patients (pts) with recurrent ovarian clear cell adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680301622&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2022
    2022, 'A multicenter phase II randomized trial of durvalumab (D) versus physician’s choice chemotherapy (PCC) in patients (pts) with recurrent ovarian clear cell adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5565 - 5565, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5565
    Conference Abstracts | 2022
    2022, 'Abstract LB511: The combination of hyper-amplification and tumor mutational burden as a pan-cancer biomarker in patients treated with tislelizumab', in Cancer Research, American Association for Cancer Research (AACR), Vol. 82, pp. LB511 - LB511, http://dx.doi.org/10.1158/1538-7445.am2022-lb511
    Conference Abstracts | 2022
    2022, 'Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study', in Gynecologic Oncology, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 165, pp. 40 - 48, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, http://dx.doi.org/10.1016/j.ygyno.2022.01.024
    Conference Abstracts | 2022
    2022, 'Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trial', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 33, pp. S779 - S779, presented at Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 09 September 2022 - 13 September 2022, http://dx.doi.org/10.1016/j.annonc.2022.07.645
    Conference Abstracts | 2022
    2022, 'Rates of paclitaxel hypersensitivity reactions using a modified Markman's infusion protocol', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 18, pp. 142 - 142, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000871956500207&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2022
    2022, 'Rates of somatic variants in homologous recombination DNA repair deficiency genes in older patients with high-grade serous ovarian carcinoma', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 18, pp. 30 - 30, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000879941200024&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2022
    2022, 'TP030/#1426 EPIK-O/ENGOT-OV61: a phase 3, randomized study of alpelisib + olaparib in patients with no germline BRCA mutation detected, platinum-resistant or -refractory, high-grade serous ovarian cancer', in E-Posters (Trials In Progress), BMJ Publishing Group Ltd, presented at IGCS 2022 Annual Meeting Abstracts, http://dx.doi.org/10.1136/ijgc-2022-igcs.539
    Conference Abstracts | 2022
    2022, 'Validity and efficiency of progression-free survival (PFS)-2 as a surrogate endpoint for overall survival (OS) in advanced cancer.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680301818&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2022
    2022, 'Validity and efficiency of progression-free survival (PFS)-2 as a surrogate endpoint for overall survival (OS) in advanced cancer.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 6518 - 6518, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.6518
    Conference Abstracts | 2021
    Bradley W; Moore K; Colombo N; Scambia G; Kim B-G; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke G; Gourley C; Banerjee S; Oza A; Gonzalez-Martin A; Aghajanian C; Cain T; Lowe E; DiSilvestro P, 2021, 'Maintenance olaparib for patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation: 5-year follow-up from SOLO1', in GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS INC ELSEVIER SCIENCE, Vol. 162, pp. S25 - S26, http://dx.doi.org/10.1016/S0090-8258(21)00694-6
    Conference Abstracts | 2021
    Friedlander M; Benson C; O'Connell RL; Reed N; Clamp A; Lord R; Millan D; Nottley S; Amant F; Steer C; Anand A; Mileshkin L; Beale P; Banerjee S; Bradshaw N; Kelly C; Carty K; Divers L; Alexander L; Edmondson R, 2021, 'Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903)', in Gynecologic Oncology, United States, Vol. 161, pp. 160 - 165, United States, http://dx.doi.org/10.1016/j.ygyno.2021.02.016
    Conference Abstracts | 2021
    Gersekowski K; Jordan S; Delahunty R; Alsop K; Goode EL; Bowtell D; DeFazio A; Friedlander M; Obermair A; Grant P; Webb P, 2021, 'Impact of BRCA mutation status and lifestyle factors on survival among women with ovarian cancer', in INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, OXFORD UNIV PRESS, Vol. 50, pp. 79 - 79, http://dx.doi.org/10.1093/ije/dyab168.217
    Conference Abstracts | 2021
    Simon S; Francis K; Dalrymple J; Gebski V; Lord S; Friedlander M; Lee CK, 2021, 'Adverse events experienced by patients in the placebo arm of maintenance therapy trials in advanced ovarian cancer', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 32, pp. S745 - S745, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 16 September 2021 - 21 September 2021, http://dx.doi.org/10.1016/j.annonc.2021.08.1195
    Conference Abstracts | 2021
    Smith D; Robledo K; Yip S; Cummins M; Kok P-S; Lee YC; Friedlander M; Baron-Hay SE; Shannon CM; Coward J; Beale PJ; Goss G; Meniawy T; Lombard JM; Spurdle AB; Andrews J; Stockler MR; Mileshkin LR; Antill YC, 2021, 'Tumor-associated immune cells and progression-free survival in advanced endometrial cancer (EC), results from the PHAEDRA trial (ANZGOG 1601).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 39, presented at Virtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 04 June 2021 - 08 June 2021, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.5584
    Conference Abstracts | 2021
    Woodford R; Zhou D; Kok P-S; Lord S; Marschner I; Friedlander M; Lee CK, 2021, 'The validity of progression-free survival (PFS) 2 as a surrogate endpoint for overall survival (OS) in randomized controlled trials (RCTs) of advanced solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.1516
    Conference Papers | 2021
    2021, 'Abstract 1045: Combined targeting of actin/tropomyosin and microtubules underlies a potential treatment strategy of epithelial ovarian cancer with cell-cycle dependent synergy', in Cancer Research, American Association for Cancer Research (AACR), pp. 1045 - 1045, presented at Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA, http://dx.doi.org/10.1158/1538-7445.am2021-1045
    Conference Papers | 2021
    2021, 'Abstract PS11-03: Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: A subgroup analysis of germline BRCA1 or BRCA2 mutations from the phase 3 BROCADE3 trial', in Cancer Research, American Association for Cancer Research (AACR), presented at Abstracts: 2020 San Antonio Breast Cancer Virtual Symposium; December 8-11, 2020; San Antonio, Texas, http://dx.doi.org/10.1158/1538-7445.sabcs20-ps11-03
    Conference Abstracts | 2021
    2021, 'Assessment of HR deficiency in ovarian cancer to increase PARP inhibitor targets beyond BRCA1/2', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 17, pp. 54 - 55, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000693805000103&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2021
    2021, 'Combined targeting of actin/tropomyosin and microtubules underlies a potential treatment strategy of epithelial ovarian cancer with cell-cycle dependent synergy.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000680263503257&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2021
    2021, 'Cyclin E1 (CCNE1) gene amplification assessment in prospectively recruited ovarian cancer patients', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 17, pp. 67 - 68, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000693805000129&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2021
    2021, 'Pattern of invasion in stage I mucinous ovarian cancer is prognostic within 2-years of diagnosis', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 17, pp. 47 - 48, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000693805000088&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2021
    2021, 'Phase II study of IV vinorelbine in relapsed platinum resistant or refractory C5 high grade serous primary peritoneal, fallopian tube or ovarian cancer (VIP)', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 32, pp. S736 - S736, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 16 September 2021 - 21 September 2021, http://dx.doi.org/10.1016/j.annonc.2021.08.1179
    Conference Abstracts | 2021
    2021, 'Two Cases of Intraplacental Choriocarcinoma Causing Severe Fetal Anaemia at Term', in AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, WILEY, Vol. 61, pp. 7 - 7, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000651190000006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2020
    Sivakumaran T; Krasovitsky M; Freimund A; Chen Lee K; Webber K; So J; Norris C; Friedlander M; Mileshkin L; Au-Yeung G, 2020, '402 Treatment patterns post PARP inhibitor in epithelial ovarian cancer patients: results from an Australian, retrospective, multi-institute cohort study', in Poster, BMJ Publishing Group Ltd, presented at IGCS 2020 Annual Meeting Abstracts, http://dx.doi.org/10.1136/ijgc-2020-igcs.347
    Conference Papers | 2020
    Sivakumaran T; Krasovitsky M; Lee YC; Norris C; Friedlander M, 2020, '403 Treatment patterns post PARP inhibitor in epithelial ovarian cancer patients: results from an Australian, retrospective, multi-institute cohort study', in Poster, BMJ Publishing Group Ltd, presented at IGCS 2020 Annual Meeting Abstracts, http://dx.doi.org/10.1136/ijgc-2020-igcs.348
    Conference Abstracts | 2020
    2020, 'Anti-tumor activity of veliparib during combination phase with chemotherapy in velia study', in GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS INC ELSEVIER SCIENCE, Vol. 159, pp. 52 - 53, http://dx.doi.org/10.1016/j.ygyno.2020.06.110
    Conference Abstracts | 2020
    2020, 'Are The ACSM Exercise Guidelines Safe And Achievable For Women Receiving Chemotherapy For Ovarian Cancer?', in MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 52, pp. 483 - 484, presented at American-College-of-Sports-Medicine (ACSM) Virtual Conference, ELECTR NETWORK, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000590026301686&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2020
    2020, 'Characteristics of patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer who achieved durable response in the phase III BROCADE3 study', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 31, pp. S374 - S374, presented at ESMO Virtual Congress, ELECTR NETWORK, 19 September 2020 - 18 October 2020, http://dx.doi.org/10.1016/j.annonc.2020.08.427
    Conference Abstracts | 2020
    2020, 'Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 38, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368302431&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2020
    2020, 'Health-related quality of life (HRQoL) changes with veliparib in patients (pts) with metastatic or locally advanced breast cancer in the phase III BROCADE 3 study', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 31, pp. S348 - S349, presented at ESMO Virtual Congress, ELECTR NETWORK, 19 September 2020 - 18 October 2020, http://dx.doi.org/10.1016/j.annonc.2020.08.376
    Conference Papers | 2020
    2020, 'MAINTENANCE OLAPARIB IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER AND A BRCA MUTATION: SUBGROUP ANALYSIS BY RISK IN THE PHASE III SOLO1 STUDY', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, BMJ PUBLISHING GROUP, pp. A76 - A77, http://dx.doi.org/10.1136/ijgc-2020-ESGO.130
    Conference Papers | 2020
    2020, 'Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S1334 - S1334, presented at ESMO Asia Virtual Congress, ELECTR NETWORK, 20 November 2020 - 22 November 2020, http://dx.doi.org/10.1016/j.annonc.2020.10.228
    Conference Papers | 2020
    2020, 'Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S613 - S613, presented at ESMO Virtual Congress, ELECTR NETWORK, 19 September 2020 - 18 October 2020, http://dx.doi.org/10.1016/j.annonc.2020.08.950
    Conference Papers | 2020
    2020, 'Objective response rate as an intermediate surrogate endpoint to predict overall survival at 12 months', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S715 - S715, presented at ESMO Virtual Congress, ELECTR NETWORK, 19 September 2020 - 18 October 2020, http://dx.doi.org/10.1016/j.annonc.2020.08.1162
    Conference Abstracts | 2020
    2020, 'PFS by blinded independent central review (BICR) in the VELIA trial of veliparib (V) plus carboplatin/paclitaxel (CP) and as monotherapy in newly diagnosed patients (pts) with high-grade serous ovarian cancer (HGSC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 38, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368302501&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2020
    2020, 'Patient reported outcome scores used in chemotherapy-induced peripheral neuropathy: Defining minimal important differences', in JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, WILEY, ELECTR NETWORK, Vol. 25, pp. 481 - 481, presented at Virtual Conference of Peripheral-Nerve-Society, ELECTR NETWORK, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000596008100112&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2020
    2020, 'Safety of veliparib in combination with chemotherapy and as maintenance in front-line ovarian cancer: Results in BRCAm, hrd, and whole populations from the velia trial', in GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS INC ELSEVIER SCIENCE, pp. 20 - 21, http://dx.doi.org/10.1016/j.ygyno.2020.06.040
    Conference Abstracts | 2020
    2020, 'TREATMENT PATTERNS POST PARP INHIBITOR IN EPITHELIAL OVARIAN CANCER PATIENTS: RESULTS FROM AN AUSTRALIAN, RETROSPECTIVE, MULTI-INSTITUTE COHORT STUDY', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, BMJ PUBLISHING GROUP, Vol. 30, pp. A166 - A167, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000616549600346&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2020
    2020, 'The cognitive, affective, social and environmental drivers of inappropriate ovarian cancer screening: A survey of women and their clinicians using the theoretical domains framework', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S958 - S958, presented at ESMO Virtual Congress, ELECTR NETWORK, 19 September 2020 - 18 October 2020, http://dx.doi.org/10.1016/j.annonc.2020.08.2057
    Conference Papers | 2020
    2020, 'The development and evaluation of a nationwide training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 62 - 62, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000790145400011&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2020
    2020, 'Veliparib (V) monotherapy (monoTx) following combination therapy with V plus carboplatin/paclitaxel (CP) in patients with gBRCA-associated advanced breast cancer: Exploratory results from BROCADE3.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 38, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368300309&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2020
    2020, 'Veliparib (V) monotherapy after progression on placebo (PL) plus carboplatin/paclitaxel (CP) in patients with advanced HER2-negative gBRCA-associated breast cancer: Crossover outcomes and exploratory biomarker analyses in BROCADE3.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 38, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368300315&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2020
    2020, 'Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: Results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S65 - S65, presented at ESMO Breast Cancer Virtual Meeting, ELECTR NETWORK, 23 May 2020 - 24 May 2020, http://dx.doi.org/10.1016/j.annonc.2020.03.241
    Conference Abstracts | 2019
    Friedlander ML; Moore K; Colombo N; Scambia G; Kim B-G; Oaknin A; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; Gonzalez-Martin A; Aghajanian C; Bradley W; Lowe E; Hettle R; Flood E; DiSilvestro P, 2019, 'Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Barcelona, Vol. 30, presented at 44th Congress of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 27 September 2019 - 01 October 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000491295503045&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2019
    2019, 'Abstract CT084: Long-term exposure (LTE) to Tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human Phase I study', in Clinical Trials, American Association for Cancer Research, presented at Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA, http://dx.doi.org/10.1158/1538-7445.sabcs18-ct084
    Conference Papers | 2019
    2019, 'Abstract GMM-048: CTDNA RESPONSE TO THE PARP INHIBITOR RUCAPARIB PREDICTS PROGRESSION-FREE SURVIVAL AND BEST OVERALL RESPONSE ON THE ARIEL2 TRIAL', in Clinical Cancer Research, American Association for Cancer Research (AACR), presented at Abstracts: 12th Biennial Ovarian Cancer Research Symposium; September 13-15, 2018; Seattle, Washington, http://dx.doi.org/10.1158/1557-3265.ovcasymp18-gmm-048
    Conference Abstracts | 2019
    2019, 'Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.5501
    Conference Abstracts | 2019
    2019, 'Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Phase III SOLO1 trial.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.5539
    Conference Papers | 2019
    2019, 'Do all patients with recurrent ovarian cancer need systemic therapy?', in Cancer, pp. 4602 - 4608, http://dx.doi.org/10.1002/cncr.32476
    Conference Abstracts | 2019
    2019, 'Does physical activity improve chemotherapy completion in women receiving chemotherapy for ovarian cancer?', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 15, pp. 82 - 83, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000493438400077&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2019
    2019, 'Does physical activity participation associate with the degree of chemotherapy-induced peripheral neuropathy after neurotoxic treatment?', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 15, pp. 179 - 179, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000493438400288&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2019
    2019, 'Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.5551
    Conference Papers | 2019
    2019, 'First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: Planned subgroup analysis from the phase 3 BROCADE3 trial', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, presented at 42nd Annual San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2019 - 14 December 2019, http://dx.doi.org/10.1158/1538-7445.SABCS19-PD4-01
    Conference Abstracts | 2019
    2019, 'How long have we got? The accuracy of physicians' estimates and scenarios for survival time in 898 women with recurrent ovarian cancer (ROC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.5549
    Conference Abstracts | 2019
    2019, 'Impact of radiological disease progression on the health status of patients (pts) with BRCA-mutated advanced ovarian cancer (OC) treated with maintenance olaparib (OL) or placebo (PL) after first-line platinum chemotherapy', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SINGAPORE, Singapore, Vol. 30, presented at European-Society-for-Medical-Oncology (ESMO) Asia Congress, SINGAPORE, Singapore, 22 November 2019 - 24 November 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000503487700218&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2019
    2019, 'Long-term exposure (LTE) to Tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human Phase I study', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), GA, Atlanta, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-CT084
    Conference Papers | 2019
    2019, 'MAINTENANCE OLAPARIB AFTER PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER AND A BRCA MUTATION: EFFICACY BY THE TIMING OF SURGERY AND RESIDUAL TUMOUR STATUS FOLLOWING UPFRONT OR INTERVAL CYTOREDUCTIVE SURGERY IN THE PHASE III SOLO1 TRIAL', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, BMJ PUBLISHING GROUP, pp. A14 - A15, http://dx.doi.org/10.1136/ijgc-2019-ESGO.17
    Conference Abstracts | 2019
    2019, 'MAINTENANCE OLAPARIB FOR BRCA-MUTATED OVARIAN CANCER (OC) PATIENTS IN 1ST LINE AND PLATINUM-SENSITIVE RELAPSED (PSR) SETTINGS: MAXIMIZING TREATMENT OPPORTUNITIES', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, BMJ PUBLISHING GROUP, Vol. 29, pp. A133 - A133, http://dx.doi.org/10.1136/ijgc-2019-IGCS.321
    Conference Abstracts | 2019
    2019, 'Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Efficacy by surgical and tumor status in the Phase III SOLO1 trial.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.5541
    Conference Abstracts | 2019
    2019, 'Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SINGAPORE, Singapore, Vol. 30, presented at European-Society-for-Medical-Oncology (ESMO) Asia Congress, SINGAPORE, Singapore, 22 November 2019 - 24 November 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000503487700217&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2019
    2019, 'Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Barcelona, Vol. 30, pp. 857 - +, presented at 44th Congress of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 27 September 2019 - 01 October 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000491295500133&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2019
    2019, 'SOLACE2: A phase II randomised trial of immune priming by olaparib-cyclophosphamide prior to olaparib-durvalumab in asymptomatic, platinum-sensitive recurrent ovarian cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 15, pp. 160 - 161, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000493438400250&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2019
    2019, 'Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): Phase III SOLO1 trial', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Barcelona, Vol. 30, pp. 405 - 405, presented at 44th Congress of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 27 September 2019 - 01 October 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000491295503044&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2019
    2019, 'Updated results of activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SINGAPORE, Singapore, Vol. 30, presented at European-Society-for-Medical-Oncology (ESMO) Asia Congress, SINGAPORE, Singapore, 22 November 2019 - 24 November 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000503487700534&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2019
    2019, 'VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Barcelona, Vol. 30, pp. 895 - 896, presented at 44th Congress of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 27 September 2019 - 01 October 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000491295500127&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2019
    2019, 'Validation of progression-free survival (PFS) as surrogate endpoint in randomised trials of immune checkpoint inhibitors in advanced solid cancers', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Barcelona, Vol. 30, pp. 520 - 520, presented at 44th Congress of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 27 September 2019 - 01 October 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000491295503324&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2018
    Beesley VL; Webber K; Nagle C; Grant P; DeFazio A; Obermair A; Friedlander M; Webb PM, 2018, 'When will i feel normal again? Exploring the trajectories and predictors of patient-reported outcomes after completion of primary therapy for ovarian cancer', in PSYCHO-ONCOLOGY, WILEY, Vol. 27, pp. 50 - 50, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000448188000128&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2018
    Friedlander M; Meniawy T; Markman B; Mileshkin LR; Harnett P; Millward M; Lundy J; Freimund AE; Norris C; Wu J; Paton V; Wang L; Gao B, 2018, 'A Phase 1B Study of the Anti-PD-1 Monoclonal Antibody, Tislelizumab, in Combination with the Parp Inhibitor, Pamiparib, in Advanced Solid Tumors', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 14, pp. 58 - 59, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000439493100023&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2018
    Friedlander M; Scott CL; Lindeman GJ; Gibbs E; Badger HD; Paterson RJ; Macnab L; Zdenkowski N; Kwan EM; Boyle FM; Lee CK, 2018, 'A Phase 1 Trial of Olaparib and Oral Metronomic. Cyclophosphamide in Patients with Metastatic BRCA-Associated Breast/Ovarian Cancers or Non-BRCA Associated Triple-Negative Breast Cancer/High Grade Serous Ovarian Cancers', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 14, pp. 59 - 59, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000439493100024&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2018
    Hasenburg A; Harter P; Park-Simon T-W; Gropp-Meier M; Heitz F; Soergel P; Ataseven B; Friedlaender M; Hilpert F; Pujade-Lauraine E, 2018, 'Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer: SOLO2 Phase III', in ONCOLOGY RESEARCH AND TREATMENT, KARGER, Vol. 41, pp. 88 - 89, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000424914300235&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2018
    Peate M; Jayasinghe Y; Gamage NR; Allingham C; Meiser B; Friedlander M; Hickey M, 2018, 'From development to implementation: The Australian experience of oncofertility decision aids', in PSYCHO-ONCOLOGY, WILEY, Vol. 27, pp. 44 - 45, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000448188000113&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2018
    Peate M; Patterson T; Girgis A; Friedlander M; Durcinoska I; Hickey M; Sousa MS, 2018, 'Genitourinary and sexual health after breast cancer: The role of breast care nurses in providing support and care', in PSYCHO-ONCOLOGY, WILEY, Vol. 27, pp. 184 - 185, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000448188000492&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2018
    Sandhu SK; Hill AG; Gan HK; Friedlander M; Voskoboynik M; Barlow P; Townsend AR; Song J; Zhang Y; Shen Z; Qi Q; Desai J, 2018, 'Preliminary results from patients with urothelial carcinoma (UC) in a phase 1A/1B study of bgb-A317, an anti-PD-1 monoclonal antibody.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, CA, San Francisco, presented at Genitourinary Cancers Symposium, CA, San Francisco, 08 February 2018 - 10 February 2018, http://dx.doi.org/10.1200/JCO.2018.36.6_suppl.445
    Conference Papers | 2018
    2018, 'A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at ASCO-SITC Clinical Immuno-Oncology Symposium, CA, San Francisco, 25 January 2018 - 27 January 2018, http://dx.doi.org/10.1200/JCO.2018.36.5_suppl.48
    Conference Papers | 2018
    2018, 'A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SWITZERLAND, Geneva, presented at ESMO Immuno-Oncology Congress, SWITZERLAND, Geneva, 13 December 2018 - 16 December 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000459294800077&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2018
    2018, 'AGO-OVAR 16: A phase III study to evaluate the efficacy and safety of pazopanib (PZ) monotherapy versus placebo in women who have not progressed after first line chemotherapy for epithelial ovarian, fallopian tube, or primary peritoneal cancer-Overall survival (OS) results', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.5518
    Conference Papers | 2018
    2018, 'ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled, phase 3 study of rucaparib plus nivolumab following front-line platinum-based chemotherapy in ovarian cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 196 - 196, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000449544200343&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2018
    2018, 'COMPARING THE IMPACT OF DOSE REDUCTIONS/ DELAYS ON OVARIAN CANCER OUTCOMES USING THREE WEEKLY OR DOSE DENSE CARBOPLATIN/ PACLITAXEL REGIMENS IN THE NATIONAL PROSPECTIVE OPAL COHORT', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, BMJ PUBLISHING GROUP, pp. 770 - 770, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000471152401334&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2018
    2018, 'CTDNA RESPONSE TO THE PARP INHIBITOR RUCAPARIB PREDICTS PROGRESSION-FREE SURVIVAL AND BEST OVERALL RESPONSE ON THE ARIEL2 TRIAL', in CLINICAL CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, WA, Seattle, Vol. 25, pp. 112 - 112, presented at 12th Rivkin-Centre Biennial Ovarian Cancer Research Symposium, WA, Seattle, 13 September 2018 - 15 September 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000497337700065&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2018
    2018, 'Changing a nation: The development and evaluation of a training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients.', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, BMJ PUBLISHING GROUP, pp. 202 - 203, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000471153100137&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2018
    2018, 'Characterization and predictors of long term (>= 10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer patients.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.5556
    Conference Papers | 2018
    2018, 'Comparative efficacy and tolerability of the PARP inhibitors, olaparib 300 mg tablets BID, niraparib 300 mg capsules QD and rucaparib 600 mg tablets BID as maintenance treatment in BRCA-mutated (BRCAm) platinum-sensitive relapsed ovarian', in GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS INC ELSEVIER SCIENCE, pp. 43 - 44, http://dx.doi.org/10.1016/j.ygyno.2018.04.094
    Conference Papers | 2018
    2018, 'Comparing the impact of dose reductions and delays on ovarian cancer patient outcomes with three-weekly versus dose dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.5568
    Conference Abstracts | 2018
    2018, 'EXPLORING THE IMPACT OF RADIOGRAPHIC PROGRESSIVE DISEASE AND FIRST SUBSEQUENT THERAPY ON HEALTH STATE UTILITY VALUES IN GERMLINE-BRCA-MUTATED (GBRCAM) PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER (PSROC) PATIENTS ON OLAPARIB TABLETS AS MAINTENANCE MONOTHERAPY', in VALUE IN HEALTH, ELSEVIER SCIENCE INC, Vol. 21, pp. S73 - S73, http://dx.doi.org/10.1016/j.jval.2018.09.429
    Conference Papers | 2018
    2018, 'Getting the most out of follow-up: A prospective study using the Measure of Ovarian Symptoms and Treatment concerns (MOST) symptom index to evaluate and track adverse effects (AEs) and detect symptoms of recurrence in patients with ovarian cancer (OC) following first line chemotherapy (1LT).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.10062
    Conference Papers | 2018
    2018, 'Inter and intra-observer variability with the assessment of RECIST in ovarian cancer.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.5555
    Conference Papers | 2018
    2018, 'Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, GERMANY, Munich, pp. 727 - 727, presented at 43rd ESMO Congress (ESMO), GERMANY, Munich, 19 October 2018 - 23 October 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000459277305017&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2018
    2018, 'Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial', in Annals of oncology : official journal of the European Society for Medical Oncology, OXFORD UNIV PRESS, Singapore, SINGAPORE, pp. viii727, presented at European-Society-for-Medical-Oncology Asia Congress, Singapore, SINGAPORE, 23 November 2018 - 25 November 2018, http://dx.doi.org/10.1093/annonc/mdy424.041
    Conference Abstracts | 2018
    2018, 'Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy', in Annals of oncology : official journal of the European Society for Medical Oncology, OXFORD UNIV PRESS, Munich, GERMANY, Vol. 29, pp. viii340, presented at 43rd ESMO Congress (ESMO), Munich, GERMANY, 19 October 2018 - 23 October 2018, http://dx.doi.org/10.1093/annonc/mdy285.158
    Conference Papers | 2018
    2018, 'P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poorrisk metastatic germ cell tumors (GCTs).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, CA, San Francisco, presented at Genitourinary Cancers Symposium, CA, San Francisco, 08 February 2018 - 10 February 2018, http://dx.doi.org/10.1200/JCO.2018.36.6_suppl.TPS574
    Conference Papers | 2018
    2018, 'PARAGON: A phase 2 study of anastrozole (An) in patients with estrogen receptor(ER) and / progesterone receptor (PR) positive recurrent/metastatic granulosa cell tumors/sex-cord stromal tumors (GCT) of the ovary', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.5524
    Conference Papers | 2018
    2018, 'REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal (IP) bevacizumab (bev) for recurrent ascites in advanced, chemotherapy-resistant, epithelial ovarian cancer (CR-EOC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.10097
    Conference Papers | 2018
    2018, 'The Ovarian cancer Prognosis And Lifestyle (OPAL) study.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2018 - 05 June 2018, http://dx.doi.org/10.1200/JCO.2018.36.7_suppl.88
    Conference Papers | 2018
    2018, 'The hidden burden of anxiety and depression in ovarian cancer: A prospective longitudinal study from diagnosis.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.10081
    Conference Papers | 2018
    2018, 'The hidden burden of anxiety and depression in ovarian cancer: A prospective study from diagnosis.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2018 - 05 June 2018, http://dx.doi.org/10.1200/JCO.2018.36.7_suppl.155
    Conference Papers | 2018
    2018, 'Tislelizumab, an anti-PD-1 antibody, in patients with urothelial carcinoma (UC): Results from an ongoing phase I/II study', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SWITZERLAND, Geneva, pp. 28 - 28, presented at ESMO Immuno-Oncology Congress, SWITZERLAND, Geneva, 13 December 2018 - 16 December 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000459294800083&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2018
    2018, 'When will I feel normal again? Quality of life trajectories after first-line chemotherapy for ovarian cancer.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2018 - 05 June 2018, http://dx.doi.org/10.1200/JCO.2018.36.7_suppl.172
    Conference Abstracts | 2017
    Friedlander M; Gebski V; Gibbs E; Bloomfield R; Hilpert F; Wenzel LB; Joly F; Eek D; Rodrigues M; Clamp A; Penson R; Provencher D; Korach J; Huzarski T; Vidal L; Salutari V; Scott C; Nicoletto MO; Tamura K; Pujade-Lauraine E, 2017, 'HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND PATIENT-CENTRED OUTCOMES WITH OLAPARIB MAINTENANCE POST-CHEMOTHERAPY IN PATIENTS WITH GERMLINE BRCA-MUTATED PLATINUM-SENSITIVE RELAPSED SEROUS OVARIAN CANCER (PSR SOC)', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, Vol. 27, pp. 1941 - 1941, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000423235205225&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2017
    Friedlander M; Meniawy T; Markman B; Mileshkin LR; Harnett PR; Millward M; Lundy J; Freimund AE; Norris C; Mu S; Wu J; Paton VE; Wang L; Gao B, 2017, 'A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.3013
    Conference Papers | 2017
    Friedlander M; Pujade-Lauraine E; Ledermann JA; Penson RT; Oza AM; Korach J; Huzarski T; Poveda A; Pignata S; Colombo N, 2017, 'Treatment with Maintenance Olaparib Significantly Improves Progression-Free Survival in Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Results of SOLO2 Study', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 51 - 51, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000427542700014&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2017
    Hettle R; Sackeyfio A; Gill J; Siddiqui K; Nussey F; Friedlander M, 2017, 'COMPARATIVE EFFICACY AND SAFETY OF OLAPARIB 300 MG TABLETS BID AND NIRAPARIB 300 MG TABLETS QD AS MAINTENANCE TREATMENT AFTER RESPONSE TO CHEMOTHERAPY IN PATIENTS WITH PLATINUM-SENSITIVE RELAPSED GERMLINE BRCA-MUTATED OVARIAN CANCER (PSROC)', in VALUE IN HEALTH, ELSEVIER SCIENCE INC, Vol. 20, pp. A412 - A412, http://dx.doi.org/10.1016/j.jval.2017.08.088
    Conference Papers | 2017
    Joly F; Hilpert F; Okamoto A; Stuart G; Ochiai K; Friedlander M, 2017, 'Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer', in European Journal of Cancer, pp. 133 - 138, http://dx.doi.org/10.1016/j.ejca.2017.03.019
    Conference Abstracts | 2017
    Meagher NS; deFazio A; Russell K; Voss A; Ramus SJ; Friedlander ML, 2017, 'Mucinous Ovarian Cancers of Uncertain Primary (MO-CUP) - Does the Site of Origin Really Matter?', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 13, pp. 73 - 73, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000413954500039&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2017
    Meniawy T; Richardson G; Townsend A; Desai J; Gan H; Friedlander M; Horvath L; Jameson MB; Sandhu S; Wu Z; Qin Z; Kang K; Markman B, 2017, 'Preliminary results from a subset of patients (pts) with advanced ovarian cancer (OC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Madrid, presented at 42nd European-Society-for-Medical-Oncology Congress (ESMO), SPAIN, Madrid, 08 September 2017 - 12 September 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000411324001049&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2017
    Peate M; Jayasinghe Y; Allingham C; Hucker A; Kemertzis M; Meiser B; Friedlander M; Hickey M, 2017, 'Supporting fertility decision-making: the role of decision aids in oncofertility.', in PSYCHO-ONCOLOGY, WILEY, pp. 166 - 166, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000407688900459&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2017
    Penson R; Kaminsky-Forrett M-C; Ledermann J; Brown C; Plante M; Korach J; Huzarski T; Lista AG D L; Pisano C; Friedlander M; Colombo N; Gropp-Meier M; Nakai H; Sonke GS; Kim J-W; Vergote I; Allen A; Pujade-Lauraine E, 2017, 'Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: Phase III SOLO2 trial (ENGOT Ov-21)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Madrid, presented at 42nd European-Society-for-Medical-Oncology Congress (ESMO), SPAIN, Madrid, 08 September 2017 - 12 September 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000411324002120&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2017
    Ritchie G; Gasper H; Man J; Lord S; Friedlander M; Lee C; Marschner I, 2017, 'is objective response rate (ORR) a valid primary endpoint in phase 2 trials (Ph2t) of immune checkpoint inhibitors (ICI) for advanced solid cancers?', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Madrid, presented at 42nd European-Society-for-Medical-Oncology Congress (ESMO), SPAIN, Madrid, 08 September 2017 - 12 September 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000411324003027&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2017
    Sackeyfio A; Gill J; Hettle R; Siddiqui K; Friedlander M; Ledermann JA, 2017, 'COMPARATIVE EFFICACY AND SAFETY OF OLAPARIB 400 MG CAPSULES BID AND NIRAPARIB 300 MG TABLETS QD AS MAINTENANCE TREATMENT AFTER RESPONSE TO CHEMOTHERAPY IN PATIENTS WITH PLATINUM-SENSITIVE RELAPSED NON-GERMLINE BRCA-MUTATED OVARIAN CANCER (PSROC)', in VALUE IN HEALTH, ELSEVIER SCIENCE INC, Vol. 20, pp. A412 - A412, http://dx.doi.org/10.1016/j.jval.2017.08.087
    Conference Papers | 2017
    Wong N; Nayar N; Lawrence N; Stockler M; Martin A; Yip S; Yeung A; Friedlander M; Mazhar D; Pashankar F; Quinn D; Walker R; Winstanley M; Weickhardt A; Hanning F; Stevanovic A; Davis I; Toner G; Grimison P, 2017, 'P3BEP (ANZUP 1302): An International Randomised Phase III Trial of Accelerated Versus Standard BEP Chemotherapy for Adult and Pediatric Male and Female Patients With Intermediate and Poor-Risk Metastatic Germ Cell Tumours (GCTS)', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 168 - 168, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000413954500265&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2017
    2017, 'Abstract AP27: FEASIBILITY OF MONITORING RESPONSE TO THE PARP INHIBITOR RUCAPARIB WITH TARGETED DEEP SEQUENCING OF CIRCULATING TUMOR DNA (CTDNA) IN WOMEN WITH HIGH GRADE OVARIAN CARCINOMA ON THE ARIEL2 TRIAL', in Clinical Cancer Research, American Association for Cancer Research (AACR), pp. AP27 - AP27, presented at Abstracts: 11th Biennial Ovarian Cancer Research Symposium; September 12-13, 2016; Seattle, WA, http://dx.doi.org/10.1158/1557-3265.ovcasymp16-ap27
    Conference Papers | 2017
    2017, 'Abstract CT002: A Phase IB study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors', in Cancer Research, American Association for Cancer Research (AACR), pp. CT002 - CT002, presented at Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC, http://dx.doi.org/10.1158/1538-7445.am2017-ct002
    Conference Abstracts | 2017
    2017, 'CLINICALLY SIGNIFICANT LONG-TERM MAINTENANCE TREATMENT WITH OLAPARIB IN PATIENTS WITH PLATINUM-SENSITIVE RELAPSED SEROUS OVARIAN CANCER (PSR SOC)', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, Vol. 27, pp. 1942 - 1943, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000423235205226&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2017
    2017, 'Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline (g) BRCA-mutated (m) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): SOLO2 phase III trial', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.5507
    Conference Papers | 2017
    2017, 'Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.5506
    Conference Papers | 2017
    2017, 'P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.TPS4592
    Conference Papers | 2017
    2017, 'Predictors of stopping chemotherapy early and short survival in patients with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) who have had >= 3 lines of prior chemotherapy: The GCIG symptom benefit study (SBS).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.5575
    Conference Papers | 2017
    2017, 'Should MMMT of the endometrium/ovary be treated with anthracycline instead of taxane based chemotherapy?', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.5563
    Conference Papers | 2017
    2017, 'Symptom burden and outcomes in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive ROC receiving ≥3 lines of chemotherapy (PPS ≥3) – The Gynecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS)', in Geburtshilfe und Frauenheilkunde, Georg Thieme Verlag KG, presented at Jahrestagung der Österreichischen Gesellschaft für Gynäkologie und Geburtshilfe (OEGGG) gemeinsam mit der Bayerischen Gesellschaft für Geburtshilfe und Frauenheilkunde e.V (BGGF), 14 June 2017 - 17 June 2017, http://dx.doi.org/10.1055/s-0037-1602307
    Conference Papers | 2017
    2017, 'Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: Results from the phase III SOLO2 study', in GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS INC ELSEVIER SCIENCE, pp. 219 - 220, http://dx.doi.org/10.1016/j.ygyno.2017.03.505
    Conference Papers | 2016
    Dieras V; Han HS; Robson ME; Palacova M; Marcom PK; Jager A; Bondarenko I; Citrin D; Campone M; Telli ML; Domchek SM; Friedlander M; Kaufman B; Ratajczak C; Coates A; Bonnet P; Qin Q; Qian J; Giranda VL; Shepherd SP; Puhalla S; Isakoff SJ, 2016, 'Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V plus TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc) plus C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 06 December 2016 - 10 December 2016, http://dx.doi.org/10.1158/1538-7445.SABCS16-P4-22-02
    Conference Papers | 2016
    Han HS; Dieras V; Robson ME; Palacova M; Marcom PK; Jager A; Bondarenko I; Citrin D; Campone M; Telli ML; Domchek SM; Friedlander M; Man BK; Ratajczak C; Coates A; Bonnet P; Qin Q; Qian J; Giranda VL; Shepherd SP; Isakoff SJ; Puhalla S, 2016, 'Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc) plus C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: A randomized, phase 2 study', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 06 December 2016 - 10 December 2016, http://dx.doi.org/10.1158/1538-7445.SABCS16-S2-05
    Conference Papers | 2016
    Hickey M; Sousa MS; Peate M; Jarvis S; Friedlander M, 2016, 'SHORT-TERM FINDINGS OF THE PEGASUS STUDY: GENITOURINARY SYMPTOMS, SEXUALITY AND QUALITY OF LIFE IN BREAST CANCER SURVIVORS ON ENDOCRINE THERAPY - WHAT ARE WE MISSING?', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 71 - 71, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000387769900021&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2016
    Hipert F; Friedlander M; Stockler M; O'Connell R; Joly F; Lanceley A; Okamoto A; Aotani E; Pignata S; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Sjoquist K; Gillies K; Butow P; King M, 2016, 'Symptom burden and outcomes in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive ROC receiving >= 3 lines of chemotherapy (PPS >= 3) - GCIG Symptom Benefit Study (AGO PRO1).', in ONCOLOGY RESEARCH AND TREATMENT, KARGER, pp. 138 - 139, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000371353700449&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2016
    Lawrence N; Grimison P; Stockler M; Martin A; Buizen L; Thomson D; Gebski V; Friedlander M; Yeung A; Gurney H; Rosenthal M; Singhal N; Kichenadasse G; Wong S; Lewis C; Vasey P; Toner G, 2016, 'LONG-TERM OUTCOMES OF ACCELERATED BEP (BLEOMYCIN, ETOPOSIDE, CISPLATIN) FOR ADVANCED GERM CELL TUMORS: UPDATED ANALYSIS OF AN AUSTRALIAN MULTICENTER PHASE II TRIAL (3033)', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 48 - 48, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000380005100014&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2016
    Lawrence N; Martin A; Toner G; Stockler M; Buizen L; Thomson D; Gebski V; Friedlander M; Yeung A; Gurney H; Rosenthal M; Singhal N; Kichenadasse G; Wong S; Lewis C; Vasey P; Grimison P, 2016, 'LONG-TERM OUTCOMES OF ACCELERATED BEP (BLEOMYCIN, ETOPOSIDE, CISPLATIN) FOR ADVANCED GERM-CELL TUMORS: UPDATED ANALYSIS OF AN AUSTRALIAN MULTICENTER PHASE II TRIAL', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 28 - 28, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000380004900011&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2016
    Mercieca-Bebber R; Calvert MJ; Kok P-S; Friedlander M; Kyte DG; Stockler M; King M, 2016, 'Does the patient-reported outcome (PRO) content of protocols impact PRO completion rates and the standard of reporting? A review of international ovarian cancer randomized controlled trials (RCTs)', in QUALITY OF LIFE RESEARCH, SPRINGER, pp. 119 - 119, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000398451600288&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2016
    Piskorz AM; Lin KK; Morris J; Mann E; Oza A; Coleman RL; O'Malley DM; Friedlander M; Cragun JM; Ma L; Giordano H; Raponi M; McNeish IA; Swisher E; Brenton JD, 2016, 'Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high grade ovarian carcinoma on the ARIEL2 trial', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, GERMANY, Munich, pp. S123 - S123, presented at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, GERMANY, Munich, 29 November 2016 - 02 December 2016, http://dx.doi.org/10.1016/S0959-8049(16)32966-5
    Conference Papers | 2016
    Wenzel L; King M; Lee C; Kirby A; Friedlander M; Hilpert F; Stockler M; Gelski V, 2016, 'Relationship between distress and survival in women with platinum-resistant ovarian cancer (PROC)', in QUALITY OF LIFE RESEARCH, SPRINGER, pp. 125 - 125, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000398451600301&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2016
    2016, 'A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.3066
    Conference Papers | 2016
    2016, 'Baseline quality of life (QOL) as a predictor of stopping chemotherapy early, and of overall survival, in platinum-resistant/refractory ovarian cancer (PRROC): The GCIG symptom benefit study (SBS).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.5508
    Conference Papers | 2016
    2016, 'Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high-grade serous carcinoma on the ARIEL2 trial.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.5549
    Conference Papers | 2016
    2016, 'Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumors: updated analysis of an Australian multicenter phase II trial.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.e16056
    Conference Papers | 2016
    2016, 'Overall survival (OS) in patients (pts) with platinum sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: An interim analysis.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.5501
    Conference Papers | 2016
    2016, 'Phase II study of anastrozole in recurrent estrogen (ER) / progesterone (PR) positive endometrial cancer: The PARAGON trial-ANZGOG 0903.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.5520
    Conference Papers | 2016
    2016, 'Quality of life (QOL) to predict overall survival (OS) in women with platinum-resistant ovarian cancer (PROC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.5575
    Conference Papers | 2016
    2016, 'Risk of uterine cancer in BRCA1 and BRCA2 mutation carriers.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.1529
    Conference Papers | 2016
    2016, 'Where have we gone wrong? Phase II trials (Ph2t) do not inform the results of phase III trials (Ph3t) in platinum resistant ovarian cancer (PROC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.5559
    Conference Papers | 2015
    Banerjee S; Ledermann J; Matulonis U; Molife LR; Friedlander M; Fielding A; Robertson JD; Spencer S; McMurtry E; Kaye S, 2015, 'Management of nausea and vomiting during treatment with the capsule (CAP) and tablet (TAB) formulations of the PARP inhibitor olaparib', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, AUSTRIA, Vienna, pp. S550 - S550, presented at European Cancer Congress, AUSTRIA, Vienna, http://dx.doi.org/10.1016/S0959-8049(16)31525-8
    Conference Papers | 2015
    Beale P; O'Connell R; Sjoquist K; Martyn J; Cannon D; Bonaventura T; Grant P; Goh J; Antill Y; Friedlander M; Scurry J, 2015, 'PARAGON-AN ANZGOG PHASE 2 STUDY OF ANASTRAZOLE IN ASYMPTOMATIC WOMEN WITH ESTROGEN (ER)/PROGESTERONE (PR) POSITIVE OVARIAN CANCER WITH A CA125 PROGRESSION AFTER FIRST LINE TREATMENT', in Asia-Pacific Journal of Clinical Oncology, WILEY-BLACKWELL, pp. 118 - 118, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000364320800164&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2015
    Debernardo R; Mahdi H; Russell K; Xiu J; Millis SZ; Reddy SK; Friedlander M, 2015, 'Molecular profile comparison of endometrial, renal and ovarian clear cell carcinoma: Is it the same disease at different sites?', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5595
    Conference Papers | 2015
    Domchek SM; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmana J; Mitchell G; Fried G; Stemmer SM; Hubert A; Rosengarten O; Loman N; Robertson JD; Mann H; Kaufman B, 2015, 'Efficacy and safety of olaparib monotherapy in a subgroup of patients with a germline BRCA1/2 mutation and advanced ovarian cancer from a Phase II open-label study.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5529
    Conference Papers | 2015
    Friedlander M; Russell K; Millis SZ; Gatalica Z; Voss A, 2015, 'Molecular profiling of mucinous epithelial ovarian carcinomas (mEOC): Opportunities for clinical trials.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5540
    Conference Papers | 2015
    Friedlander M; Stockler M; O'Connell R; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Pignata S; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Sjoquist K; Gillies K; Butow P; King MT, 2015, 'IS IT TIME TO CHANGE THE PRIMARY ENDPOINT IN CLINICAL TRIALS IN RECURRENT OVARIAN CANCER (ROC)? SYMPTOM BURDEN AND OUTCOMES IN PATIENTS WITH PLATINUM RESISTANT/REFRACTORY (PRR) AND POTENTIALLY PLATINUM SENSITIVE ROC RECEIVING >= 3 LINES OF CHEMOTHERAPY (PPS) - THE GYNECOLOGIC CANCER INTERGROUP (GCIG) SYMPTOM BENEFIT STUDY (SBS)', in Asia-Pacific Journal of Clinical Oncology, WILEY-BLACKWELL, pp. 111 - 111, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000364320800146&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2015
    Friedlander M; Stockler MR; O'Connell R; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Pignata S; Donnellan PP; Oza AM; Avall-Lundqvist E; Berek JS; Sjoquist KM; Gillies K; Butow P; King MT, 2015, 'Is it time to change the primary endpoint in clinical trials in recurrent ovarian cancer (ROC)?: Symptom burden and outcomes in patients with platinum resistant/ refractory (PRR) and potentially platinum sensitive ROC receiving >= 3 lines of chemotherapy (PPS >= 3)-The Gynecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5536
    Conference Papers | 2015
    Huggins-Puhalla SL; Han HS; Dieras V; Friedlander M; Somlo G; Arun B; Wildiers H; Kaufman B; Ayoub J-PM; Shah M; Burmedi D; Qin Q; Qian J; Giranda VL; Shepherd SP, 2015, 'Phase III randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2-BRCA-associated locally advanced or metastatic breast cancer (BC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Breast Cancer Symposium of the American-Society-of-Clinical-Oncology (ASCO), CA, San Francisco, 25 September 2015 - 27 September 2015, http://dx.doi.org/10.1200/jco.2015.33.28_suppl.155
    Conference Papers | 2015
    King M; Stockler M; O'Connell R; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Pignata S; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Buizen L; Sjoquist K; Butow P; Friedlander M; Gillies K; Martyn J, 2015, 'VALIDATION OF A PATIENT REPORTED OUTCOME MEASURE (PROM) OF OVARIAN CANCER SYMPTOMS AND TREATMENT RELATED CONCERNS (MOST-OSI) WITH CHEMOTHERAPY IN RECURRENT OVARIAN CANCER (ROC).', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 457 - 458, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000377145701081&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2015
    King M; Stockler M; O'Connell R; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Pignata S; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Buizen L; Sjoquist K; Gillies K; Butow P; Friedlander M, 2015, 'Validation of the measure of ovarian symptoms and treatment concerns (MOST), a patient-reported outcome measure (PROM) of symptom burden and subjective benefit with chemotherapy in recurrent ovarian cancer (ROC)', in QUALITY OF LIFE RESEARCH, SPRINGER, pp. 22 - 23, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000361991100056&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2015
    Lawrence N; Toner G; Martin A; Stockler M; Yeung A; Wong N; Thomson D; Gebski V; Yip S; King M; Friedlander M; Quinn D; Tan TH; Chan H; Hanning F; Weickhardt A; Jeffery M; Stevanovic A; Hovey E; Wyld D; Davis I; Grimison P, 2015, 'A RANDOMISED PHASE 3 TRIAL OF ACCELERATED VERSUS STANDARD BEP CHEMOTHERAPY FOR PATIENTS WITH INTERMEDIATE AND POOR-RISK METASTATIC GERM CELL TUMOURS: THE P3BEP TRIAL (ANZUP 1302)', in Asia-Pacific Journal of Clinical Oncology, WILEY-BLACKWELL, pp. 146 - 147, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000364320800237&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2015
    Lee C; Gibbs E; Roncolato FT; Davies LC; Le Maignan C; Meier W; Lanza MA A; Rosenberg P; Marchetti C; Vergote I; Witteveen P; Bamias A; Serra S; Provencal J; De Rauglaudre G; Gebski V; Friedlander M; Pujade-Lauraine E, 2015, 'Development and validation of a prognostic nomogram to predict overall survival (OS) in platinum-resistant ovarian cancer (PROC): An AURELIA substudy.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5547
    Conference Papers | 2015
    Matulonis U; Friedlander M; Du Bois A; Gourley C; Vergote I; Rustin GJ S; Scott CL; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; McMurtry E; Spencer S; Mann H; Parry D; Ledermann JA, 2015, 'Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5550
    Conference Papers | 2015
    Matulonis UA; Harter P; Gourley C; Friedlander M; Vergote IB; Rustin GJ S; Fielding A; Spencer S; Parry D; Ledermann JA, 2015, 'Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for post-progression PARP inhibitor therapy', in GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS INC ELSEVIER SCIENCE, pp. 8 - 8, http://dx.doi.org/10.1016/j.ygyno.2015.01.015
    Conference Papers | 2015
    Phillips K-A; Collins IM; Milne RL; Fisher R; Stern C; Kannemeyer G; Smith C; Friedlander M; McLachlan S-A; Hickey M; Hopper JL, 2015, 'Do women with BRCA1 or BRCA2 mutations have reduced ovarian reserve?', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.1537
    Conference Papers | 2015
    Puhalla S; Han HS; Dieras V; Friedlander M; Somlo G; Arun B; Wildiers H; Kaufman B; Ayoub J-PM; Shan M; Burmedi D; Qin Q; Qian J; Giranda VL; Shepherd SP, 2015, 'Phase 3 randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2-BRCA-associated locally advanced or metastatic breast cancer (BC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 51st Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.tps1102
    Conference Papers | 2015
    Rafii S; Gourley C; Ang JE; Kumar R; Geuna E; Rye T; Ashcroft L; Powell B; Shapira-Frommer R; Friedlander M; Chen L-M; Matulonis U; Kaufman B; De Greve J; Oza AM; Banerjee SN; Gore ME; Molife LR; Kaye SB; Yap TA, 2015, 'What clinical factors influence advanced BRCA1/2 mutant ovarian cancer patient (BMOC pt) outcomes to poly(ADP-ribose) polymerase inhibitor (PARPi) treatment?', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5546
    Conference Papers | 2015
    Roncolato F; O'Connell R; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Pignata S; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Sjoquist K; Gillies K; Butow P; Stockler M; King M; Friedlander M; Kok P-S, 2015, 'BASELINE PREDICTORS OF EARLY TREATMENT FAILURE IN PATIENTS WITH PLATINUM RESISTANT/REFRACTORY (PRR) AND POTENTIALLY PLATINUM SENSITIVE (PPS) RECURRENT OVARIAN CANCER (ROC) RECEIVING >= 3 LINES OF CHEMOTHERAPY- THE GYNAECOLOGIC CANCER INTERGROUP (GCIG) SYMPTOM BENEFIT STUDY (SBS)', in Asia-Pacific Journal of Clinical Oncology, WILEY-BLACKWELL, pp. 125 - 125, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000364320800179&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2015
    Roncolato FT; O'Connell R; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Pignata S; Donnellan PP; Oza AM; Avall-Lundqvist E; Berek JS; Sjoquist KM; Gillies K; Butow P; Stockler MR; King MT; Friedlander M, 2015, 'Baseline predictors of early treatment failure in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive (PPS >= 3) recurrent ovarian cancer (ROC) receiving >= 3 lines of chemotherapy: The Gynaecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5564
    Conference Papers | 2015
    2015, 'TOPS - a randomised controlled trial of a multidisciplinary intervention for post-cancer fatigue', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, Chicago, presented at 2015 ASCO Annual Meeting, Chicago, 29 May 2015 - 02 June 2015, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000358036902066&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
    Conference Papers | 2014
    Friedlander M; Russell K; Millis SZ; Gatalica Z; Voss A, 2014, 'COMPARISON OF OVARIAN AND RENAL CLEAR CELL CARCINOMA BY COMPREHENSIVE TUMOR PROFILING', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 148 - 148, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500123&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2014
    Friedlander M; Russell K; Millis SZ; Gatalica Z; Voss A, 2014, 'Molecular profiling of clear cell ovarian carcinoma.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.5516
    Conference Papers | 2014
    Friedlander M; Sjoquist KM; Beale P; Sommeijer DW; Mileshkin L; Martyn J; McNally O; O'Connell R; Grant P; Hadley A; Gillies K; Goh J; Bonaventura A, 2014, 'PARAGON (ANZGOG0903): PHASE 2 STUDY OF ANASTROZOLE IN WOMEN WITH ESTROGEN(ER)/PROGESTERONE (PR) POSITIVE PLATINUM RESISTANT/REFRACTORY RECURRENT OVARIAN CANCER (PRROC)', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 38 - 38, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500030&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2014
    Friedlander M; Stockier MR; Butow PN; Oza AM; O'Connell R; Martyn J; Glilles K; Sjoquist KM; King M, 2014, 'Measuring subjective improvement of palliative chemotherapy in women with platinum-resistant or -refractory ovarian cancer: The symptom benefit study (ANZGOG-0701/GCIG/PoCoG).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.tps5615
    Conference Papers | 2014
    Hadley AM; Ryland G; Christie M; Antill Y; Bae S; Hunter S; Lipton L; Boussioutas A; Bowtell D; Jobling T; Friedlander M; Fox S; DeFazio A; Wakefield M; Campbell I; Gorringe K; Pyman J; Scott CL; Ananda S, 2014, 'HIGH-GRADE MUCINOUS OVARIAN CANCER: CLINICAL AND MOLECULAR ANNOTATION OF A RARE CANCER, ORIGINS AND THERAPEUTIC POTENTIAL', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 426 - 427, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500300&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2014
    Harter P; Johnson T; Berton-Rigaud D; Park SY; Friedlander M; del Campo JM; Shimada M; Forget F; Mirza MR; Colombo N; Zamagni C; Chan JK; Imhof M; Herzog TJ; O'Donnell D; King K; Stinnett S; Barrett C; Jobanputra M; Chun-Fang X; du Bois A, 2014, 'BRCA1/2 MUTATIONS ASSOCIATED WITH PROGRESSION FREE SURVIVAL IN OVARIAN CANCER PATIENTS WHO RECEIVED PAZOPANIB OR PLACEBO IN THE AGO-OVAR16 STUDY', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 40 - 41, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500032&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Presentations | 2014
    Hayes S; Friedlander M; Obermair A; Mileshkin L; Janda M; Gordon L; Barnes E; Beesley V; Eakin E; Sommeijer D; Martyn J; Stockler M; Gebski VA L; Naumann F; Schmitz K; Webb P, 2014, 'EXERCISE DURING CHEMOTHERAPY FOR OVARIAN CANCER (ECHO): STUDY DESIGN FEATURES AND OUTCOMES OF A CANCER AUSTRALIA AND CANCER COUNCIL AUSTRALIA FUNDED RANDOMISED, CONTROLLED TRIAL', Vol. 24, pp. 200 - 201, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500161&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2014
    Inglis H; Boyle F; Friedlander M; Watson S, 2014, 'DRY EYES & AIS', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 33 - 33, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344745100087&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2014
    Inglis H; Boyle F; Friedlander M; Watson S, 2014, 'DRY EYES & AIS', in CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, WILEY-BLACKWELL, pp. 65 - 65, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344530600094&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2014
    Inglis H; Friedlander M; Watson SL, 2014, 'Dry Eyes and AIs', in INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, ASSOC RESEARCH VISION OPHTHALMOLOGY INC, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000433199700013&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2014
    King MT; Stockler MR; Butow P; O'Connell R; Voysey M; Oza AM; Gillies K; Donovan HS; Mercieca-Bebber R; Martyn J; Sjoquist K; Friedlander ML, 2014, 'A new patient-reported outcome measure for symptom benefit with chemotherapy: the Measure of Ovarian Symptoms and Treatment concerns (MOST)', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 20 - 20, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500017&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2014
    Lheureux S; Ledermann J; Kaye S; Gourley C; Friedlander M; Bowtell D; De Greve J; DeFazio A; Frommer R; De Bono JS; Audeh MW; Kohn E; Alsop K; Scott C; Matulonis U; Kaufman B; Burger B; Robertson J; Ho T; Oza A, 2014, 'A PILOT INTEGRATED ANALYSIS OF LONG-TERM BENEFIT OF OLAPARIB IN OVARIAN CANCER: RESULTS OF FEASIBILITY TESTING.', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 141 - 142, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500119&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2014
    Lheureux S; Ledermann JA; Kaye SB; Gourley C; Friedlander M; Bowtell D; De Greve J; deFazio A; Shapira-Frommer R; De Bono JS; Audeh MW; Kohn EC; Alsop K; Scott CL; Matulonis U; Kaufman B; Burger B; Robertson JD; Ho T; Oza AM, 2014, 'Characterization of ovarian cancer long-term responders on olaparib.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.5534
    Conference Papers | 2014